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Abstract
Introduction: Blepharitis is a chronic inflammatory disorder of the eyelid margin.
Blepharitis patients routinely present to and are managed by optometrists and
ophthalmologists in practice. Demodex folliculorum is associated with anterior blepharitis.
Presently, treatment with 50% tea tree oil is recommended by the American Academy of
Ophthalmology for Demodex blepharitis. However, over-the-counter products have been
developed and marketed at being effective for treating Demodex blepharitis.
Purpose: To examine the efficacy of over-the-counter lid hygiene products and warm
compress therapy for the treatment of Demodex blepharitis.
Methods: Two hundred and forty-six participants were examined at multiple visits over
four studies, for the presence and quantity of Demodex folliculorum. OCuSOFT® Lid
Scrub® PLUS, dr.organic® tea tree face wash, Johnson’s® No More Tears® baby
shampoo, MGDRx EyeBag® and the OPTASETM Moist Heat Mask were examined for
treating Demodex blepharitis.
Results and Conclusions: OCuSOFT® Lid Scrub® PLUS significantly reduced the
quantity of Demodex folliculorum when used over two and four weeks. Dr.organic® tea
tree face wash significantly reduced the quantity of Demodex folliculorum when used
over four weeks. The OPTASETM Moist Heat Mask significantly reduced the quantity of
Demodex folliculorum when used over eight weeks. The MGDRx EyeBag® did not
demonstrate a significant reduction in the quantity of Demodex folliculorum over the
duration of the study. Johnson’s® No More Tears® baby shampoo had no effect on the
quantity of Demodex folliculorum and demonstrated a significant increase in tear film
instability when used over an eight-week treatment period.
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CHAPTER ONE: DEMODEX BLEPHARITIS
1.1 Background
Blepharitis is a common inflammatory disorder of the eyelid margins, that can affect
patients of all ages and ethnicities.1 It can be classified based on three factors; onset,
location, and underlying aetiology.2 Firstly blepharitis can be classified as acute or chronic.
The majority of blepharitis cases tend to be chronic in nature.2,3 Secondly, it can affect the
anterior eyelid margin, eyelashes and eyelash follicles; or the posterior eyelid margin and
meibomian glands. Thirdly, it can be classified as staphylococcal, seborrheic or parasitic.1–
3

Blepharitis can disrupt the tear film, leading to signs and symptoms of ocular surface

disease.1,2
Anterior blepharitis relates to the anterior eyelid margin, eyelashes and follicles. It is
typically anterior blepharitis that is classified according to underlying aetiology2:
staphylococcal, seborrheic or parasitic. Posterior blepharitis relates to the posterior eyelid
margin and meibomian glands. Meibomian gland dysfunction (MGD) is often considered a
sub-type of posterior blepharitis; however, MGD can also exist separate from blepharitis.
Due to their close proximity with one another, there is often overlap in signs, symptoms
and aetiology between disorders of the eyelashes and meibomian glands.4–7
Blepharitis is one of the most common conditions presenting at ophthalmology and
optometry clinics worldwide.8–10 In a questionnaire style survey conducted by Lemp et al10
in 2009 in the United States, 120 ophthalmologists and 84 optometrists reported blepharitis
prevalence values of 37% and 47% in their respective clinics. Traditionally the majority of
blepharitis cases have been treated within ophthalmology departments. However, with the
development of newer ocular hygiene products, and better training and information
20

available, optometrists are becoming more adept and confident at treating minor eye
conditions such as blepharitis. In 2008, Needle et al11 surveyed optometrists practicing in
the United Kingdom (UK) to investigate their current therapeutic practice, and ascertain
their opinion on the broadening clinical role of optometrists. The results of the survey
showed that optometrists were routinely managing > 70% of blepharitis and dry eye patients
in-house.11
The clinical goal for practitioners is to identify the type of blepharitis, choose an
effective treatment accordingly, and instruct and involve the patient in the long-term
management of their condition.1 The Blepharitis Preferred Practice Pattern® (BPPP)
developed by the American Academy of Ophthalmology (AAO) and the College of
Optometrists, recognise Demodex folliculorum (DF) is associated with chronic re-calcitrant
blepharitis.1,3 Ocular hygiene using a 50% tea tree oil (TTO) preparation is the
recommended treatment by the BPPP and the College of Optometrists.1,3 Briefly this
involves applying the diluted TTO solution to the eyelid margin three times in 5 - 10 minute
intervals.6,12–17 The BPPP also recommend systemic ivermectin in the treatment of ocular
Demodex infestations.1 However, these treatments have several disadvantages (discussed
in more detail in Section 1.9). Thus, the need to elucidate if less severe treatments can
provide therapeutic efficacy. This thesis investigates alternative therapeutic options
available to practitioners for the treatment of DF blepharitis.
1.2 Systematic Review
On commencing this research degree, a search of the available literature was conducted
to collate information on DF. Of particular interest was research that concentrated on the
prevalence of DF with respect to ophthalmology and current treatment methods. Prevalence
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of DF in different cohorts was of interest as, at the time, there was limited knowledge within
the optometric sector on ocular DF, and an early aim of the PhD was to investigate this
further using a questionnaire. Google Scholar, PubMed, and Scopus databases were
searched with the following keywords: “Demodex folliculorum” AND (“treatment” OR
“prevalence” OR “symptoms”, OR “dry eye”) OR “ocular demodicosis” OR “Demodex
blepharitis” AND (“treatment” OR “prevalence” OR “symptoms” OR “dry eye”) OR
(“Demodex” AND “meibomian gland dysfunction”).
The following is a systematic review of the literature available at the start of the
research project. The search strategy is presented in Figure 1.18 Table 1 summarises the
literature identified as meeting the study criterion of reporting on prevalence of ocular DF
among different cohorts and relationship with signs and symptoms of dry eye. Table 2
examines treatment methods for Demodex blepharitis. Detailed descriptions on Demodex,
their pathogenic potential, risk factors and associated conditions, associated ocular surface
inflammation, and methods used for diagnosis and treatment are discussed in more
throughout the chapter. Subsequent relevant publications have been included in the relevant
sections throughout the thesis.
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Identification
Screening

Articles identified through database
searches: Google Scholar, PubMed,
Scopus
(n = 1378)

Records after
duplicates removed
(n = 537)

Eligibility

Full-text articles assessed
for eligibility
(n = 72)

Included

Records excluded:
Not relevant to
prevalence, signs and
symptoms, treatments
(n = 465)

Full-text articles reviewed
(n = 27)

Full-text articles
excluded: not related to
ocular DF
Did not use lash
manipulation
(n = 45)

Figure 1. PRSIMA flow diagram illustrating the search strategy conducted.18
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Table 1. Studies reporting on ocular Demodex folliculorum prevalence, signs and symptoms among different cohorts.
Study

Aim/Purpose

KosikBogacka et
al, (2013)19

Examination of DF
and DB in healthy and
immune-compromised
patients
Prevalence DF in
patients with
proliferative diabetic
retinopathy compared
to healthy subjects
Compare incidence of
DF in normal versus
blepharitis patients

Yamashita et
al, (2011)20

Türk M et al,
(2007)21

Population
(n)
n = 1186

Clinical
Examination
Slit-lamp
examination

Symptom
Assessment
Questionnaire
– name not
given

Sampling Method

Main Results

Lash epilation (2 from
each upper lid)

22.9% prevalence in
controls
20% in immunecompromised
54.8% prevalence diabetic
38.1% healthy
Age and gender were not
found to be significant

n = 84

Modified Coston method
(3 lashes from each
eyelid)

n = 96

Lash epilation

Czepita et al
(2005)22

Prevalence and role of
Demodex in
pathogenisis of
chronic blepharitis

n = 435

Lash epilation (4 from
each eyelid)

Kemal et al,
(2005)23

Prevalence of DF in
seborrheic blepharitis
patients and controls

n = 500

Lash epilation (3 from
each eyelid)

24

29.72% prevalence
blepharitis
9.09%
blepharoconjunctivitis
4.16% healthy
13% ages 3–15 years
34% ages 19-25 years
69% ages 31-50 years
87% ages 51-70 years
95% ages 71-96 years
58% in chronic blepharitis
28.8% in blepharitis
subjects
26.7% in controls
No significant diff with age
or gender

Ozcelik et al,
(2007)24

Prevalence of DF in
patients with chronic
kidney deficiency

n = 85

Kim et al,
(2011)17

Analysis of cytokine
levels in lacrimal fluid
to evaluate casue of
ocular surface
inflammation in
Demodex blepharitis

n = 45

Gao et al,
(2005)25

Prevalence of DF in
eyelashes with CD

n = 55

Liang et al,
(2014)26

Investigate correlation
between Demodex and
chalazia

n = 155

Wesolowska
et al,
(2014)27

Prevalence of
Demodex in eyelash
follicles of different
populations and its
relationship with eye
symptoms

n = 290

Lee et al,
(2010)28

Relationship between
the prevalence of
demodex in eyelashes
and the severity of
ocular discomfort

n = 170

Skin surface biopsy and
lash epilation (8 lashes, 2
each eyelid)
Tear sampling
Slit lamp
examination
TBUT
Schirmer II
(with
anaesthetic)
Routine eye
examination

Modified Coston method
(8 lashes, 2 each eyelid)

Slit lamp
examination
Surgical
removal of
chalazia

Lash epilation (2 from
each eyelid in adults + 4
from each eyelid in
paediatrics)

TBUT
Schirmer
Slit-lamp

Modified Coston method
(8 lashes, 2 each eyelid)

Specially
designed
questionnaire
containing
demographic
and clinical
data

Lash epilation (10
eyelashes each
participant)

Modified
OSDI

Modified Coston method
(8 lashes, 2 each eyelid)
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12.76% in eyelashes of
patients with kidney disease
5.26% in controls (not
significant)
Concentration of IL-17
significantly higher in DF
blepharitis group than nonDF blepharitis and control
groups

100% prevalence in CD
groups
22% in non-CD group
Demodicosis significantly
more prevalent in chalazia
(69.2% vs 20.3%)
DB more prevalent than DF
54.7% prevalence inpatients
40.0% in health
professionals
33.7% in medical students
23.5% in drug abusers
No difference in gender
Symptoms not significantly
associated with Demodex
70% prevalence.
No difference between sex.
No relationship with
systemic disease.

Bhandari &
Reddy,
(2014)29

Incidence and density
of DF on the lashes:
normal eyelids,
anterior blepharitis,
MGD, and mixed
blepharitis

n = 200

de Venecia
& Siong,
(2011)30

Incidence and density
of DF on the lashes:
normal eyelids,
anterior blepharitis,
MGD, and mixed
blepharitis

n = 167

Huang et al,
(2013)31

Ocular demodicosis as
a risk factor in
pterygium recurrence

94

Standard eye
examination

Irritation,
itchiness,
eyelid
heaviness,
sticky or moist
sensation of
the lids,
mucous
discharge:
method not
given
Irritation,
itchiness,
eyelid
heaviness,
sticky or moist
sensation of
the lids,
mucous
discharge, FB
sensation,
transient
blurring of
vision,
redness, eye
pain, tearing:
method not
given

Tear sampling
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Lash epilation

90% incidence in anterior
blepharitis
60% in MGD
90% in mixed blepharitis
18% in controls

Modified Coston method
(8 lashes, 2 each eyelid)

95% incidence in anterior
blepharitis
85% in MGD
97% in mixed blepharitis
34% in controls
Most common symptoms:
itchiness and FB sensation

Modified Coston method
(8 lashes, 2 each eyelid)

High correlation between
tear
IL-17 levels in pterygium
and demodicosis

Hauswirth et
al, (2014)32

ARVO meeting
abstract: comment on
symptoms associated
with DF

72

Li et al,
(2010)33

Investigate the
relationship between
ocular Demodex
infestation and rosacea

59

OSDI
SESoD
SEFoI
TOSS

Routine
complete eye
examination

Modified Coston method
(8 lashes, 2 each eyelid)

OSDI: 36.1% classified as
symptomatic for dry eye
SESoD: 23.6% clinically
significant dryness
SEFoI: 20.8% clinically
significant itch
TOSS: 27.7% clinically
significant

Modified Coston method
(8 lashes, 2 each eyelid)

Demodex count higher in
patients with positive facial
rosacea.
Prevalence Demodex less in
patients with aqueous
deficient dry eye

DF: Demodex folliculorum; DB: Demodex brevis; CD: cylindrical dandruff; TBUT: tear break-up time; IL: inter-leukin; MGD: meibomian gland
dysfunction; FB: foreign body; OSDI: Ocular Surface Disease Index; SESoD: Subjective Evaluation of Symptom of Dryness; SEFoI: Subjective Evaluation
of Frequency of Itch; TOSS: Total Ocular Surface Score
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Table 2. Studies reporting on current treatment methods for ocular Demodex folliculorum.
Study

Aim/Purpose

Population
(n)
n = 12

Holzchuh
et al,
(2011)34

Treatment of DF by
systemic ivermectin.

Gao et al,
(2005)12

Effect of TTO on ocular
Demodex.

n=9

Gao et al,
(2012)35

Treatment of ocular
itching with 5% TTO
ointment.

n = 24

Koo et al,
(2012)13

Relationship between
ocular discomfort and DF.
Therapeutic effects of
TTO for DF blepharitis.

n = 160

Salem et al,
(2013)36

Efficacy of ivermectin
and combined ivermectinmetronidazole therapy in
treatment of ocular DF.

n = 120

Clinical
Examination
NITBUT
Schirmer
TMH
corneal
staining

Degree of
itching
(Graded 0 – 3
for increasing
severity)
Slit-lamp
examination

Symptom
Assessment

OSDI
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Sampling
Method
Lash epilation:
12 lashes (3
each eyelid)

Intervention

Main Results

Ivermectin

Modified
Coston method
(8 lashes, 2
each eyelid)
Lash epilation

Weekly in-office
scrubs 50% TTO.
Home lid scrubs
tea tree shampoo
CTC
5% TTO ointment

Modified
Coston method
(8 lashes, 2
each eyelid)

Weekly in-office
scrubs 50% TTO
Home lid scrubs
tea tree shampoo

Lash epilation:
3 lashes from
each lower
eyelid

Metronidazole
Ivermectin

Prevalence of DF lower
lid > upper lid.
Significant reduction in
quantity DF post
treatment.
In-office scrubs with
home scrubs reduce DF
count to zero in 7 out of
9 patients.
No change in itching and
DF counts with CTC.
Improvement in itching
and reduced DF count
with 5% TTO ointment
DF in 84% patients with
ocular discomfort.
Quantity DF associated
with age and OSDI
score.
TTO significantly
reduced DF count posttreatment.
Combined therapy
superior for decreasing
DF counts to normal
levels.

Kheirkhah
et al,
(2007)6

Retrospective report on
corneal manifestations
associated with DF
infestation.

n=6

Slit-lamp
examination

Modified
Coston method
(8 lashes, 2
each eyelid)

Weekly in-office
scrubs 50% TTO
Home lid scrubs
tea tree shampoo

Improvement in ocular
surface irritation and
pain.
Improvement in
conjunctival redness.
DF count reduced posttreatment.

Liang et al,
(2010)14

Retrospective report on
DF infestation in
paediatric blepharoconjunctivitis.

n = 12

Eye
examination

Modified
Coston method
(8 lashes, 2
each eyelid)

Fulk et al,
(1996)37

Case series, interventional

n = 22

Weekly in-office
lid scrubs 50%
TTO
5% TTO ointment
eyelid massages
4% pilocarpine
gel

Resolution of ocular
irritation and
inflammation.
Reduction in quantity
DF
Reduction in quantity DF
with 4% pilocarpine gel

Filho et al,
(2011)38

Efficacy of oral
ivermectin for the
treatment of chronic DF
blepharitis.
Retrospective review:
Treating ocular
demodicosis with TTO lid
scrubs.

n = 19

TBUT
Slit-lamp
examination

n = 11

CD
MGD

Gao et al,
(2007)15

Subjects
rated feelings
of itch,
burning,
grittiness or
fullness
(scale 1-4) in
a log
OSDI

Lash epilation
6 lashes (3
from each eye)

Lash epilation
(3 per eyelid)

oral ivermectin

Reduction in quantity DF
with oral ivermectin

Self-reported
symptoms

Modified
Coston method
(8 lashes, 2
each eyelid)

Weekly in-office
lid scrubs 50%
TTO
Home lid scrubs
with tea tree
shampoo

DF associated with
ocular surface
inflammation –
MGD/trichiasis/conjuncti
vitis/madarosis.
Reduction in DF count
with TTO
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Kojima et
al, (2011)16

Kim et al,
(2011)39

Use of in-vivo laser
scanning confocal
microscopy in the
diagnosis of ocular
demodicosis.

Investigate clinical and
immunological responses
to Demodex on the ocular
surface.

n = 23

n = 10

Slit lamp
examination
TBUT
Ocular surface
staining
Schirmer I

Visual
analogue
scale scores

Lash epilation
(3 lashes from
superior lid
one eye)

Weekly lid scrubs
50% TTO and
daily lid scrubs
with tea tree
shampoo

Confocal laser
scanning
microscopy

Slit lamp
examination
Tear sampling

Modified
Coston method
(8 lashes, 2
each eyelid)

Weekly lid scrubs
with 50% TTO
and daily lid
scrubs with 10%
TTO shampoo

Itch and FB sensation
greater in DF subjects.
Ocular surface staining
greater in DF subjects.
No significant difference
in mite count between
methodologies.
DF count reduced post
treatment.
Pre Tx: corneal opacities,
corneal vascularization,
corneal erosion and
infiltration, chronic
conjunctival
inflammation.
Post Tx: Demodex count
reduced, tear
concentrations of IL-1β
and IL-17 significantly
reduced and clinical
improvement observed in
all patients.

DF: Demodex folliculorum; NITBUT: non-invasive tear break-up time; TMH: tear meniscus height; TTO: tea tree oil; CTC: chlortetracycline
hydrochloride; OSDI: Ocular Surface Disease Index; TBUT: tear break-up time; CD: cylindrical dandruff; MGD: meibomian gland dysfunction; IL: interleukin; FB: foreign body
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1.3 Introduction to Demodex
Demodex are a group of microscopic ectoparasites that live in the pilosebaceous units
of mammals. Although there are more than 100 known species of Demodex parasites, they
are believed to be host specific. Demodex canis, ubiquitous to dogs, is the most well
documented and investigated of the Demodex mites, due to its ability to cause demodectic
mange in immuno-suppressed dogs. There are two known Demodex species that infest the
pilosebaceous units of humans: DF and Demodex brevis (DB) (collectively referred to as
Demodex throughout this thesis).
Demodex folliculorum were first described in the literature by Simon in 1842,40
although it was not until 1963 that Akbulatova first described DB as a separate species.41,42
In 1967, Coston first described the potential association between Demodex and
blepharitis.43 However, it is only in the last 15 years that significant ground has been broken
in ocular associations of Demodex infestations: including prevalence,23,44,45 symptoms,35,45–
47

complications,6,46,48,49 examination,25,49–51 and treatment.15,52,53
Demodex mites are photophobic40 and most active at night,54 travelling across the skin

at a speed of up to 16 mm/hr.42 They feed on skin cells and sebum, and are most commonly
found in areas rich in sebaceous glands: cheeks, nose, chin and the periocular area42,43,55;
although, they have been found in other locations on the body also.56–59
Demodex are susceptible to desiccation, and therefore cannot live for long outside of
the body.40 As a result, it is believed that direct contact is required for transference. 42,49,54
Palopoli et al60 discovered that DNA lineages of DF were more likely to be shared within
families and between spouses than between unrelated individuals; concluding that close
contact was required for transmission.
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1.4 Classification

Figure 2. Demodex structure: head, four pairs of legs and a long body tail (x 400 mag).
Demodex are translucent, spindle shaped mites, with a head, four pairs of legs and a
long body tail (Figure 2).43,57 Mating occurs at the opening of the hair follicle, and the
female retreats inside the follicle or sebaceous gland to lay her eggs.42,43 The eggs evolve
to become larva and then protonypmh, inside the follicle. Finally, they move to the follicle
orifice to complete maturation to deutonymph and adult.40,42,43 The overall lifespan of
Demodex mites is believed to be approximately 14 - 18 days.40,42,43,61
1.4.1 Demodex folliculorum
Adult DF is approximately 0.4 mm in length, and is larger at all developmental stages
than the corresponding DB stages.41,42 Demodex folliculorum reside in clusters in the
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follicles,41,43,62

eyelash

and

are

therefore

often

associated

with

anterior

blepharitis.22,46,49,63,64 Figure 3 shows multiple DF found on one eyelash.

Figure 3. Several Demodex folliculorum along an epilated eyelash (x 200 mag).
1.4.2 Demodex brevis
Adult DB is smaller than DF, approximately 0.2 mm.42 Demodex brevis typically
resides in solidarity in the eyelash sebaceous glands and meibomian glands, and therefore
has been associated with MGD.26,41,61,62,65 Figure 4 shows a single DB found on eyelash
epilation.
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Figure 4. Demodex brevis (x 400 mag).
1.5 Pathogenicity
Demodex mites have a complex role to play as microflora in our cutaneous ecosystem.
Several investigators believe they are simply commensal organisms66–68: feeding on their
host, without causing damage, but without purpose. It has also been suggested that there
may be a mutualistic Demodex – host relationship, whereby Demodex ingest bacteria and
other micro-organisms within the follicular canal, helping the host.66 The host’s immune
system then appears to regulate the quantity of Demodex present, preventing mite
proliferation that could cause an inflammatory response. However, when Demodex
quantities increase beyond a ‘critical level’, they acquire a pathogenic role, causing injury
to the host.69,70 Thus, pro-inflammatory cytokines/chemokines are released, and the
immune inflammatory response follows with clinically visible cutaneous changes.17,66,69
Although studies have discovered the presence of Demodex on normal, healthy
individuals71,72; associations have been repeatedly made between an increased presence of
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Demodex and inflammatory conditions such as rosacea and blepharitis.6,28,46,47,70 Thus, it
has been suggested that Demodex mites are in fact opportunistic parasites: beginning as
commensals, but have pathogenic potential in susceptible individuals.66 It appears that the
pathogenic potential of Demodex increases as the quantity of mites present increases.61,66
Underlying factors that may affect Demodex proliferation are further discussed in detail in
Section 1.6.
A third theory on the pathogenicity of Demodex is that they may act as vectors for
bacteria. Researchers have begun to question whether it is not the presence of Demodex that
causes problems, but whether the Demodex are ‘ill’.68 This hypothesis has arisen from the
fact that treatment with tetracycline antibiotics resulted in clinical improvement of rosacea,
even though the antibiotics had no effect on the Demodex mites themselves.54 Bacillus
oleronius is a Gram-negative bacterium that has been found on Demodex mites in rosacea
patients.33,73 Neutrophils are a type of white blood cell, that are released as part of our
immune response to bacterial infections.74 O’ Reilly et al75 examined the response of
neutrophils to inflammatory proteins released from Bacillus oleronius. The authors found
that neutrophils exposed to proteins from Bacillus oleronius increased their levels of
migration, degranulation and production of inflammatory cytokines75: suggesting that
bacteria play a role in the inflammation associated with Demodex infestation.
In 1993, Forton & Seys71 examined the density of DF in skin samples of rosacea
participants compared to healthy control participants. The authors discovered a mean
density of 10.8 mites/cm2 in rosacea participants in comparison to a mean of 0.7 mites/
cm2, and < 5 mites/cm2 in 98% of the healthy control skin samples; and concluded that low
quantities of DF could be considered normal.71 In 2014, Thoemmes et al72 investigated the
prevalence of Demodex on adults (> 18 years of age) using DNA extracted from individual
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skin scrapings. Briefly, a metal laboratory spatula was gently scraped across the nose and
cheek to extract sebum from the pores in the skin. After extraction, the sebum was placed
in a drop of mineral oil on a cover slip and the sample was examined to note presence or
absence of visible Demodex mites. Each sample was then transferred to a microcentrifuge
for DNA extraction. The result of their study discovered the presence of Demodex DNA on
100% of individuals tested.72 In the same study, the authors discovered only a 14%
prevalence of Demodex mites based on visually observing the presence of Demodex within
their samples.72 These findings are in keeping with other studies that have also found low
prevalence of Demodex among normal individuals.23,76
1.6 Risk Factors and Associated Conditions
There are several factors that may affect an individual’s susceptibility to proliferation
of Demodex to a pathogenic level. These factors, in addition to potential inhibitory factors,
are outlined in detail below.
1.6.1 Age
Increasing age is the most prevalent risk factor with regards to the presence of
DF.13,28,77,78 Since DF have been located on the nipple, one theory that has been proposed
is that human infants acquire DF from their mothers during nursing; and as the child grows,
the mites proliferate.79 This results in a naturally higher prevalence of DF among older
individuals. It has also been suggested that proliferation of DF increases with age due to a
natural change in sebum composition and secretion that facilitates the growth of DF in the
elderly.27,80 Other studies have indicated a link between ocular hygiene and age: suggesting
that older individuals may have a reduced ability to clean the eyelids thoroughly, thus
resulting in an increased prevalence of DF.28 This conclusion was established when Lee et
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al28 found that the prevalence of DF was higher among younger individuals with poor eyelid
hygiene, in comparison to older individuals with good eyelid hygiene.
1.6.2 Rosacea
The hair follicles and sebaceous glands of the skin are the main sites of involvement
for DF and DB; therefore, it is not surprising that Demodex have been associated with
several skin conditions, such as rosacea, pityrisasis folliculorum, and pustular
folliculitis.33,54,70,81,82 However, Demodex mites, unlike other mites such as scabies, have
not been proven to cause dermatologic issues.83 This is due to the fact that low numbers of
Demodex mites can be found in healthy skin.71 It is has been established that it is an increase
in density of Demodex mites that appears to cause issues.71
Rosacea is a chronic, inflammatory, non-contagious skin disease that predominantly
affects facial skin. It most commonly presents with various degrees of facial flushing,
telangiectasia and papulo-pustular rashes.54,84,85 The majority of cases are diagnosed after
the age of 30 years, and it is consistently found to be more common in women than in
men.86–88 There are several underlying factors that are believed to play a role in the
underlying pathophysiology of rosacea.84 Genetics is considered an important factor
regarding susceptibility of an individual to developing rosacea.84 Up to one third of
individuals with rosacea have a relative with rosacea.84,89 Rosacea can affect patients of any
ethnicity; however, it is more common in fair skinned individuals, with a
Scandinavian/Celtic ancestory.84,87 It has been proposed that darker skin pigmentation
could conceal some of the distinguishing features, thus causing potential underdiagnosis in
darker skinned individuals.90 Exposure to UV light is considered to contribute to the
development of rosacea by altering the elastic and collagen fibres of the blood vessel walls,
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making them more susceptible to damage over time.84 Heat, stress, spicy food and alcohol
have all been considered secondary triggers for rosacea development in susceptible
individuals.84 However, smokers appear to have a lower risk of developing rosacea to nonsmokers.86
The association between rosacea and Demodex has been well established in the
literature.69,70,81 However, the underlying aetiology remains a much debated topic. As
mentioned previously in Section 1.4, one hypothesis on the aetio-pathogenicity of Demodex
in rosacea is that Demodex act as a vector for bacteria and micro-organisms that cause skin
inflammation, such as that seen with rosacea.54 Another hypothesis is that Demodex cause
perifollicular inflammation when they penetrate the dermis, stimulating the release of
lymphohistiocytic infiltrates within the follicles.71 A third hypothesis is that Demodex
proliferate in favourable conditions: hyper-vascularised skin, lack of washing and immune
status.70 When mites proliferate, some individuals experience a type IV hypersensitivity
immune reaction against the mites, causing the development of the redness and papulopustular rash commonly associated with rosacea.69–71
1.6.3 Immunodeficiency
Researchers have been looking at associations between Demodex mites and the
underlying health status of an individual. As a broad variety of patients, with a wide range
of underlying health conditions, present daily to clinical practice for eye examinations and
ocular health checks, it is important to understand how their systemic conditions may affect
their ocular health: both internal e.g. retinopathy, and external e.g. blepharitis and dry eye.
The immune status of the individual is believed to play a major role in suppressing
Demodex proliferation to pathogenic levels.66 A deficient immune system cannot control
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the numbers of Demodex, the mites proliferate, and induce an inflammatory response.66
Several case reports in the literature have found significant DF infestation among
individuals

with

acquired

immunodeficiency

syndrome

(AIDS)

and

human

immunodeficiency virus (HIV), supporting this theory.91–94 However, larger scale studies
have found no association between immune-deficiency and DF infestation.19,27 In the study
conducted by Wesolowska et al,27 the authors inferred that the use of anti-retroviral therapy
for the treatment of HIV may have improved participants immune condition to the extent
where they were no longer immunocompromised enough to facilitate Demodex
proliferation. Although DF infestation has been reported among immunocompetent
children,14,95,96 the majority of cases of paediatric demodicosis reported in the literature
have been associated with leukaemia and HIV92,97–101; as such, practitioners should be
suspicious of an underlying immune condition in children who present with severe DF
infestation.
Diabetes is a group of metabolic diseases, characterised by hyperglycaemia, resulting
from abnormal insulin secretion, action or both.102 Several studies have found an increased
prevalence of DF among diabetics,20,103,104 suggesting that hyperglycemia and the
immunosuppressive nature of diabetes may play a role.104,105 A recent study examining the
effect of blood glucose regulation on the presence of DF infestation in type II diabetics,
showed a higher incidence of DF infestation in diabetics with poor blood glucose control;
suggesting that good glucose control reduces susceptibility to DF infestation in type II
diabetics.106 In 2014, Kurt et al107 demonstrated a significantly higher prevalence of DF
infestation in participants with gestational diabetes compared to controls (pregnant
participants without gestational diabetes) (24.2% versus 3.3%; p < 0.001). Furthermore, in
agreement with earlier research,106 participants with gestational diabetes with poor blood
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glucose control were found to have a higher density of DF compared to those with good
blood sugar control.107
Chronic kidney disease is a progressive loss of kidney function that may occur over
many years. The main function of the kidneys is to maintain homeostasis; by filtration of
waste products from the blood, reabsorption and transportation of nutrients from the blood,
balancing electrolyte levels in the body, and controlling blood pressure. When kidney
function is impaired, there is a loss to homeostasis within the body, and skin changes similar
to those seen with DF infestation develop.108 Researchers have found a positive correlation
between end stage kidney disease and DF infestation.24,108 Similar to diabetes, an
underlying impairment in the immune system of such individuals, may allow proliferation
of DF to pathogenic levels.109
Polycystic ovarian syndrome is a common, endocrine disorder affecting up to 10% of
premenopausal women110: causing anovulation, increased androgen secretion and increased
insulin resistance.111,112 A higher prevalence of DF has been discovered in participants with
polycystic ovarian syndrome.111,113 This is likely due to the associations of polycystic
ovarian syndrome with hyperglycaemia,110 and the associations of Demodex infestation
with uncontrolled blood sugar levels.106
1.6.4 Contact Lenses
Jalbert and Rejab114 found contact lens wearers were prone to higher rates of DF
infestation. The reason for this is unknown, however it is postulated that increased handling
of the eyelids by contact lens wearers can increase the presence of bacteria at the eyelid
margin, resulting in a higher prevalence of blepharitis. Thus, making the eyelids of contact
lens wearers a more desirable environment for DF to inhabit. Tarkowski et al115 also
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discovered a positive correlation between DF infestation and a significant increase in
contact lens discomfort causing contact lens drop out, among previous successful
comfortable contact lens wearers. Contact lens wearers were included in the preliminary
epidemiological study, and the relationship found between contact lens wear and DF
infestation is discussed further in Chapter 3.
1.6.5 Makeup
Horváth et al116 and Elston and Elston79 have proposed that makeup may act as a
deterrent for DF infestation; suggesting that the lipids in cosmetics may affect DF growth
and therefore could be responsible for the lower presence of DF found among women. It is
also possible that the use of makeup may increase good lid and facial hygiene; which has
been shown to be associated with reduced numbers of DF.28 Horváth et al116 and Elston and
Elston’s79 investigations into Demodex and makeup were conducted using skin surface
biopsies. Currently, no data exists that examines the relationship between ocular Demodex
and use of makeup. Chapter 3 reports on the prevalence of DF discovered amongst makeup
wearers in a preliminary epidemiological study conducted during this research project.
1.7 Ocular Surface Inflammation
1.7.1 Dry Eye
Dry eye has been defined as:
“… a multifactorial disease of the ocular surface characterised by a loss of
homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film
instability and hyperosmolarity, ocular surface inflammation
neurosensory abnormalities play etiological roles.” 117
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Dry eye disease (DED) can be classified into two main types: aqueous deficient dry
eye and evaporative dry eye. There are many underlying factors that can cause or exacerbate
DED including but not limited to age, female sex, ethnicity, contact lens wear, blepharitis,
refractive surgery, medications, auto-immune disease, air-conditioned dry environment,
computer use, and smoking.118–124 The prevalence of DED varies from approximately 5% 33%,125,126 depending on the definition of DED incorporated and study conditions; with
increasing age and female sex being the predominant risk factors for disease progression.121
Demodex mite infestation can be associated with DED through its close association with
blepharitis and MGD.
1.7.2 Blepharitis
Blepharitis has been previously defined in Section 1.1. As mentioned previously,
blepharitis has been classified in different ways; however at present, the general accepted
classification is by location of inflammation on the eyelids: anterior and posterior.2,9
Demodex folliculorum infestation is associated with anterior blepharitis, due to its residence
and effect within the eyelash follicles.7,43,46,49,78,127 Researchers have also linked DB with
posterior blepharitis,41,61,62,65 this is discussed in more detail in Section 1.6.3 below.
In susceptible individuals, the existence of Demodex causes direct damage to the
anterior ocular structures.43,62 Demodex folliculorum use their claws to scrape at the internal
walls of the lash follicles. This causes the follicles to widen, the eyelashes within to become
looser, and increased hyperkeratinisation of the epithelial cells: which becomes visible as a
gelatinous collar at the base of the eyelash.62 This is clinically known as cylindrical dandruff
(CD) and is now considered a pathognomonic sign for presence of DF (refer Figure 5).25
Cylindrical dandruff is believed to be caused by the abrasive movement of the mites within
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the eyelash follicles,62 or as an inflammatory cicatrix formed from dead mites within the
follicle.128 As there is a greater quantity of eyelashes on the upper eyelids than one th lower
eyelids, it may be easier to detect, and there may be a greater amount of CD present, on the
upper eyelids.

Figure 5. Cylindrical dandruff: collar at the base of the eyelashes (x24 mag).

The presence of CD at the base of the eyelash follicles is one of the methods utilised
to differentially diagnose between the subtypes of blepharitis. Demodex blepharitis has CD:
gelatinous collars at the base of the eyelashes (as shown in Figure 5).25 By comparison,
staphylococcal collarettes tend to be crusty sleeves, often stuck together, that can leave a
bleeding ulcer when removed, and may be present anywhere along the length of the
eyelash.129 Seborrheic collarettes are usually greasy and soft, they don’t leave a bleeding
ulcer when removed, and are associated with seborrheic dermatitis.9,129
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Despite the relatively high prevalence of blepharitis in ophthalmic clinics, the exact
aetiology remains unknown, and there is still no ‘cure’ for chronic blepharitis.2
1.7.3 Meibomian Gland Dysfunction
Meibomian gland dysfunction is a chronic, diffuse abnormality of the meibomian
glands, that is associated with posterior blepharitis and is the most common cause of
evaporative dry eye.130
The meibomian glands provide the main source of lipids for the human tear film. Their
functions include: preventing evaporation of the aqueous layer, stabilising the tear film and
providing a smooth optical surface for light refraction and improved visual acuity.131–136
Disruption to this lipid layer causes tear film instability, hyperosmolarity and subsequent
ocular surface inflammation, which further increases the instability of the tears, causing
DED. Although DF typically inhabits the eyelash follicles, a high prevalence of DF has
been found in patients with MGD and mixed blepharitis (anterior blepharitis and
MGD).30,127,137 As DB inhabits the sebaceous glands, often in solitude, it is suggested that
DB contributes to MGD by causing granulomatous changes to the glandular cells, and
physically blocking the gland orifice and preventing the flow of meibum to the ocular
surface.41,61,62,65
At present, the most common treatment for MGD involves using compression
therapies to unblock the glands.138–141 It is postulated that frequent and regular heating of
the abnormal meibum clears any obstructions allowing a smooth passage of meibum to the
ocular surface. This increased availability of meibum thickens the lipid layer of the tear
film, reducing evaporation of the aqueous layer, thus increasing the stability of the tears,
restoring normal osmolarity and normal tear function.138,139,141
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Although it is DB that tends to reside in the meibomian glands, a high prevalence of
DF has been found in the eyelashes of MGD sufferers.30 Chapter 7 discusses the efficacy
of warm compresses in the treatment of MGD and DF blepharitis.
1.7.4 Symptoms
The symptoms of DF infestation, blepharitis and DED are very similar, as they all
involve the ocular adnexa and manifest on the ocular surface: dryness, itch, irritation,
burning sensation and foreign body sensation have all been recorded in the
literature.6,13,15,16,45–47,49 Demodex can promote an inflammatory reaction on the ocular
surface.17 Kim et al17 demonstrated that the presence of DF caused an increase in the tear
protein IL-17, which is associated with lid margin inflammation.
Previous research has shown that the type and severity of symptoms can vary
depending on the condition and time of day.142 Blepharitis and MGD are often associated
with a foreign body sensation and sticky eyes in the morning; while aqueous deficient dry
eye tends to worsen as the day goes on.142 Several studies have found itch to be the symptom
most significantly associated with Demodex infestation.16,46,47 The movement of DF within
the follicle may indirectly be accountable for the signs and symptoms exhibited by many
affected patients. As DF are photophobic and only active at night, one might expect patients
to be most symptomatic at night or in the morning after the mites have been most active.
However, at present there is no data available regarding the diurnal variation of symptoms
with respect to DF infestation.
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1.7.5 Ocular Morbidity
Ocular surface inflammation as a result of DF infestation and subsequent DED not
only causes physical symptoms but can cause functional symptoms also. Ocular morbidity
associated with DED and inflammation of the ocular surface has been recognised as a public
health concern.121 As previously discussed, DF infestation can cause ocular surface
inflammation which can manifest as DED and blepharitis in many patients. Subsequently,
this can cause physical and functional symptoms, ranging from mild to severe, requiring
differing levels of treatment and management. Chronic inflammation of the eyelids and
eyelashes from DF infestation can cause loss of lashes, ocular discomfort, corneal
neovascularisation, infiltration, opacities and scars.6,143 This can impact an individuals’
quality of life in several ways: physically, socially, emotionally, professionally, and
financially.121,142 Chronic inflammation from underlying DF and DED can cause physical
discomfort, reduced vision and increased discomfort in contact lenses.115 It can interfere
with leisure activities and social interactions causing stress, anxiety and depression in
severe cases.144 It can also cause a reduction in productivity and time out of work and it can
require many visits with a clinician, with ongoing cost of treatment resulting in increased
medical bills. Early intervention and patient education could go a long way towards
preserving good ocular health, comfort and vision, and preventing chronic disease that can
cause ocular morbidity.
1.8 Diagnostic Methodologies
Diagnosis of Demodex infestation will often depend on the discipline. Dermatologists
use skin surface biopsy techniques to assess density of DF in the skin. Whereas
ophthalmologists and optometrists are concerned with DF and DB infestation of the eyelids
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and eyelashes. Confirming the presence of DF, and thus diagnosis of Demodex blepharitis,
is most commonly achieved by eyelash epilation and microscopic examination the eyelash
with a light microscope,25 or smartphone.145 In recent years, laser confocal microscopy has
also been utilised to view DF in vivo.16,65,146
Investigation of the eyelashes by epilation involves gently rotating an eyelash using
sterile forceps and epilating the lash in order to count the number of DF mites present. There
is no standard technique for epilating the eyelashes. However, the two most utilised
methods discussed in the literature for epilating the eyelashes and counting the DF are the
conventional Coston method and the modified Coston method.
1.8.1 Conventional Coston Method
The conventional Coston method was described by Coston43 in 1967 and involves the
random epilation of non-adjacent eyelashes on the eyelid. The epilated eyelash is placed on
a microscope slide, one drop of peanut oil is placed on the eyelash and the coverslip is
placed on top. However, there are several limitations to the conventional Coston method.
Firstly, randomly selecting any eyelash could result in under-counting, as there is a much
better chance of detecting DF if lashes with CD are present and are selectively chosen.25
Secondly, by adding the peanut oil before the coverslip, non-adherent DF may float away,
resulting in under-counting.25,29 Thirdly, if DF are embedded in compact CD they cannot
be counted accurately.25,29 Finally, very often not all DF get removed with the eyelash
leaving some DF behind in the follicle, resulting in under-counting.25,29 These limitations
led to investigators utilising the modified Coston method in more recent studies.
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1.8.2 Modified Coston Method
The modified Coston method was developed by Gao et al25 in an attempt to overcome
some of the limitations outlined above. The modified Coston method firstly involves
selectively choosing lashes with CD, if present, then placing the coverslip on top of the
epilated eyelashes, and finally pipetting a drop (20µl) of saline at the edge of the microscope
slide on lashes without CD, and alcohol and fluorescein on lashes with retained CD. By
selectively choosing lashes with CD there is a greater chance of finding DF. Placing the
coverslip on top of the microscope before the saline/alcohol prevents loose DF from
floating away. The alcohol dissolves compact CD allowing embedded DF to become visible
and easier to count. Fluorescein increases the proficiency of counting DF mites embedded
in CD.51
The modified Coston method was utilised for counting DF after eyelash epilation in
all studies discussed in this thesis. Eyelashes were prepared and examined immediately
after removal.
1.8.3 Confocal Laser Scanning Microscopy
Confocal laser scanning microscopy is a modern technique that has been used in recent
years to detect DF in-vivo.16,65,146 It is a non-invasive technique in which a probe is
positioned against the area of interest and the underlying tissue structure, at different depths,
can be pictured with histological resolution.146 Confocal laser microscopy has the advantage
of being less invasive than eyelash epilation, and may be more sensitive to detecting
presence and quantity of Demodex.147 Although, several studies comparing laser confocal
microscopy to the modified Coston method have found no significant difference in
prevalence or quantity of DF detected between either method.16,65
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1.8.4 Eyelash Manipulation
Previous investigators have described the use of eyelash manipulation as an adjunct
procedure prior to eyelash epilation in an attempt to stimulate DF, if present, to move
towards the opening of the eyelash follicle.12,61 In 2013, Mastrota50 indicated that it was
possible to view, on the slit-lamp biomicroscope, DF tails emerging from the eyelash
follicles as the eyelash was rotated in-situ. This involved the rotation of the eyelash in
clockwise and counter-clockwise directions using sterile forceps. If DF were present, this
stimulated the mites to emerge from the eyelash follicles and could be seen on slit lamp
magnification and counted. Anecdotally, higher magnifications on slit-lamps (x 40 mag)
have been accepted as the required magnification to identify Demodex within the follicle.50
However, in the current study it is possible to identify Demodex tails at lower
magnifications also (circa x 16-24 mag). It has been noted, that eyelash epilation alone often
results in miscounting, as many DF remain within the follicle after the eyelash has been
removed.25,29,50
Chapter 8 will discuss the clinical use of eyelash manipulation in the examination of
Demodex blepharitis, showing that complete epilation of the eyelash is not always
necessary in a clinical setting; and that eyelash manipulation may be a better indicator for
severity of infestation than eyelash epilation.
1.9 Current Treatment Methods
1.9.1 Tea Tree Oil
Tea tree oil is an essential oil that comes from the tea tree, Melaleuca alternifolia. It
has been used historically among the Aborigines for its medicinal benefits. In more recent
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years, investigators have attempted to examine the efficacy of TTO as an antibacterial,
antimicrobial and anti-inflammatory agent, with promising results.53,148,149 Terpinen-4-ol
has been found to be the active ingredient in TTO effective at killing DF. 53 Studies have
shown 50% TTO to be effective in reducing quantity of DF.6,13,15 This is an important
discovery in the treatment of chronic, recalcitrant blepharitis. At present 50% TTO applied
in-clinic by an experienced practitioner is the recommended treatment for Demodex
blepharitis by the AAO and the College of Optometrists.1,3 However, the use of TTO at the
eyelid margin is not without its disadvantages. It is toxic to the ocular surface, 3,150 can be
irritating and uncomfortable for the patient,13,15 and needs to be applied weekly in-house by
an expert clinician resulting in increased chair-time and cost to the patient.
1.9.2 Ivermectin
Ivermectin is a very effective anti-parasitic drug, and recent studies investigating the
efficacy of ivermectin in treating DF infestation are showing promising results.34,36,38
Single-dose oral ivermectin or combined therapy may be recommended treatment options
for chronic, recalcitrant blepharitis or patients with poor compliance.34,36,38 However,
ivermectin is a broad-spectrum anti-parasitic drug primarily prescribed to treat human
threadworm, and control river-blindness.151 The use of ivermectin for the treatment of
parasitic infections has been associated with several adverse reactions with varying degrees
of severity: diarrhoea, dizziness, nausea, abdominal pain, hypotension, hepatitis, headache,
paraesthesia, allergic reactions, ocular pain, skin swelling, tachycardia, breathing
difficulties, fever, joint pain.152–157 The safety of ivermectin for use by pregnant and nursing
mothers, and young children has not been well established and its use is therefore contraindicated by the Food and Drugs Administration (FDA).151 The FDA have also advised
caution in the treatment of elderly individuals with ivermectin; as it is not well established
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whether older individuals respond differently to younger individuals, and in general there
is an increased frequency of hepatic, renal, cardiac or concomitant disease and other drug
therapy in elderly patients.151 It does appear that the severity of adverse reactions is directly
associated with the severity of parasitic infection, suggesting adverse reactions are due to
the effect of dying parasites in the skin and not as a result of drug toxicity.153 The majority
of these adverse reactions have been associated with severe parasitic infections such as river
blindness and Lao filariasis in developing countries and may not apply to DF infestations.
The off-label use of ivermectin in the treatment of Demodex blepharitis has been
successfully examined in clinical studies.34,36,38 However, there is a need to be cautionary
when prescribing the drug, and potentially only consider when other treatment options have
been unsuccessful.
1.9.3 Metronidazole
Metronidazole is a commonly used anti-protozoal agent, prescribed for the treatment
of bacterial vaginosis in non-pregnant women. However, several studies have investigated
its efficacy at treating DF infestation.158–160 As with ivermectin it has some side effects
which can be severe; nausea, vomiting, anorexia, dizziness, dry mouth, metallic taste,
insomnia, vertigo have all been reported in the literature.161 Metronidazole is
contraindicated in patients with a previous hyper-sensitivity reaction to other
nitroimidazole derivatives; in patients who have taken disulfiram concurrently; and alcohol
use.162 Its use is also cautioned in patients with kidney and liver disease, blood disorders,
pregnant and nursing mothers, and paediatric and geriatric patients.162 Metronidazole has
been found to be carcinogenic in mice and rats; the FDA recommend avoiding un-necessary
use of the drug.162
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Recent studies have shown that ornidazole, an anti-amoebic agent from the same
family as metronidazole, is a safer and more effective treatment option, with fewer side
effects than metronidazole.160 Nausea, headache and dizziness have been reported in the
literature.161 Also initial treatment with ornidazole and metronidazole causes an initial
aggravation of facial inflammation due to foreign body reaction in the skin to dead mites;
therefore anti-inflammatory therapy is also required with these treatments.160 However,
ornidazole does not feature on the FDA register, the European Medicines Register, or the
Irish Health Products Regulatory Authority register at present.
1.9.4 Honey
Honey has historically been used for dressing wounds due to its natural antimicrobial
properties.163 However, it was dismissed in the 1970’s as harmless but ineffective,164 and
has since begun to make its comeback.165 This is in part due to the recent growth of
antibiotic resistant bacteria, promoting the need to look at ‘alternative’ antimicrobial
options.165 Kanuka honey has shown to be effective as a topical treatment for rosacea.166 In
2018, researchers in New Zealand found that methylglyoxal (MGOTM) Manuka honey is as
effective at killing DF in vivo as 50% TTO.167 A micro-emulsion prepared for ocular use
has also shown good antimicrobial potency, with no immediate adverse reactions noted
when applied to rabbit eyes; thus leading the way for future studies to look at the efficacy
of MGOTM Manuka honey for the treatment of blepharitis in human studies.168
1.10 Conclusion
As mentioned earlier, optometrists are increasingly managing blepharitis, including
Demodex blepharitis, in practice, often without the need for further referral.11 As Demodex
blepharitis gains increased recognition, practitioners are investigating for and treating it
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more frequently. As mentioned in Section 1.1 and Section 1.9, the current guidelines
available for practitioners recommend 50% TTO and/or ivermectin for treating Demodex
blepharitis.1,3 However, as 50% TTO is toxic to the ocular surface and should be used with
caution, and ivermectin would require a prescription and is not currently available for
medical practitioners to administer in Ireland or the UK; the aim of this post-graduate
research project was to examine if any other lid hygiene products, that could be comfortably
recommended by practitioners for patients to use at home, were effective at treating
Demodex blepharitis.
On commencing this research project the vast majority of previous Demodex research,
regarding associated risk factors and underlying health conditions, was focussed on
Demodex within skin samples. There was limited literature available on ocular Demodex
infestation and its associated risk factors. The main aim of the research project was to
examine efficacy of treatments for Demodex blepharitis. However, as presence of ocular
Demodex was being examined in participants, the opportunity was taken to look for
commonalities within the population that may pre-dilect or prevent Demodex infestation.
Research methodologies used throughout the course of this research project are
discussed in Chapter 2. The products included in each study and reasoning for each is also
discussed in Chapter 2. The results on the safety and efficacy of lid hygiene products and
warm compresses are discussed in Chapter 5, Chapter 6 and Chapter 7.
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CHAPTER TWO: RESEARCH METHODOLOGY
The research consisted of four recruitment phases; encompassing four prospective
randomised interventional studies (discussed in Chapters 5, 6 and 7) and two observational
studies (discussed in Chapters 3, 4 and 8). Inclusion and exclusion criteria varied for each
phase of recruitment. Detailed inclusion and exclusion criteria are discussed for each phase
in relevant chapters throughout. All participants involved in the research project were
recruited through the National Optometry Centre’s student and private optometry clinics in
the Technological University Dublin (TU Dublin). Informed consent was obtained from all
participants prior to enrolment, to permit the use of their data pseudo-anonymously
(participants were assigned a number-letter code) for research purposes (refer Appendix 1).
All examinations and data analysis were conducted by the PhD Candidate (Murphy, O).
New participants were recruited for each stage of the research project. All participants were
Caucasian. Sample size calculations were carried out for each study and are described in
detail in their relevant sections. A brief outline of the four recruitment phases of this
research project is outlined in Table 3. below. The recruitment phases do not follow
chronological order, as the recruitment phase four was a follow-on study from recruitment
phase two. As such, results from recruitment phase four are discussed in Chapter 6.
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Table 3. The four recruitment phases of the PhD research project. OCuSOFT® Lid
Scrub® PLUS (OCuSOFT), Johnson’s® No More Tears® baby shampoo (baby
shampoo), dr.organic® tea tree face wash (TTFW), MGDRx EyeBag® (Eyebag),
OPTASETM Moist Heat Mask (Optase).
Chapter
Chapter 5

Chapter 5

Chapter 6

Chapter 7

Aim

Phase

Treatment

Compare
efficacy of
treatments
Compare
efficacy of
treatments
Evaluate the
effect of
treatments on the
tear film and
ocular surface
Compare
efficacy of
treatments

Phase One
OCuSOFT vs
(Pilot
baby shampoo
Study)
OCuSOFT vs
Phase Two TTFW vs
BlephExTM

Duration

No. of
Participants

Two
weeks

41

Four
weeks

86

Phase
Four

OCuSOFT vs
TTFW vs baby
shampoo

Eight
weeks

48

Phase
Three

Eyebag vs Optase
vs warm face
cloth

Eight
weeks

42

2.1 Ethics Statement
All studies described in this report were conducted under the Tenets of Helsinki
Declaration of Human Studies169 after approval by the TU Dublin, formerly known as
Dublin Institute of Technology, Research Ethics Committee (refer Appendix 2).
2.2 Statistical Analysis
All data was examined for normality using Shapiro Wilk statistical test. Parametric
data is expressed as mean ± standard deviation (SD), non-parametric data is expressed as
median and inter-quartile range (IQR) where relevant throughout the report. For all
statistical tests p ≤ 0.05 was considered statistically significant unless otherwise stated. A
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brief explanation of each of the statistical tests applied throughout the thesis are outlined
below.
One-way analysis of variance (ANOVA) was used on parametric data to examine for
differences between the means of three or more independent groups, where the dependent
variable was continuous or ordinal in nature.
Repeated measures ANOVA was used for parametric data to compare means of
repeated measurements. It was used to detect change after treatment at follow-up visits.
Kruskal-Wallis (KW) statistical test was used as the non-parametric equivalent of a
one-way ANOVA. It was used to examine for statistically significant difference between
two or more groups of an independent variable with a continuous or ordinal dependent
variable.
Friedman’s was used as the non-parametric equivalent to the repeated measures
ANOVA: used to detect change after treatment at follow-up visits.
Wilcoxon Signed Ranks (WSR) test was used as the non-parametric equivalent of the
paired t-test; to compare two related, matched or repeated measurements to examine for
differences in their population mean ranks.
Mann Whitney – U (MWU) test was used as the non-parametric equivalent of the
independent t-test. It was used to compare two independent groups where the dependent
variable was either continuous or ordinal.
Spearman’s correlation (rs) was used to assess the strength and direction of a
relationship between two continuous variables.
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Chi-square (X2) analysis was used to examine the relationship between categorical or
nominal variables.
2.3 Examination
The following sub-sections consist of a list of examinations that were carried out in
order of least invasive to most invasive, in order to best preserve the integrity of each test,
at each appointment.170,171 As the research progressed, several procedures were included or
removed as required; this is highlighted where relevant throughout.
2.3.1 Questionnaire
The development and validation of the general health and lifestyle (GHL)
questionnaire (refer Appendix 3) is discussed in Chapter 3. The development and validation
of the modified ocular surface disease index (OSDI) symptom questionnaire (refer
Appendix 4) is discussed in Chapter 4. The GHL questionnaire was completed by
participants who took part in the pilot study and four-week treatment study: discussed in
Chapter 5. The modified OSDI symptom questionnaire was completed by every participant,
at every visit, throughout all of the studies.
2.3.2 Habitual Visual Acuity
Habitual visual acuity was measured as a means of monitoring the safety of treatments;
ensuring the treatments did not have a negative effect on vision. Each participant’s habitual
VA was measured using a Thompson logMar chart (Test Chart 2000, Thompson Software
Solutions, London, UK). Habitual VA was defined as a participant’s general everyday
distance vision: recorded as aided or unaided as appropriate. Best acuity was recorded using
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letter by letter scoring with each letter corresponding to 0.02 logMar units.172,173 Due to
time restrictions and number of appointments, refraction was not measured.
2.3.3 Non-Invasive Tear Break-Up Time
Non-invasive tear break-up time (NITBUT) is a method frequently utilised to assess
the quality of the tear film.171 This was measured in seconds using the tear film analysis
function on the Medmont E300 corneal topographer (Medmont International Pty Ltd.,
Victoria, Australia). The Medmont E300 has been shown to have a sensitivity of 81.5% and
specificity of 94.4% for diagnosing DED, with good repeatability (coefficient of variation
9.4%, 95% CI 7.1% - 14.0%).174 Looking straight ahead, participants were requested to
focus on the central fixation target, blink twice gently and then to hold open their eyelids
for as long as possible. An average of three readings were recorded for each eye, beginning
with the right eye and alternating between them.174 Due to availability of equipment,
NITBUT has only been measured for studies conducted in phase three and four only
(Chapters 8 and 6 respectively). The system was calibrated by external technicians every
six months, as required.
2.3.4 Osmolarity
Osmolarity refers to the concentration of dissolved particles in a solution.
Hyperosmolarity of the tears occurs as a result of evaporation of aqueous tear from the
ocular surface, or aqueous deficiency, or a combination of these.117 Increased tear
osmolarity has been recognised as one of the hallmark signs of DED.175 Due to availability
of equipment, the TearLabTM osmolarity system (TearLab Corporation, San Diego,
California) was used in phases three and four of the research only (Chapter 7 and Chapter
6, respectively). One measurement from each eye was taken. Participants were asked to
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gaze superior-nasally, and a measurement was taken from the lower temporal tear meniscus
in each eye. The recommended threshold, using the TearLabTM, most sensitive for detecting
dry eye is 308 mOsm/L, with a sensitivity of 90.7% and specificity of 81.3%.176 Increasing
inter-eye difference has been found to correlate with increasing disease severity: variability
between two eyes in normal, mild to moderate dry eye and severe dry eye patients has been
found to be 6.9 ± 5.9 mOsm/L, 11.7 ±10.9 mOsm/L, and 26.5 ± 22.7 mOsm/L,
respectively.176 An inter-eye variability of ≥ 8mOsms/L is associated with tear film
instability and dry eye: with the higher reading indicating greater disease severity.176,177 The
eye with the highest tear osmolarity measurement at baseline was chosen as the study eye;
and this eye was used for all data analysis in each relevant study. TearLabTM has been shown
to provide repeatable and reproducible tear osmolarity measurements (coefficients of
variation 1.6% - 1.9%).178 Quality control checks, as recommended by the manufacturer,
were conducted: daily using the electronic check cards and with each new supply of test
cards using the control solutions.
2.3.5 Ocular Surface Staining and Fluorescein Tear Break-Up Time
Ocular surface staining was assessed using fluorescein dye and graded using the
Oxford Scheme.179 A fluorescein impregnated strip (Fluorets; Chauvin Pharmaceuticals,
UK) was wetted with a single drop of saline. Excess saline was shaken off, and the tip of
the strip was lightly touched off the lower bulbar conjunctiva while participants looked
upwards. Fluorescein was instilled in the right eye first at each visit. Staining was assessed
30 seconds after instillation.180 Corneal, nasal and temporal bulbar conjunctival staining
were graded individually on a 6 point scale (0 - 5 for each location) to provide a composite
score (0 - 15) for each eye.179 A yellow Wrattan filter was used to enhance any ocular
staining present.181 The Oxford scheme is not widely used in clinical practice, however it
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is recommended for grading ocular surface staining in clinical trials; as it uses a wider range
of scores, thus allowing for the detection of smaller changes.182
After staining was assessed fluorescein tear break-up time (TBUT) was measured.
Fluorescein TBUT is an alternative method for measuring the evaporation rate of the tears.
In many practices, using fluorescein is the only way practitioners have to determine TBUT.
Participants were requested to blink twice and then hold their eyes open for as long as they
could, during which time the tear film was observed and the time to the 1st visible dry spot
appearing was counted. This was measured in seconds using the slit lamp (x 24 mag) and
a Wrattan filter. An average of three readings was recorded. Fluorescein TBUT was
measured in phase one and two only (Chapter 5). As NITBUT is considered more accurate
than fluorescein TBUT171; NITBUT was incorporated for the subsequent phases of
research.
2.3.6 Schirmer I
The Schirmer I test is an invasive procedure, commonly used in dry eye clinics to
measure a participants’ ability to produce tears. The Schirmer strip (Tear Flo; HUB
Pharmaceutical, UK) was folded at the notch, and positioned into the lower lateral eyelid
margin. Participants were asked to close their eyes,183 and the score was measured as the
wetting length in mm/5 min. No anaesthetic was used. This was performed for phase three,
MGD warm compress treatment study only (Chapter 8). The Schirmer test has been known
for its poor repeatability. However, at the time of developing study protocol, Schirmer
remained on the recommended battery of dry eye tests according to DEWS I, and it had
previously been used in many Demodex related studies (Table 1).
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2.3.7 Cylindrical Dandruff
As previously described in Section 1.7.2, CD is pathognomonic for DF infestation.
The degree of CD present on the base of the eyelashes of each eyelid was graded as
described by Milton Hom at the American Academy of Optometry annual meeting in 2013,
on the diagnosis and treatment of Demodex infestation (Table 4).184 ‘Clumps’ refer to the
joining of CD from two or more adjacent lashes to form one CD ‘clump’.
Table 4. Cylindrical dandruff grading scheme (Milton Hom)184

Grade

Description

G0

Normal, clean eyelid margin

G1

Occasional fragments, 1 – 5 collarettes

G2

Few fragments, 6 – 20 collarettes

G3

Many fragments, 21 – 40 collarettes ± 1 – 2
clumps

G4

> 3 clumps ± 40 collarettes

2.3.8 Meibomian Gland Dysfunction Evaluation
Slit-lamp bio-microscopy (Topcon SL-D701, Topcon Medical Systems Inc., Dublin,
Ireland) was conducted to examine the meibomian glands in accordance with the diagnostic
subcommittee of the International Workshop on Meibomian Gland Dysfunction185; firm
digital pressure was applied to the centre of each eyelid margin, and the quality of meibum
expressed and the number of glands expressible was graded on a four-point scale: Table 5.
As recommended, composite scores derived from the expression of both upper and lower
eyelids were generated and used for statistical analysis.185
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Table 5. Meibomian gland dysfunction grading as recommended by the International
Workshop on Meibomian Gland Dysfunction.185
Grade

Quality

Expressibility

G0

Clear fluid

All glands expressible

G1

Cloudy fluid

3 – 4 glands expressible

G2

Cloudy particulate fluid

1 – 2 glands expressible

G3

Inspissated like toothpaste

No glands expressible

2.3.9 Demodex Investigation
Finally, each participant was assessed for the presence and quantity of DF. This
involved the rotation of the eyelash in clockwise and counter-clockwise directions using
sterile forceps. If DF were present, this stimulated them to emerge from the eyelash follicles
and could be seen on slit lamp magnification (circa X 16 – 24 magnification). There is no
gold standard method for manipulating eyelashes to investigate for the presence of DF. In
an attempt to standardise eyelash manipulation, each eyelash was manipulated by rotating
it four times anti-clockwise and then four times clockwise, in situ, using sterile forceps
(Figure 6).

Figure 6. Demodex folliculorum visible emerging from the follicle during eyelash
manipulation with sterile forceps, black arrow (x24 mag).
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Following this, the manipulated eyelashes were removed and placed on a microscope
slide and counted using the modified Coston method described earlier (Section 1.8.2). This
method was used to count DF in all studies described in this thesis. Chapter 8 compares the
two techniques, eyelash manipulation and eyelash epilation, and their use in the
investigation of DF blepharitis.
Two eyelashes from each eyelid were removed at each visit in the pilot study (Chapter
5). Only one eyelash was removed from each eyelid at each visit in the subsequent studies.
This decision was made due to an increase in number of appointments, and therefore an
increase in the number of eyelashes that would need to be removed. Many of the
participants were older, some with chronic MGD and blepharitis and therefore had a
reduced number of eyelashes. Hence, it was difficult to get participants to agree to have
double the quantity of eyelashes removed at each visit.
2.4 Treatments
The most recent official guidelines for the initial management and treatment of all
types of blepharitis from The College of Optometrists and the AAO in 2018 are to first
advise warm compresses and eyelid cleansing; which can be accomplished in several ways,
including diluted baby shampoo or dedicated commercial eyelid cleansers.1,3 If this is ineffective topical/systemic antibiotic therapy followed by topical/systemic antiinflammatory therapy is advised. In recalcitrant cases, it is then recommended to consider
Demodex as the underlying aetiology and treat accordingly. Products targeted at treating
DF are continuously being developed and marketed. However, there is little evidence
available that examines the efficacy of these treatments being administered to patients. The
aim of this research is to investigate the safety and efficacy of several of these blepharitis
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treatments available for the treatment of Demodex blepharitis. The treatments used
throughout this study are described below.
2.4.1 Baby Shampoo
For years, lid scrubs with diluted baby shampoo was considered the ‘go-to’ or
‘traditional’ method practitioners use to treat general blepharitis. As mentioned previously,
it remains a recommendation on the guidelines developed for practitioners to use.1
However, baby shampoo has no medicinal qualities; and furthermore, a recent study
conducted by Sung et al186 discovered that long-term use of baby shampoo could have
negative effects on the goblet cell function, thus causing damage to the ocular surface.
However, at the time the studies were being developed, baby shampoo remained a
recommendation for blepharitis treatment on the guidelines by the College of Optometrists
in the UK.
Baby shampoo was utilised in the phase one, pilot study (Chapter 5) and in phase four
(Chapter 6) of this research project. Participants were provided with instructions to create
a 10% solution of baby shampoo for home lid scrubs. These instructions can be seen in
Appendix 5 (a) and Appendix 5 (b) for the pilot study and phase four, respectively.
Guidelines given to participants for home lid scrubs with baby shampoo is described in
Table 4.
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Figure 7. Johnson’s® No More Tears® Baby shampoo.
2.4.2 OCuSOFT® Lid Scrub® PLUS
OCuSOFT wipes (Figure 8) were supplied by Scope Ophthalmics Ltd (Dublin,
Ireland). The active ingredient in OCuSOFT is 1,2-Octanediol; a substance with
pediculicide potential in as low as 1% concentration.187 At higher concentrations 1,2Octanediol is considered toxic to the ocular surface.150 A 0.5% concentration of 1,2Octanediol is used in OCuSOFT wipes to ensure the wipes are non-irritating, and their
efficacy when used repeatedly for a period of time was examined. OCuSOFT wipes were
utilised in the pilot study and the extended study to examine the efficacy against DF
blepharitis (discussed in Chapter 5). OCuSOFT foam was utilised in phase four to examine
the effect OCuSOFT has on the tear film and ocular surface (discussed in Chapter 6). The
guidelines given to participants for home lid scrubs are described in Table 6.
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Figure 8. OCuSOFT® Lid Scrub® PLUS.
2.4.3 dr.organic® Tea Tree Face Wash
The TTFW utilised in phase two and four of the research project (discussed in Chapters
5 and 6, respectively) was supplied by dr.organic Ltd. (Swansea, UK) (Figure 9). The active
ingredient in TTO, terpinen-4-ol, has been found to be effective at killing DF in a dose
dependent manner.12,53 At the time of study development, previous studies had shown 50%
TTO applied weekly was effective at reducing DF infestation,6,12,13 and a new lid wipe
containing 0.5% terpinen-4-ol (Cliradex®) was showing promising results in the US,188
however, it was not available for purchase in Ireland at the time. Chapter 5 examines the
efficacy of daily lid scrubs with TTFW for the treatment of DF blepharitis. The TTFW used
in this research project had a 38% concentration of terpinen-4-ol. The guidelines given to
participants for home lid scrubs is described in Table 6.
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Figure 9. dr.organic® Tea Tree Face Wash.

Table 6. Home Lid Scrub Instructions. Step-by-step instructions provided to
participants for nightly lid scrubs at home. Baby shampoo: Johnson’s® No More Tears®,
OCuSOFT: OCuSOFT® Lid Scrub® PLUS, TTFW: dr.organic® tea tree face wash.
TTFW/Baby
shampoo
Place a small
amount of shampoo
dilution/ face wash
on a cotton pad

Control

OCuSOFT Foam

OCuSOFT Wipes

Step 1:

Using cooled
boiled water, wet
one of the cotton
pads provided

Place a small
amount of
OCuSOFT foam on
a cotton pad

Remove the
OCuSOFT wipe
from its packet

Step 2:

Gently but thoroughly scrub the eyelid and lash margin in circular movements, ensuring
to scrub along the base of the eyelashes

Step 3:

Step 4:

Step 5:

Begin with the eyes closed to scrub along the top of the lashes. To scrub along the inner
layer of lashes, look downwards to avoid contact with the cornea and gently pull the
upper eyelid upwards. To scrub along the lower eyelashes, look upwards and gently pull
down on the lower lid.
Using a clean cotton
Using a clean
This is a leave-on
This is a leave-on
pad, rinse the
cotton pad, repeat formula, do not rinse formula, do not rinse
shampoo/face wash
on the other eye
until morning
until morning
from the eyelids
Using a clean cotton
Using a clean cotton
Using a new wipe,
pad, repeat on the
pad, repeat on other
repeat on other eye
other eye
eye
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2.4.4 Microblepharoexfoliation
Microblepharoexfoliation is the mechanical debridement and exfoliation of the eyelash
margin using a hand-held electromechanical unit189: BlephExTM (Figure 10). The
BlephExTM device was utilised in phase two (Chapter 5), and was supplied by Scope
Ophthalmics Ltd. (Dublin, Ireland).

Figure 10. BlephExTM device.
BlephExTM is a patented hand-held device, developed for the treatment of ocular
surface disorders including blepharitis.190 Manufacturing guidelines and instructions for use
are described in Table 7
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Table 7. In – house microblepharoexfoliation procedure with BlephExTM, as per
manufacturer’s guidelines.
BlephExTM Microblepharoexfoliation procedure
Step 1:

Soak the sterile micro-sponge tip in cleaning solution (OCuSOFT® Lid Scrub®
Plus foam was used for this study)

Step 2:

Once soaked, insert one tip into the BlephExTM chuck

Step 3:

Instruct the patient to lean their head back. Treat one eyelid at a time, using a new
tip for each lid.
For the upper eyelid; gently pull up on the upper eyelid and instruct the patient to
look downwards.
For the lower eyelid; gently pull down on the lower eyelid and instruct the patient
to look upwards.

Step 4:

To scrub; apply the spinning micro-sponge to the edge of the eyelid and lash line
and sweep from nasal to temporal and back again in a scrubbing motion for 20-30
seconds or until as much debris as possible is removed.

Step 5:

After scrubbing with BlephExTM, clean the patient’s eyelids with saline to rinse off
the formula.

2.4.5 Warm Face Cloth
Face cloths were utilised in phase three as part of the MGD treatment study, to act as
a control ‘traditional’ style warm compress (Chapter 7). Each participant received a clean,
new face cloth to use for the duration of the study. Participants were instructed to pour
200ml of boiled water into a bowl and allow it to cool for 10 minutes before beginning
treatment. This created a water temperature ranging from 50 °C to 39 °C over the 10-minute
treatment time (tested using a HYGIPLAS Easy temperature pocket catering thermometer
and porcelain bowl). Participants’ were then required to re-heat the face cloth every two
minutes, by immersing it in the same bowl of cooled, boiled water: to maintain temperature
at therapeutic levels.191,192 Each participant was directed to use the treatment for 10 minutes
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twice a day for the first two weeks. Frequency of treatment was reduced to 10 minutes once
a day from weeks three to eight. The instructions given to participants are attached in
Appendix 6 (a).
2.4.6 MGDRx EyeBag®
The MGDRx EyeBag® (Eyebag) is a silk and cotton microwaveable device that has
been shown to be a safe and effective treatment method for MGD (Figure 11).141 The
Eyebag is filled with flax seed, providing a dry heat compress. Manufacturers recommend
it for the relief of MGD, blepharitis, dry eye syndrome, and rosacea, amongst others. The
Eyebags utilised in the MGD treatment study (Chapter 8) were supplied by Scope
Ophthalmics Ltd. Participants were instructed to heat their compress in the microwave for
15 – 30 seconds depending on the power of their microwave, as per manufacturers’
guidelines. Each participant was directed to use the treatment for 10 minutes twice a day
for the first two weeks. Frequency of treatment was reduced to 10 minutes once a day from
weeks three to eight. The step-by-step heating instructions given to participants are attached
in Appendix 6 (b).

Figure 11. MGDRx EyeBag®
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2.4.7 OPTASETM Moist Heat Mask
The OPTASETM Moist Heat Mask (Optase) is a microwaveable warm compress
(Figure 12). It contains HydroBeadTM Technology, which absorbs moisture from the air,
and when heated, releases the moisture to provide a natural moist heat. The manufacturers
of Optase claim that the moist heat helps to soften and loosen collarettes in patients with
anterior blepharitis and re-establishes moisture to the eye and surrounding area; while
improving meibum flow, tear film quality and reducing tear film evaporation.193 The Optase
masks utilised in the MGD treatment study (Chapter 8) were supplied by Scope
Ophthalmics Ltd. Participants’ were instructed to heat their compress in the microwave for
15 – 30 seconds depending on the power of their microwave, as per manufacturers’
guidelines. Each participant was directed to use the treatment for 10 minutes twice a day
for the first two weeks. Frequency of treatment was reduced to 10 minutes once a day from
weeks three to eight. The step-by-step heating instructions given to participants are attached
in Appendix 6 (c).

Figure 12. OPTASETM Moist Heat Mask
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2.5 Summary
This thesis focuses specifically on DF blepharitis and the safety and efficacy of the
over-the-counter treatments listed above, in the treatment of DF blepharitis. The following
Chapters 3 – 8 discuss the results of the interventional and observational studies that have
stemmed from the four recruitment phases of this research project.
Chapter 3 focusses on the development, validation and use of the GHL questionnaire
and Chapter 4 on the development, validation and use of the modified OSDI questionnaire.
A paper on the validation and use of the modified OSDI questionnaire has been published
in International Ophthalmology (refer List of Publications).
Chapter 5 discusses the results of the pilot study (phase one) and the extended fourweek treatment study (phase two). A paper on the results of the extended four-week study
has been published in Contact Lens Anterior Eye (refer List of Publications).
Chapter 6 examines the results of phase four of the research project: an extension of
phase one and two, developed from peer-reviewed feedback received throughout the
research project. This study extended treatment to eight weeks, eliminated the confounding
effect of age on results, and facilitated the investigation of the effect eyelid hygiene had on
the tear film and ocular surface. A paper discussing the results of this study has been
recently accepted for publication in Contact Lens Anterior Eye (refer List of Publications).
Chapter 7 discusses the effect of heat on DF infestation, and examines the efficacy of
warm compresses in the treatment of DF blepharitis. A paper discussing the results of the
effect of heat therapy on DF has been recently accepted for publication in Current Eye
Research (refer List of Publications).
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Finally, Chapter 8 considers the second observational finding derived from phase’s
one and two: comparing eyelash manipulation and eyelash epilation in the examination of
DF blepharitis. These techniques are both described in detail in Section 1.8.4 and Section
1.8.2 respectively, and in Chapter 8. A paper discussing this observation has been accepted
for publication in Eye & Contact Lens (refer List of Publications).
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CHAPTER THREE: DEVELOPMENT AND VALIDATION OF A GENERAL
HEALTH AND LIFESTYLE QUESTIONNAIRE FOR THE INVESTIGATION OF
DEMODEX FOLLICULORUM BLEPHARITIS
3.1 Abstract
Purpose: To develop and validate a GHL questionnaire that could be used to evaluate
the relationship between general health and lifestyle choices, and DF infestation. To
determine the prevalence of DF infestation in an Irish population.
Methods: One hundred and fifty-six participants were enrolled in an epidemiological
cross-sectional prevalence study. Each participant completed the novel questionnaire on
general health and lifestyle. Participants were assessed for the presence and quantity of DF.
Data was analysed to search for significant links between general health and lifestyle and
DF infestation.
Results: The overall prevalence of DF detected was 67.99%. The total median number
of DF detected was 1.00 mites (IQR: 0.00 – 5.00). Significant associations were found
between the presence and quantity of DF with age (p = 0.001 and p < 0.001, respectively),
and makeup (p = 0.03 and p = 0.04, respectively). No significant association was
demonstrated between DF infestation and contact lens wear, frequency of bed linen hygiene
or frequency of cleaning eyelids. The GHL questionnaire demonstrated moderate but
acceptable inter-rater reliability (κ ≥ 0.61).
Conclusion: Increasing age remains the most significant risk factor for DF infestation.
Makeup may provide a preventative effect to reduce the occurrence of DF.
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3.2 Introduction
Demodex mites are common human ectoparasites, described in detail in Section 1.3
and Section 1.4. Their clinical importance and association with underlying medical
conditions is discussed in Section 1.6.3. As previously described in Section 1.5, although
Demodex have been found in larger quantities in certain individuals, there remains a
question mark surrounding their pathogenicity. Therefore, researchers are attempting to
explain why certain individuals appear to be more susceptible to greater proliferation of
mites, and therefore pathogenic DF infestation, than others.
General health and lifestyle choices as risk factors for many ocular disorders have been
well documented. Family history is a risk factor for some posterior eye diseases: age-related
macular degeneration194 and glaucoma.195 Diabetes and high blood pressure are risk factors
for potentially sight threatening vascular changes at the back of the eye.196 Laser surgery,
contact lens wear, smoking, working in an air-conditioned environment are risk factors for
dry eyes.121 Demodex folliculorum infestation is a relatively newly recognised condition,
and researchers are currently investigating risk factors that may exist causing a predilection
to higher or lower numbers of mites for an individual.
Previous research has shown that factors such as increasing age (Section 1.6.1), health
factors (Section 1.6.3), and contact lens wear (Section 1.6.4) are associated with increased
risk of developing pathogenic DF infestation.13,20,24,77,108,113–115 It has also been suggested
that the anatomical position of the eyelids, protected by the bony protrusion of the cheek
and brow bones, creates an area that is unlikely to receive as vigorous a hygiene regime as
the rest of the face: causing a potential habitat for increased DF numbers.61 To further
strengthen this hypothesis, lower numbers of DF were found among participants with better
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lid hygiene regardless of age.13,28 The routine use of makeup has also been associated with
lower numbers of DF.79,116 To investigate these areas further, questions on type and
frequency of lid hygiene, and use of makeup were included in the questionnaire.
As mentioned previously in Section 1.3, DF are photophobic and most active at night
while one is asleep.40,54 Therefore, it could be expected that DF may be found on pillow
cases. Thus, the longer the period between changing pillowcases, the higher the potential
for a greater risk for DF proliferation. Furthermore, the kill temperature of DF is between
54 - 58 oC.197 Hence, in theory, cleaning bed-linen above this temperature would kill any
DF present on the bed-linen and therefore potentially reduce the risk of DF proliferation. A
previous study examining the role of water temperature in reducing dust mites found that
temperatures below 45oC were ineffective.198 Questions regarding frequency and
temperature of bed-linen cleaning, and method of drying bed-linen were included in the
GHL questionnaire to investigate if there were any associations with DF infestation.
The GHL questionnaire was developed in an effort to gain a better understanding of
potential underlying risk factors for DF infestation (Appendix 3). These may provide the
basis for a screening mechanism for the presence of DF in the future.
3.3 Methods
3.3.1 Examination
Participants attending the National Optometry Centre private and student optometry
clinics, and staff and students of TU Dublin were invited to take part in a cross-sectional
prevalence study for DF blepharitis. Signed informed consent was received before
participation.
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Minimum sample size required for statistical significance was calculated using
G*Power analysis. A priori analysis for two-tailed t test, difference between two
independent means was conducted; alpha = 0.05, Power = 0.8, arbitrary effect size = 0.5;
minimum sample size required n = 128.
•

Inclusion criteria: ≥ 18 years of age.

•

Exclusion criteria: participants presently being treated for blepharitis or who
had used treatment in the past 6 months, active ocular infection (excluding
blepharitis) or ocular surgery within the past 6 months.

One hundred and fifty-six participants were examined between October 2014 and May
2016. Seventy males and 86 females, with a median age of 45.00 years (IQR: 28.25 – 62.00)
completed the novel questionnaire and were assessed for the presence of DF. Presence of
DF was defined as: positive observation of DF on eyelash manipulation (Section 1.8.4)
and/or one or more DF counted on microscopic examination (Section 1.8.2). The overall
prevalence of DF, and any association between general health and lifestyle choices, and
symptoms, and the presence and quantity of DF was examined.
3.3.2 Questionnaire Development
The GHL questionnaire was developed to observe potential correlations between DF
and certain lifestyle choices and health status of participants’ (refer Appendix 3).
Participants were questioned about the use of contact lenses, makeup, current lid hygiene
regime, the presence of any medical conditions, and several other questions, to examine for
potential risk factors for DF infestation. Participants were allowed to tick multiple answers
on the GHL questionnaire where relevant. Answers from these questions may provide the
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foundation for a screening mechanism for the presence of DF. It was not intended that the
GHL questionnaire be used to assess the severity of DF infestation, if present.
3.3.3 Questionnaire Validation
Cross tabulation and Cohen’s kappa (κ) co-efficient were calculated to assess the interrater reliability of the GHL questionnaire. These validation methods were chosen as they
are appropriate for measuring agreement in categorical data.199 This was measured by
giving the GHL questionnaire to 50 individuals not included in the study and asking them
to repeat the questionnaire two weeks later with no change in their general circumstances.
This sample size was below the desired number for several questions, this is discussed later
as a limitation (Section 3.5.1). A value of ≥ 0.6 was desirable and considered to have a
moderate level of agreement, ≥ 0.8 considered strong level of agreement and ≥ 0.9 was
considered almost perfect agreement.200
3.3.4 Statistical analysis
Statistical analysis was performed using the Statistical Package for Social Sciences
(SPSS) version 25.0 (IBM Corp, Armonk, NY, USA). Data was assessed for normal
distribution using Shapiro-Wilk. All outcome measures investigated were determined to
have a non-normal distribution (p < 0.001). The data between categorical variables was
assessed using X2 analysis. Between group data was assessed using the MWU test and KW
test where appropriate. Spearman’s correlation co-efficient was used to assess scaled and
continuous variables. All summarised continuous data was expressed as median and IQR,
p ≤ 0.05 was considered statistically significant.
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3.4 Results
3.4.1 Questionnaire Validation
Response frequencies and their respective κ values from the cross-tabulation of
answers for the GHL questionnaire are shown in Table 8. Questions on makeup and contact
lens wear showed strong agreement. For all other questions, κ values fell between 0.61 –
0.79, indicating a moderate but acceptable reliability.199
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Table 8. Cohen’s kappa co-efficient and cross-tabulation of test re-test results.
1st attempt: n, (%)
CL

None,
45(90%)

MU

Daily, 3 (6%)

None,
14
(29%)

Every
Night, 24
(49%)

Type Lid
Hygiene

None,
16
(33%)

C/T, 7
(15%)

Bed linen
Freq

> once a
week, 4
(8%)

Temp No

≤ 30 oC, 7 (14%)

Linen
Dried

Two Weekly, 1
(2%)

Yes, 23 (47%)

Lid
Hygiene

Air Dry, 27
(54%)

MUR
,4
(8%)

Once a
week, 14
(28%)

Monthly, 1
(2%)

None, 46
(92%)

No, 26 (53%)

3-4 times a
week, 4
(8%)
FW, 5
(10%)

1-2 times a
week, 5
(10%)
JJ, 1
(2%)

Once a
fortnight,
20 (40%)
40 oC, 30 (61%)

Tumble Dry,
17 (34%)

κ

2nd attempt: n, (%)

Other, 8
(17%)

Once a
month, 11
(22%)

None,
12
(24%)

Every
Night, 25
(50%)

Multi, 7
(15%)

None,
12
(25%)

C/T, 7
(15%)

< once a
month, 1
(2%)

Air + Tumble
Dry, 4 (8%)

Two Weekly,
1 (2%)

Yes, 24 (49%)

< once a
week, 2
(4%)

≥ 60 oC, 12 (25%)

Laundrette,
2 (4%)

Daily, 2 (4%)

> once a week,
3 (6%)

Air Dry, 30
(60%)

80

No, 25 (51%)

3-4 times a
week, 1 (2%)

MUR,
1 (2%)

Once a
week, 13
(26%)

≤ 30 oC, 7 (14%)

Monthly, 1
(2%)

FW, 8
(17%)

1-2 times a
week, 5
(10%)
JJ, 1
(1%)

Once a
fortnight,
19 (38%)

40 oC, 26 (54%)

Tumble Dry,
14 (28%)

Laundrette,
1 (2%)

0.88

0.92

< once a
week, 7
(14%)

0.63

Other,
12
(25%)

Multi, 7
(15%)

0.79

Once a
month,
12 (24%)

< once a
month, 3
(6%)

0.72

≥ 60 oC, 15
(31%)

0.66

Air + Tumble
Dry, 5 (10%)

0.61

1st attempt: n, (%)
Med
Cond
Meds

κ

2nd attempt: n, (%)

Yes, 4 (8%)

No, 46 (92%)

Yes, 5 (10%)

No, 44 (90%)

0.63

Yes, 5 (10%)

No, 45 (90%)

Yes, 5 (10%)

No, 45 (90%)

0.78

Allergies

None, 22
(44%)

Skin
Conds

None,
29
(58%)

SL, 11
(22%)
ROS,
9
(18%)

AA, 1
(2%)

ECZ,
4
(8%)

ANE,
2
(4%),

SS, 4
(8%)

DT, 4
(8%)

PSRS, 0
(0%)

MTPL, 8
(16%)

SnS, 5
(10%)

M, 1
(2%)

None, 23
(47%)
None, 32
(64%)

SL, 15
(31%)
ROS,
9
(18%)

AA, 1
(2%)
ECZ,
1 (2%)

SS, 3
(6%)
ANE,
2 (4%)

PSRS,
1 (2%)

DT, 1
(2%)
SnS, 4
(8%)

MTPL,
6 (12%)

0.65
2

M, 1
(2%)

0.76
4

* κ = Cohen’s kappa; CL = Contact Lens Modality; MU = Makeup; Lid Hygiene: C/T = cleanser/toner, MUR = makeup remover, FW =
face wipes, JJ = Johnson + Johnson lid scrubs, Other = other lid scrubs, Multi = multiple lid hygiene methods; Allergies: SL = seasonal, AA =
asthma, SS = skin sensitivity, DT = dust, MTPL = multiple allergies; Skin conditions: ROS = rosacea, ECZ = eczema, ANE = acne, PSRS =
psoriasis, SnS = sensitive skin, M = multiple skin conditions
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3.4.2 Questionnaire Application
One hundred and fifty-six participants (median 45.00 years, IQR: 28.25 – 62.00)
completed the questionnaire and were assessed for the presence and quantity of DF. An
overall prevalence of 67.99% DF was detected amongst the study cohort. The overall
quantity of DF discovered, per participant, on microscopic examination was median 1.00,
IQR: 0.00 – 5.00. There was no significant difference in presence or quantity of DF between
genders (p = 0.13 and p = 0.17, respectively) (refer Table 9).
Table 9. Comparison of age and presence and quantity of Demodex folliculorum for male
and female study participants. Age (median, IQR), Demodex folliculorum quantity (median,
IQR); A = Mann Whitney-U: B = Chi-square.
N

Age (yrs.)

Presence
(%)

Quantity
Demodex (n)

Male

70

44.50 (27.00 – 59.00)

74.29

2.00 (0.00 – 5.00)

Female

86

45.50 (29.00 – 63.00)

62.79

1.00 (0.00 – 6.00)

p = 0.43 (A)

p = 0.13 (B)

p = 0.17 (A)

There was a significant increase in prevalence of DF with increasing age (MWU; p <
0.001). Similarly, there was also a low but significant correlation between increasing
quantity of DF and increasing age (rs 0.39; p < 0.001) (refer Figure 13).
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Correlation between Age and quantity of Demodex
folliculorum

Demodex folliculorum (n)

30
25
20

15
10

R² = 0.1319

5
0
15

25

35

45
55
Age (years)

65

75

85

Figure 13. Correlation between increasing age and increasing quantity of Demodex
folliculorum (rs 0.39; p < 0.001).

Table 10. shows the relationship between contact lens wear and DF. A slightly higher
presence and quantity of DF was detected among the non-contact lens wearers. However, noncontact lens wearers were significantly older than contact lens wearers (MWU: p = 0.046).
Furthermore, the difference in DF presence and quantity between contact lens wearers and noncontact lens wearers was not found to be significant (refer Table 10).
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Table 10. Contact lens wear descriptives: age, prevalence and quantity Demodex
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR); A =
Mann Whitney-U: B = Chi-square. *Significant results highlighted in bold.
N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

No

128

46.00 (29.00 – 62.00)

69.67

2.00 (0.00 – 5.00)

Yes

28

34.00 (25.50 – 48.00)

57.14

0.50 (0.00 – 4.00)

*p = 0.046 (A)

p = 0.20 (B)

p = 0.22 (A)

Table 11 shows relationship between DF and makeup. Overall, the presence and
quantity of DF was significantly lower amongst makeup wearers than non-makeup wearers
(X2: p = 0.03 and MWU: p = 0.04, respectively). Age was not found to be an influencing
factor in the result; but both male and female participants were included in the analysis.
Table 11. Overall makeup descriptives: age, prevalence Demodex folliculorum and
quantity Demodex folliculorum. Age (median and IQR), Demodex folliculorum quantity
(median, IQR);

A = Mann Whitney-U: B = Chi-square. *Significant results
highlighted in bold.

N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

No

85

46.00 (29.00 – 62.00)

75.29

2.00 (0.00 – 7.00)

Yes

71

40.00 (28.00 – 62.00)

59.15

1.00 (0.00 – 5.00)

p = 0.33 (A)

*p = 0.03 (B)

*p = 0.04 (A)
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Females accounted for 100% of makeup wearers, and 82.56% of females reported
wearing makeup. When analysing for females alone, the presence and quantity was still
lower amongst makeup wearers, although not significantly (X2: p = 0.13 and MWU: p =
0.21, respectively). Furthermore, female makeup wearers were significantly younger than
non-makeup wearers (MWU p = 0.005) (refer Table 12), which is likely to have impacted
the results.
Table 12. Female-only makeup descriptives: age, prevalence and quantity Demodex
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR); A =
Mann Whitney-U: B = Chi-square. *Significant results highlighted in bold
N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

No

15

69.00 (55.00 – 70.00)

80.00

1.00 (0.00 – 10.00)

Yes

71

40.00 (28.00 – 62.00)

59.15

1.00 (0.00 – 5.00)

*p = 0.005 (A)

p = 0.13 (B)

p = 0.21 (A)

The majority of makeup wearers (63.38%) reported cleaning their eyelids every night,
however, the frequency of eyeld hygiene among female makeup wearers was not found to
be significant (KW p = 0.32). The most popular methods of removing makeup were:
cleanser/toner (25.35%), eye makeup remover (25.35%) or a combination of methods
(21.13%). The method of lid hygiene used by female makeup wearers was also not found
to be significant (KW p = 0.30).
The relationship between the presence and quantity of DF and wearing mascara was
found to be significant (X2: p = 0.01 and KW: p = 0.01 respectively). As only females
reported wearing mascara, only female participants were included in the analysis. Post-hoc
analysis demonstrated: quantity DF was lowest amongst participants using waterproof
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mascara. Applying Bonferroni correction α ≤ 0.05/6 = 0.0083. The only significant
difference in quantity of DF was between participants not wearing mascara (median: 3.50,
IQR: 1.00 – 10.00) and those wearing waterproof mascara (mean: 0.00, IQR: 0.00 – 1.00)
(MWU: p = 0.003). Similarly, these results are significantly influenced by age: those not
wearing mascara were significantly older (MWU: p < 0.001). When analysing for female
makeup wearers only, mascara and eyeliner were not found to be significant factors (KW
p = 0.06 and p = 0.26, respectively).
Table 13 illustrates the relationship found between presence and quantity of DF and
reported frequency of eyelid hygiene. As can be seen from Table 13, those that reported the
lowest frequency of eyelid hygiene demonstrated the highest presence (74.42%) and
quantity (median: 3.00, IQR: 0.00 – 9.00) of DF, although the difference was not found to
be significant (X2: p = 0.69 and KW: p = 0.35, respectively). Nonetheless, participants with
the lowest frequency of eyelid hygiene appeared to be significantly older than those that
reported more regular eyelid hygiene (KW: p = 0.02), which is likely to have influenced
the result. However, after post-hoc analysis (with Bonferroni correction 0.05/10 = 0.005),
none of the comparisons between the subgroups were found to be significant (MWU p >
0.005 in all groups). Lid hygiene frequency was significantly associated with grade of CD
(KW p = 0.02). After post-hoc analysis (with Bonferroni correction 0.05/10 = 0.005) the
only significant difference was between participants who cleaned their eyelids nightly and
those that never cleaned their eyelids (median CD grade: 0.00 IQR 0.00 – 1.00 versus 1.00
IQR 0.00 – 2.00, respectively. MWU p = 0.001).
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Table 13. Frequency of lid hygiene descriptives: age, prevalence and quantity
Demodex folliculorum. Age (median, IQR), Demodex folliculorum quantity (median,
IQR); A = Kruskal-Wallis: B = Chi-square. * Significant results highlighted in bold
Nights/7

N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

0/7

43

55.00 (37.00 – 69.00)

74.42

3.00 (0.00 – 9.00)

< 1/7

17

36.00 (25.00 – 46.00)

70.59

1.00 (0.00 – 5.00)

1-2/7

14

49.00 (33.00 – 58.00)

71.43

3.00 (0.00 – 7.00)

3-4/7

20

35.00 (24.00 – 47.50)

70.00

2.00 (0.00 – 5.00)

6-7/7

62

44.00 (28.00 – 62.00)

61.29

1.00 (1.00 – 2.00)

*p = 0.02 (A)

p = 0.69 (B)

p = 0.35 (A)

Table 14 examines the type of lid hygiene reported by participants. As can be seen
from the results in Table 14, no significant relationship was found between type of lid
hygiene and presence or quantity of DF.
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Table 14. Type of lid hygiene descriptives: age, prevalence and quantity Demodex
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR);
A = Kruskal-Wallis: B = Chi-square.
N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

None

48

52.00 (30.50 – 66.00)

75.00

2.50 (0.00 – 9.00)

Cleanser/
Toner

20

35.00 (26.00 – 45.00)

40.00

0.00 (0.00 – 3.50)

Makeup
Remover

18

34.00 (28.00 – 60.00)

61.11

0.50 (0.00 – 2.00)

Face
Wipes

12

52.50 (25.00 – 63.00)

83.33

5.00 (1.00 – 7.50)

J+J Lid
Scrubs

6

60.00 (48.00 – 69.00)

83.33

9.50 (1.00 – 15.00)

Other Lid
Scrubs

5

46.00 (39.00 – 49.00)

60.00

1.00 (0.00 – 21.00)

Other
Method

31

45.00 (31.00 – 59.00)

77.42

2.00 (0.00 – 5.00)

Multiple

16

36.00 (27.50 – 55.00)

56.25

0.50 (0.00 – 6.50)

p = 0.24 (A)

p = 0.71 (B)

p = 0.06 (A)

Table 15 presents the relationship between the frequency of cleaning bed linen and DF
presence and quantity. One might expect higher prevalence and quantities of DF among
participants who clean their bed linen less frequently. However, as can be seen from Table
15, the frequency of cleaning bed linen did not influence presence or quantity of DF.
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Table 15. Frequency of bed linen cleaned descriptives: age, prevalence and quantity
Demodex folliculorum. Age (median, IQR), Demodex folliculorum quantity (median,
IQR);

A = Kruskal-Wallis: B = Chi-square.

Freq

N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

> once a
week

38

45.00 (33.00 – 56.00)

73.68

1.50 (0.00 – 5.00)

once a
week

46

46.50 (24.00 – 63.00)

65.22

1.00 (0.00 – 7.00)

once a
fortnight

48

48.50 (31.50 – 67.50)

66.66

1.00 (0.00 – 3.50)

once a
month

17

34.00 (30.00 – 51.00)

70.59

2.00 (0.00 – 6.00)

< once a
month

7

62.00 (24.00 – 78.00)

57.14

2.00 (0.00 – 12.00)

p = 0.062 (A)

p = 0.88 (B)

p = 0.97 (A)

Similarly, as DF are affected by higher temperatures, one might expect that the
temperature bed linen is washed at could influence DF presence or quantity. Table 16.
presents the relationship between temperature of bed linen washing and DF presence and
quantity. Eleven participants reported not knowing what temperature the bed linen was
washed at, and they were removed from analysis. As can be seen from Table 16, as the
temperature increased, the prevalence of DF decreased. However, the difference between
the groups was not found to be significant (X2: p = 0.06)
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Table 16. Temperature bed linen washed descriptives: age, prevalence and quantity
Demodex folliculorum. Age (median, IQR), Demodex folliculorum quantity (median,
IQR);

A = Kruskal-Wallis: B = Chi-square.

Temp (°C)

N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

30

53

40.00 (24.00 – 60.00)

71.70

1.00 (1.00 – 6.00)

40

66

43.50 (29.00 – 62.00)

66.70

2.00 (0.00 – 7.00)

60

26

49.00 (33.00 – 62.00)

46.15

0.00 (0.00 – 2.00)

p = 0.34 (A)

p = 0.06 (B)

p = 0.10 (A)

Table 17 examines the relationship between the presence and quantity of DF with selfreported allergies: seasonal (hayfever), asthma, sensitive skin, dust or a combination of
allergies. However, no significant relationship between allergies and presence or quantity
of DF was detected.
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Table 17. Allergies descriptives: age, prevalence and quantity Demodex
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR);
A = Kruskal-Wallis: B = Chi-square.
Allergies

N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

None

63

49.00 (31.00 – 64.00)

69.84

2.00 (0.00 – 5.00)

Seasonal

13

44.00 (28.00 – 65.00)

76.92

1.00 (0.00 – 4.00)

Asthma

6

29.50 (27.00 – 42.00)

33.33

0.00 (0.00 – 3.00)

Skin
Sensitivities

13

52.00 (34.00 – 56.00)

61.54

1.00 (0.00 – 9.00)

Dust

40

44.50 (22.00 – 60.00)

70.00

1.50 (0.00 – 8.00)

Multiple

21

39.00 (33.00 – 60.00)

66.66

1.00 (0.00 – 7.00)

p = 0.21 (A)

p = 0.52 (B)

p = 0.79 (A)

Table 18 illustrates the relationship between the presence and quantity of DF and selfreported skin conditions. The current study did not find any association between DF and
skin conditions. However, the numbers of individuals with skin conditions were limited
(refer Table 18).
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Table 18. Skin conditions descriptives: age, prevalence and quantity Demodex folliculorum.
Age (median, IQR), Demodex folliculorum quantity (median, IQR); A = Kruskal-Wallis: B =
Chi-square.
N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

None

71

49.00 (30.00 – 63.00)

66.20

1.00 (0.00 – 4.00)

Rosacea

6

60.00 (47.00 – 68.00)

83.33

6.00 (1.00 – 11.00)

Dermatitis

1

24.00 (24.00 – 24.00)

100

1.00 (1.00 – 1.00)

Eczema

4

31.50 (27.00 – 56.00)

75.00

4.50 (2.00 – 8.50)

Acne

6

27.50 (23.00 – 39.00)

33.33

0.00 (0.00 – 1.00)

Sensitive Skin

23

46.00 (33.00 – 59.00)

78.26

2.00 (1.00 – 5.00)

Psoriasis

4

37.00 (29.00 – 45.50)

75.00

2.50 (0.00 – 5.00)

Multiple

4

36.00 (28.00 – 54.00)

75.00

5.00 (1.00 – 12.50)

Other

37

45.00 (22.00 – 60.00)

64.86

1.00 (0.00 – 8.00)

p = 0.07 (A)

p = 0.64 (B)

p = 0.54 (A)

The current study found participants who reported an underlying systemic medical
condition to have a significantly greater presence and quantity of DF (X2; p = 0.03 and
MWU: p = 0.01, respectively) (refer Table 19). However, on further analysis this was
significantly influenced by increasing age (MWU; p < 0.001).
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Table 19. Medical Conditions descriptives: age, prevalence and quantity Demodex
folliculorum. Age (median, IQR), Demodex folliculorum quantity (median, IQR);
A = Kruskal-Wallis: B = Chi-square. *Significant results highlighted in bold.
N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

No

93

37.00 (26.00 – 49.00)

63.44

1.00 (0.00 – 4.00)

Yes

63

61.00 (40.00 – 70.00)

74.60

3.00 (0.00 – 9.00)

*p < 0.001 (A)

*p = 0.03 (B)

p* = 0.01 (A)

3.5 Discussion
The overall prevalence of DF detected in the current study (67.99%) was in good
agreement with that previously reported in the literature. Similarly, Lee et al28 reported a
general prevalence of 70% in their demographic epidemiology study. Kabataş et al46
reported a prevalence of 67.2% in participants with blepharitis compared to 54.9% in
control participants. Roth77 described a general prevalence of 84% that increased to 100%
in participants over 70 years of age. The current study discovered a prevalence of 88.89%
in participants over 70 years of age.
Increasing age continues to be the most dominant risk factor for DF infestation.13,28,77
The current study is in agreement with those of previous studies regarding significant
associations between both presence and quantity of DF and increasing age. As mentioned
previously in Section 1.6.1, one potential reason for an increase in DF with age is the
continued, progressive colonisation of DF within the epidermal hair follicles and sebaceous
glands over the years. A second hypothesis is that changes in the skin and oil of older
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individuals may be more favourable to mite proliferation and widening of the follicle orifice
may make detection on mites easier in older individuals.201
The GHL questionnaire was developed to investigate potential correlations between
DF and certain lifestyle choices, such as the use of makeup and contact lens wear, and the
health status of participants. As mentioned earlier (Section 1.6.5), Elston and Elston79
suggested that men were typically more heavily infested than women, due to a greater
androgen–induced sebum production in men. The present study did find a higher prevalence
among men, although it was not significant (X2; p = 0.13). Elston and Elston79 also proposed
that the lipids in cosmetics may affect DF growth, and therefore could be responsible for
the lower presence of DF found among women. Similarly, Horváth et al116 studied the risk
factors of Demodex among young adults and also found that the use of makeup reduced the
likelihood of Demodex infestation. All makeup wearers in this study were women, and on
further analysis, when gender was taken into consideration, the difference between makeup
wearers and non-makeup wearers was not found to be significant. Given that 82.56% of
females wore makeup, and none of the males reported wearing makeup, it cannot be ruled
out that this influenced the slightly lower rate of DF infestation detected amongst females,
and higher rate of DF infestation detected amongst the males in the study population.
Previous studies have looked at the relationship between eye makeup usage and ocular
discomfort and found that the use of eye makeup, such as eyeliner and mascara, was
associated with ocular discomfort.202 However, to the best of the author’s knowledge, no
previous studies have been conducted on whether wearing eyeliner or mascara is
preventative or proliferative to DF infestation. The current study found a lower quantity of
DF amongst females wearing mascara. However, those that did not wear mascara were
older and would be naturally more pre-disposed to higher DF infestation rates. Therefore,
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further age and sex matched control studies would be warranted to investigate any potential
relationships. Theoretically, those that wear mascara may be more inclined to clean their
eyelids at night, thus reducing the numbers of DF present. On the other hand, wearing
makeup/mascara and not removing it could help harbour DF, thus increasing the risk of DF
proliferation. As mentioned in Section 1.5, previous studies have shown an association
between eyelid hygiene and Demodex infestation.13,28 However, the GHL questionnaire
questioned participants on the frequency of eyelid hygiene, and no significant association
was established between eyelid hygiene and DF infestation.
Contact lens wear is becoming an increasingly popular form of refractive correction.
Previous studies have found significant links between contact lens wearers and DF
infestation.114,115 As such, the GHL questionnaire included questions regarding contact lens
wear frequency and modality in order to further evaluate contact lens wear as a potential
risk factor for DF proliferation. Jalbert and Rejab114 investigated the relationship between
DF and contact lens wear; observing a higher density of DF among contact lens wearers. It
was suggested that contact lens wearers may be at a higher risk of DF infestation as they
handle their eyelids more frequently. However, the authors could not come to any further
conclusion on their finding as they were unable to establish any association between DF
infestation and other signs and symptoms of discomfort and DED.114 Conversely,
Tarkowski et al115 discovered greater quantities of DF amongst contact lens wearers with
discomfort, and previously successful contact lens wearers who dropped out due to
discomfort, compared to contact lens wearers with no comfort issues. Therefore, in contact
lens wearers who were previously comfortable, and begin to complain of discomfort, or
completely drop-out of contact lens wear as a result of discomfort; it is worth investigating
for the presence of DF and treating as required. In contrast to Jalbert and Rejab114, the
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current study demonstrated lower numbers of DF among contact lens wearers. However,
there were only 28 contact lens wearers involved in the study in comparison to 128 nonlens wearers, and furthermore, contact lens wearers were significantly younger than the
non-wearers. Thus, no real value could be taken from this finding. Further investigation
into the relationship between contact lens wearers and DF is warranted.
The GHL questionnaire also asked participants to report on frequency of cleaning bed
linen and temperature at which bed linen was washed and dried, in an effort to uncover
associations with DF. It was conceived that reduced frequency of cleaning bed linen, similar
to lid hygiene, would be associated with increased prevalence of DF. As the kill temperature
of DF is between 54-58 oC,197 it was also speculated that participants who commonly clean
their bedlinen at temperatures ≥ 60 oC would have a lower prevalence of DF. However, no
association was found between frequency of cleaning bed linen or temperature at which the
bed linen was washed and dried. Demodex folliculorum cannot survive outside of the human
body for longer than a few hours.40 Therefore, it is unlikely that they would survive on a
pillow case from one night to the next. Furthermore, cleaning bed linen at ≥ 60 oC is not
likely to impact DF infestation on humans, as they are unlikely to survive outside of the
body for prolonged periods of time.
The current study did not find any association between DF and skin conditions or
allergies. However, it has been well established previously in the literature that Demodex
mites are associated with many pustular skin conditions.54,70,75,81,82 Therefore, it is important
to consider Demodex when treating blepharitis in patients with a history of rosacea and
papulo-pustular skin conditions.
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There appears to be some discrepancy in the literature about the relationship between
DF and the health status of an individual. As mentioned previously in Section 1.5.3, several
studies have found an increased prevalence of DF among individuals with health
conditions: a weakened immune system,91–93 renal failure,24,108 diabetes.20,106,107 Several
case reports have found a high prevalence of DF causing rosacea like lesions in children
with leukaemia92,97 and adults with AIDS and HIV.71,93,94 The results of these case reports
suggest that an immune-deficient state favours increased numbers of DF. However, no
significant difference in density of DF between healthy and immunocompromised patients
has also been reported in the literature19,71; suggesting no significant relationship between
DF infestation and patient immune status. In an adult who is naturally going to have higher
density and prevalence of DF with time, it is difficult to quantify the contribution of a
reduced immune system to density/prevalence of DF. Participants were questioned about
systemic conditions such as high blood pressure, diabetes, and under-active thyroid. The
current study found participants who reported underlying systemic medical conditions to
be at a higher risk of increased numbers of DF; however, this was significantly influenced
by increasing age, and the number of participants with medical conditions was too low to
take any statistically relevant meaning from the results.
3.5.1 Limitations
The GHL questionnaire lacked a continuous structure throughout. Response items to
questions varied from two to seven choice responses. This affected the minimum sample
size required for statistical significance: higher numbers were required for the dichotomous
questions.203 While further investigation into the relationship between DF infestation and
for example; contact lens wear, makeup and lid hygiene is required, a new questionnaire
with a solid structure and less ambiguous questions would need to be constructed. The use
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of focus groups would be beneficial to check wording of questions during the design
process for future questionnaires. Due to the limitations outlined above, the GHL
questionnaire was not administered to participants in any of the subsequent recruitment
phases. Furthermore, changes to exclusion criteria, such as excluding participants with
underlying systemic conditions e.g. diabetes, meant the GHL questionnaire was no longer
suitable for the study cohort being represented.
3.6 Conclusion
The novel questionnaire demonstrated moderate to good reliability. Several findings
from the study would suggest possible associations that warrant further investigation: the
association between makeup, mascara, and contact lens wear.
Chapter 3 examined the relationship between DF and participant lifestyle choices, such
as contact lens wear and makeup usage; general day to day habits, such as eyelid hygiene
frequency and methods, frequency and temperature of cleaning bed linen; and underlying
systemic conditions, such as medical conditions, allergies or skin conditions. In practice it
is important to be aware of general risk factors for problematic DF infestation, such as
increasing age and rosacea. However, it is also important to be able to recognise symptoms
that may be more indicative of DF infestation. The next chapter, Chapter 40, will discuss
the development and validation of a modified OSDI symptom questionnaire; and will
examine it’s use in the detection of DF, and the association between DF infestation and
symptoms, in particular the symptom ‘itchy eyes’.
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CHAPTER 4: DEVELOPMENT AND VALIDATION OF A MODIFIED OCULAR
SURFACE

DISEASE

INDEX

SYMPTOM

QUESTIONNAIRE

FOR

THE

INVESTIGATION OF DEMODEX FOLLICULORUM BLEPHARITIS
4.1 Abstract
Purpose: To modify and validate the OSDI symptom questionnaire for use in the
examination of the relationship between DF infestation and ocular symptoms.
Methods: One hundred and fifty-six participants were enrolled in an epidemiological
cross-sectional prevalence study. Each participant completed the modified OSDI symptom
questionnaire. Participants were assessed for the presence and quantity of DF. Data was
analysed to examine any association between DF infestation and ocular symptoms.
Results: The overall prevalence of DF detected was 67.99%. The total median number
of DF detected was 1.00 mites (IQR: 0.00 – 5.00). Participants with DF were more
symptomatic (p = 0.04). The presence and quantity of DF was most significantly associated
with the symptom ‘itchy eyes’ (p = 0.03 and p = 0.04 respectively). The modified OSDI
questionnaire demonstrated good internal consistency (Cronbach’s alpha; α > 0.7) and good
reliability (Intra-class Correlation Co-efficient; ICC > 0.7). A positive symptom result using
the modified OSDI questionnaire exhibited a sensitivity and specificity of 70.75% and
46.00%, respectively.
Conclusion: Although not all participants with DF will become symptomatic, the
prevalence of DF was significantly associated with an increase in symptoms, in particular
the symptom ‘itchy eyes’. The newly developed modified OSDI symptom questionnaire is
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reliable for measuring change in symptoms over a period of time and is suitable for
monitoring patient self-reported outcomes in interventional treatment studies.
4.2 Introduction
Anterior blepharitis, MGD, aqueous deficient and evaporative dry eye, amongst other
ocular abnormalities, share similar symptoms involving the ocular surface: itchiness,
grittiness, inflammation, burning and foreign body sensations.13,49,204 This can cause
difficulties for practitioners, to distinguish between each condition, if screening patients’
based on symptoms alone. Furthermore, dry eye is a multifactorial disease, and the
symptoms of DED and ocular surface disease fluctuate, and often do not correlate well with
the degree of ocular signs present.205–207
As mentioned previously in Section1.7.4, individual symptoms reported by
participants, and the severity of those symptoms can fluctuate depending on the underlying
aetiology, and often, time of day.142 Blepharitis and MGD have been linked with symptoms
of foreign body sensation and sticky eyes, commonly in the morning; whereas participants
with aqueous deficient dry eye often report worsening of symptoms towards the evening.142
Previous studies have found itchiness to be one of the most frequently reported symptoms
associated with DF infestation.16,45–47 As suggested earlier (Section 1.6.4), this may be as a
result of the movement of the mites across the surface of the skin. As Demodex are most
active at night,54 this could potentially cause the severity of symptoms for participants
suffering with pathogenic DF infestation to worsen at night, or in the morning, subsequent
to the Demodex being most active.
Patient reported outcomes have an increasingly important role in clinical trials.208,209
Research has shown that observing patient reported outcomes after treatment is beneficial
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for examining the effect of treatment on the patients.209 In 2011, the International Workshop
on Meibomian Gland Dysfunction considered the significance of patient reported outcomes
in clinical trials. A recommendation was made to try to ascertain distinctive symptoms for
specific conditions: as the difficulty in discerning between symptoms of different anterior
abnormalities is a continuous challenge.210 The modified OSDI symptom questionnaire
was developed and validated, to assess the relationship between DF and dry eye symptoms.
The questionnaire’s ability to function as a diagnostic screener for DF blepharitis, and its
ability to detect change in symptoms post treatment were investigated.
4.3 Methods
4.3.1 Questionnaire Development
The modified OSDI symptom questionnaire was adapted from the validated OSDI
symptom questionnaire. The OSDI format was chosen as it has shown suitable repeatability
and validity for assessing the severity of dry eye.211 Furthermore, it is one of the most
commonly used symptom questionnaires that has been administered to participants in DF
related clinical trials.13,28,114 In keeping with Lee et al28, the questionnaire was modified to
incorporate questions connecting to blepharitis (itchy eyes and matter along the eyelid
margin), in order to augment the questionnaires sensitivity to detect DF. Questions from
several other validated dry eye questionnaires were also included: McMonnies (dryness,
burning), 5 – item dry eye questionnaire (DEQ-5) (dryness, watery), Standard Patient
Evaluation of Eye Dryness (SPEED) (dryness, burning sensation, watery eyes). Equally,
questions not found in previous dry eye questionnaires, such as itch and red eyes, were
included due to increased reports of such symptoms previously in the literature (refer
Appendix 4).13,49
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As recommended by Schiffman et al211, a formula was applied to calculate the
modified OSDI symptom score, described below; which in turn could be used to establish
severity of symptoms.
Total symptom number (A) x 25/number of questions answered (B).211,212
The OSDI symptom score is marked from 0 – 100: increasing scores indicating
increasing symptoms. Each question is marked on a 4 - point Likert scale, indicating
frequency of the symptom in question: 0 = none of the time, 1 = some of the time, 2 = half
of the time, 3 = most of the time, and 4 = all of the time. Since the formula takes into account
the number of responses, it is possible to use the formula to get OSDI values for the separate
sub-scales also.211 Questions from different sub-scales have also previously been merged
to produce separate sub-scores using the OSDI formula.213
To examine the relationship between DF and symptoms, the symptom results were
analysed in three ways: the presence of symptoms, the total modified OSDI score, and the
severity of symptoms. The presence of symptoms was described as asymptomatic or
symptomatic (irrespective of severity). The total modified OSDI score was calculated using
the formula described above. The severity of symptoms was categorised from the total
modified OSDI symptom score as shown in Table 20. This classification was based on the
minimal clinically important difference for the 12-item OSDI.214
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Table 20. Severity of symptoms in accordance with the total modified OSDI score.

Grade

Modified OSDI Score

G0: Asymptomatic

0 – 12

G1 Mild

13 - 22

G2: Moderate

23 - 32

G3: Severe

33 - 100

The modified OSDI questionnaire has been completed by all participants who have
taken part in the research project.
4.3.2 Questionnaire Validation
For a symptom questionnaire to be suitable and fit for purpose it must be reliable,
reproducible, and responsive and sensitive to change. That is to say, that any change in
symptoms ascertained by the questionnaire is genuine, and not as a result of poor
repeatability.121
The reliability and reproducibility of the questionnaire was calculated in two ways.
Firstly, Cronbach’s alpha (α) was used to determine the internal consistency of the
questionnaire. In keeping with the literature, an alpha value > 0.7 was accepted.215,216
Secondly, intra-class correlation co-efficient (ICC)217 and the test-retest method were used
to determine the inter-rater reliability of the questionnaire; p < 0.4 indicated poor reliability,
0.4 ≤ p ≥ 0.75 indicated fair to good reliability and p ≥ 0.75 indicated excellent reliability.218
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The test-retest method post-treatment for both a treatment group and a non-treatment
group was used to examine responsiveness and sensitivity to change. A two–tailed t–test
was used to compare the means between the two groups (p < 0.05 significance).
Factor analysis is a validation method used on questionnaires to determine if multiple
variables (questions) have similar response patterns, and therefore load onto similar subscales or ‘factors’. Factor analysis was conducted during validation of the original OSDI
and was found to have three factors or sub-scales: ocular symptoms, vision related functions
and environmental triggers.211 A factor analysis was applied to the modified questionnaire
to determine if the sub-scales of the modified OSDI questionnaire were similar to the
original OSDI. As the data was non-parametrically distributed, the ‘principal axis factoring’
extraction method was chosen.219 Principal axis factoring gives the least number of factors
that can account for the correlation within a set of variables. Cronbach’s α was then applied
to the overall questionnaire and to each subscale.
In distinguishing between normal subjects and ‘all dry eye’ subjects OSDI has
sensitivity and specificity values of 60% and 83% respectively.211 In distinguishing
between normal subjects and ‘severe dry eye’ subjects OSDI has sensitivity and specificity
values of 92% and 83% respectively.211 A receiver operating characteristics (ROC) curve
was constructed to establish the sensitivity and specificity of the modified OSDI symptom
questionnaire for the diagnosis of DF infestation.
4.3.3 Statistical analysis
Statistical analysis was performed using the SPSS (version 25.0). Data was assessed
for normal distribution using Shapiro-Wilk. All outcome measures investigated were
determined to have a non-normal distribution (p < 0.001). The data between categorical
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variables was assessed using X2. Between group data was assessed using the MWU test and
KW test where appropriate. Spearman’s correlation co-efficient was used to assess scaled
and continuous variables. All summarised continuous data was expressed as median and
IQR; p ≤ 0.05 was considered statistically significant.
4.4 Results
4.4.1 Questionnaire Validation
Factor analysis was applied to the results from the 156 participants who filled out the
questionnaire at least once, to determine if the sub-scales of the modified OSDI
questionnaire were similar to the original OSDI. Factor analysis of the modified OSDI
questionnaire displayed three sub-scales similar to the original OSDI questionnaire; ocular
symptoms, vision related function and environmental triggers (refer Table 21).211 Burning
sensation, discomfort in cold air and discomfort in air conditioned environments loaded on
more than one factor. This was potentially due to the multi-factorial nature of dry eye and
common crossover between symptoms and causes.
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Table 21. Factor analysis of the modified OSDI questionnaire.

Symptom

Ocular Symptoms

Dryness

0.53

Gritty/Irritated

0.70

Itchy

0.64

Red Eyes

0.55

Burning Sensation

0.40

Factor
Vision Related
Function

0.37

Photophobia
Watery
Lids Stuck
Together
Reading

Environmental
Triggers

0.34
0.64
0.21
0.72

Night Driving

0.52

Computer

0.75

Television

0.50

Wind

0.24
0.89

Cold Air

0.23

Air Conditioning

0.22

0.61
0.25

0.28

Extraction method: Principal axis factoring; Rotation method: Oblimin with Kaiser
normalisation; Kaiser-Meyer-Olkin measure of sampling adequacy: 0.78

Cronbach’s α was applied to each subscale, and to the questionnaire as a whole.
Cronbach’s α for the overall symptom questionnaire was good at 0.84, each of the subscales
had a slightly lower α value, but were still > 0.7 (Table 22).215,216
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Table 22. Reliability Analysis: Cronbach’s α measuring internal consistency, and
Intraclass correlation coefficient measuring repeatability for the questionnaire. Results are
shown for each sub-scale and for the overall questionnaire. All values > 0.7.
Internal
consistency:
Cronbach’s α (95%
confidence interval)
(n=156)

Test-retest: Intra-class
Correlation Coefficient (95%
confidence interval)
(n=50)

Ocular symptoms

0.74

0.83

Vision related
function

0.80

0.73

Environmental
triggers

0.83

0.89

Whole
questionnaire

0.84

0.90

Fifty separate participants, not enrolled in any interventional treatment study,
completed the questionnaire twice for the test-retest method to examine the reliability of
the questionnaire. Participants completed the questionnaire two weeks apart, at the same
time of day, with no change to their daily routines or general circumstances between testing.
The test-retest reliability of the questionnaire was established by calculating the ICC (refer
Table 22). All scores surpassed 0.7 which was the desired criteria to be met.218
For the test-retest reliability assessment, it is expected that a participant’s condition
remains stable between the first test and the retest: as no intervention has taken place. This
is clear from the strong ICC value ascertained for total symptom score of 0.90. Taking this
into account, a post-hoc ICC was performed to compare the repeatability of the total
symptom score after two weeks of treatment in a separate interventional treatment study. It
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was predicted that the correlation would be much weaker: as participants’ symptoms should
have changed since commencing treatment. This hypothesis was confirmed with an ICC =
0.66 < 0.89. A two-tailed t-test was applied to both sets of data. There was no significant
difference in total symptom score in the test-retest group (p = 0.54). However, there was a
highly significant difference in retest total symptom score in the group that received
treatment (p < 0.001). The placebo effect of receiving treatment must be taken into
consideration when assessing how effective treatments are at improving symptoms. This is
discussed in further detail in Chapter 6. However, with regards to validating the
questionnaire and evaluating its ability to measure change in subjective symptoms, the
placebo effect is considered extraneous.
The ROC curve was generated to assess the diagnostic capacity of the symptom
questionnaire to examine for the presence of DF (refer Figure 14). The red line illustrates
the ROC curve plotted from the study test results. Each point represents a
sensitivity/specificity pair relating to a specific decision threshold. The closer the curve
follows the y axis, especially towards the top, the greater the area under the curve and the
more accurate the test. The closer the curve comes to the diagonal dotted line, the less
accurate the test. The dotted line symbolises a worthless test result. A moderately flat ROC
curve was formed, with an area under the curve of 0.61. A positive symptom result, that is
≥ G1, gives a sensitivity of 70.75% and a specificity of 46.00% for the modified OSDI
questionnaire.
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Symptom Grade
1.00

True positive rate (Sensitivity)

0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
0.00

0.25

0.50

0.75

1.00

False positive rate (1 - Specificity)

Figure 14. Receiver operator characteristics curve demonstrates the ability of the
modified OSDI questionnaire to assess for presence of Demodex folliculorum using
symptom grade (Normal – Severe: 0 – 3). Area under the curve = 0.61.

4.4.2 Questionnaire Application
One hundred and fifty-six participants completed the questionnaire and were assessed
for the presence and quantity of DF. An overall prevalence of 67.99% DF was detected
amongst the study cohort. The median quantity of DF discovered, per participant, on
microscopic examination was median 1.00, IQR 0.00 – 5.00. There was no significant
difference in presence or quantity of DF between genders (p = 0.13 and p = 0.17,
respectively) (refer Table 23). There was a significant increase in prevalence with
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increasing age and symptoms (MWU; p < 0.001 and p = 0.05, respectively) (refer Table
23).
Table 23. Comparison of age and symptoms (presence and modified OSDI score) for
subjects with and without Demodex folliculorum. Age (median, IQR), Demodex
folliculorum quantity (median, IQR); A = Mann Whitney-U: B = Chi-square. *Significant
results highlighted in bold.
Demodex
Present

N

Age (yrs)

Prevalence
Symptoms (%)

Total Modified
OSDI Score (0-100)

No

54

29.00 (24.00 – 56.00)

54.00

13.33 (7.69 – 28.57)

Yes

102

49.00 (34.00 – 66.00)

70.77

20.83 (10.00 – 39.29)

*p < 0.001 (A)

*p = 0.04 (B)

*p = 0.05 (A)

Presence of Demodex folliculorum versus Symptoms:
As shown in Table 23 above, and in Figure 15 below, there was a significantly higher
proportion of symptomatic participants (≥ G1 modified OSDI symptom) amongst
participants with DF than those without DF (70.77% versus 54.00%, X2; p = 0.04). In
keeping with this, the total modified OSDI symptom score (0 – 100) was also found to be
significantly higher in participants with DF in comparison to participants without DF (refer
Table 23). Regardless of DF, symptomatic participants were also found to be significantly
older than asymptomatic participants (49.00, IQR 33.00 – 66.00 versus 35.00, IQR 24.00 –
57.00. MWU: p < 0.001).
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80
70.77%
70

Percentage

60
50

54.00%
46.00%

40
29.22%

30

Asymptomatic
Symptomatic

20
10
0
No DF

DF

Presence of Demodex folliculorum
Figure 15. Percentage frequency distribution of symptomatic and asymptomatic
participants, with and without DF. Participants with DF were significantly more
symptomatic (X2; p = 0.04).
The severity of symptoms (Grade 0 – 3) was also examined. Participants with DF were
found to have a significantly greater severity of symptoms than those without DF (X2; p =
0.04). As can be seen from Figure 16, this was most noticeable in the severe symptom
group. Participants without DF were predominantly asymptomatic, followed by mild to
moderately symptomatic, and only a small number (n = 7) were severely symptomatic. In
contrast, participants with DF were predominantly symptomatic; the majority of which
were severely symptomatic (n=35) (refer Figure 16). As can be seen from Figure 16,
46.00% of participants without DF were asymptomatic and only 14.00% had severe
symptoms. Only 29.24% of participants with DF were asymptomatic, however 32.07% had
severe symptoms. It is also evident that the majority of symptomatic participants with DF
were severely symptomatic.
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23.58

25

22.00

18.00

20

15.09

15

14.00

10
5
0

Asymptomatic

Mild

Moderate

Severe

Symptoms
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Figure 16. Percentage frequency distribution of grade of severity of symptoms
amongst participants with and without Demodex folliculorum (X2; p = 0.04).

The prevalence of individual symptoms reported by participants with and without DF
is shown in Table 24. A significant association was detected between the symptom ‘itchy
eyes’ and the presence of DF. ‘Itchy eyes’ was more commonly reported by participants
with DF than those without (68.88% vs 52.00%) (X2; p = 0.03). However, the frequency of
the symptom ‘itchy eyes’ was not found to be significantly associated with the presence of
DF (X2; p = 0.13). Overall participants with ‘itchy eyes’ were not significantly older than
those without ‘itchy eyes’ (KW; p = 0.83). However, participant’s with ‘itchy eyes’ and DF
were significantly older than those with ‘itchy eyes’ and no DF (KW; p < 0.001).
Asymptomatic individuals with DF were also older, but not significantly (KW; p = 0.30).
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Table 24. Prevalence of symptoms reported by participants with and without
Demodex folliculorum; *Significant results highlighted in bold.

Symptoms

Participants
with DF (%)

Participants
without DF (%)

P value (X2)

Gritty / Irritated

72%

70%

0.69

Itchy

69%

52%

*0.03

Dryness

68%

68%

0.88

Wind

57%

62%

0.46

Air Conditioning

55%

44%

0.25

Watery

53%

60%

0.35

Photophobia

45%

46%

0.96

Red Eyes

45%

40%

0.38

Computer

43%

40%

0.66

Cold Air

43%

30%

0.17

Problems Reading

42%

36%

0.30

Television

42%

12%

*< 0.001

Burning Sensation

28%

18%

0.14

Lids stuck together

21%

12%

0.18

Night Driving

19%

8%

0.06
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The functional vision symptom of ‘discomfort watching television’ was also found to
be significantly associated with the presence of DF (41.55% vs 12.00%) (X2; p < 0.001).
However, on further analysis, participants reporting symptoms of ‘discomfort when
watching television’ were found to be significantly older than those without those
symptoms (MWU; p = 0.01). Given that increasing age is one of the most significant risk
factors for DF infestation; as the symptomatic group were older, they were naturally
predisposed to having an increased presence of DF, and this is likely to have impacted this
finding.13,77
Quantity of Demodex folliculorum versus Symptoms:
As mentioned previously, the median quantity of DF discovered, per participant, on
microscopic examination was median 1.00, IQR 0.00 – 5.00. Although DF was detected on
asymptomatic individuals, the median number of mites was significantly higher amongst
symptomatic participants in comparison to asymptomatic participants (2.00 IQR 0.00 –
7.00 versus 1.00 IQR 0.00 – 3.00. MWU; p = 0.02). A low positive correlation was
established between quantity of DF and the total modified OSDI score; however, it was not
found to be significant (rs = 0.12; p = 0.13). However, a low, but significant, positive
correlation was ascertained between the quantity of DF and increasing severity of
symptoms (rs = 0.16; p = 0.04) (refer Figure 17).
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Correlation between Symptom Severity and
Demodex folliculorum

Symptom Grade (0-3)
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R² = 0.0078
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Quantity Demodex folliculorum

25

30

Figure 17. Scatter plot illustrating the positive correlation between symptom severity and
quantity of Demodex folliculorum (rs = 0.16; p = 0.04).
This correlation is expressed in the equation:
Y = 0.0267 X (number of DF) + 1.2565
According to the above formula, on average 1 DF mite = G1.28 symptoms: mild
symptoms. On average an additional 28 mites are required to cause moderate symptoms,
and an additional 38 mites (minimum 66 mites) are required to cause severe symptoms.
A small, but significant, positive correlation was also established between the quantity
of DF and the severity of ‘itchy eyes’ symptom (rs = 0.17; p = 0.04) (refer Figure 18).
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Correlation between severity of Itch and
Demodex folliculorum
Severity of Itch (0-4)

4
3
R² = 0.0149
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15
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Quantity Demodex folliculorum

25

30

Figure 18. Scatter plot illustrating the positive correlation between severity of ‘itch' and
quantity of Demodex folliculorum (rs = 0.17; p = 0.04).
Spearman’s correlation demonstrated an equation similar to the one above:
Y = 0.0264 X (number of DF) + 1.0552
Similarly, this equation proposes that 1 DF = G1.08 symptoms: ‘itchy eyes’ some of
the time. On average an additional 36 mites, respectively, are required to cause respective
increases in severity of symptoms. Thus, the above equations for severity of symptoms and
severity of ‘itchy eyes’ demonstrates that just 1 DF has the ability to produce mild
symptoms. However, due to the multifactorial nature of ocular surface disease, participants
can be symptomatic in the absence of DF, as has been seen previously.
A low, but significant, correlation was detected between increasing quantity of DF and
increasing ‘discomfort when watching television’ (rs = 0.16; p = 0.04). Additional analysis
demonstrated that this increase in quantity of DF was directly correlated to an increasing
age for the same symptom (rs = 0.24; p = 0.003).
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Time of day has been reported to have an effect on symptoms depending on the
underlying aetiology.142 However, in the current study, time of day did not appear to affect
symptoms with respect to DF. No other individual symptom was found to be significantly
associated with the presence or quantity of DF.
Pathogenic Infestation
Previous studies have proposed that the presence of DF is not necessarily pathogenic;
but that an increased quantity of DF causes pathogenic infestation.65,71 Incorporating the
severity scale proposed by Randon et al65, ≥ 4 mites per follicle, data was investigated to
look at the prevalence of pathogenic DF in the current study population; and any links
between pathogenic DF infestation and age and symptoms (refer Table 25).
Pathogenic DF infestation increased significantly with age. Participants with
pathogenic DF infestation were found to be significantly older than participants with nonpathogenic DF infestation (MWU; p = 0.01), and participants with no DF (MWU; p <
0.001). Furthermore, participants with non-pathogenic DF infestation were older than
participants with no DF (MWU; p = 0.07), but not significantly.
Participants with either pathogenic or non-pathogenic DF were found to be more
symptomatic than participants with no DF. Although the difference was not found to be
significant for either group (MWU; p = 0.08 and p = 0.12 respectively). Similarly, the
greatest prevalence of the symptom ‘itchy eyes’ was detected amongst participants with
pathogenic DF. However, when compared to participants with no DF, this was not found
to be significant (X2; p = 0.08).
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Table 25. Comparison of quantity of Demodex folliculorum, age, presence of symptoms, modified OSDI score, and presence of itch for
participants with; no Demodex folliculorum, mild/normal non-pathogenic infestation, and pathogenic infestation of Demodex folliculorum.
Continuous variables expressed as median and IQR. A = KW P value: B = X2 P value. *Significant results highlighted in bold.

No Demodex
folliculorum
Mild/Normal
infestation
(< 4 mites/follicle)
Pathogenic
infestation
(≥ 4 mites/follicle)
Mites visible on lash
manipulation but
not on microscope

Presence of
Symptoms
(%)

Modified OSDI
(0-100)

Presence of
Itch (%)

29.00 (26.00 – 46.00)

54.00

13.33 (11.67 – 23.22)

52.00

1.00 (1.00 – 2.00)

39.00 (35.00 – 52.00)

64.10

25.00 (15.00 – 35.00)

66.67

60 (38.5%)

8.00 (7.00 – 10.00)

52.50 (47.00 – 61.00)

75.00

20.00 (16.67 – 26.67

71.67

7 (4.5%)

0.00 (0.00 – 0.00)

44.00 (40.00 – 63.00)

71.43

18.33 (8.33 – 81.25)

57.14

*< 0.001 (A)

0.14 (B)

0.27 (A)

0.16 (B)

Frequency,
n (%)

Quantity mites, n

50 (32%)

0.00 (0.00 – 0.00)

39 (25%)

Age, yrs
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4.5 Discussion
There is continued debate over the pathogenicity of the Demodex mites.49,66–68 The
findings in this study are in agreement with previous authors29,30; that DF can be found
amongst asymptomatic individuals. The current study discovered a median number of 1.00
mites (IQR 1.00 – 3.00) amongst asymptomatic participants. As discussed earlier in Section
1.5, Lacey et al66 suggested that generally DF is a commensal organism with a potentially
beneficial role: consuming bacteria and other micro-organisms in the lash follicle. The
presence of DF in normal healthy individuals appears to strengthen this proposal. Baima et
al

67

proposed that DF becomes pathogenic to the host when quantities of DF increased

beyond a critical level. With regards to dermatology and density of DF in the skin, Forton
et al70 suggested that > 5 mites/cm2 was the critical level for pathogenic DF infestation.
With regards to the eyelash follicles, Randon et al65 suggested the critical level to be ≥ 4
mites per follicle. As demonstrated in previous studies13,28,46,47 and in the current study also,
there was a positive association between increasing symptoms and increasing densities of
DF; which adds to the suggestion that DF has pathogenic potential as the quantity of DF
present increases. Additionally, as will be discussed in Chapter 5, symptoms were found to
improve following treatment, further strengthening the case that the DF do have pathogenic
potential.
Sędzikowska et al47 recently published results of a large scale study exploring the
relationship between DF and presence of symptoms as stated by patients, without the use
of a questionnaire. The results proposed a minimum of seven DF mites per eight epilated
eyelashes was required to produce one symptom, and a further 18 mites were required to
produce a second symptom. In the same study, the authors did not quantify the severity of
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symptoms reported by patients: intermittent vs constant, sometimes vs all of the time;
merely the presence of the symptom.47 The present study examined the severity of
symptoms reported by patients using the modified OSDI questionnaire. Applying similar
statistical analysis to that applied by Sędzikowska et al47, the current study discovered a
greater quantity (33) of DF was required to produce moderate symptoms. Although the
results of both studies are in good agreement, that increasing quantities of DF cause
increases in symptoms, they are not directly comparable: Sędzikowska et al47 counted DF
mites on eight epilated eyelashes, whereas the present study counted DF mites on four
epilated eyelashes. As previously mentioned in Section 2.3.9 only four eyelashes were
epilated as most participants were requested to attend for multiple visits, and repeat tests
over time, thus increasing the number of eyelashes that needed to be epilated.
Although there is a positive correlation between symptoms and presence of DF, they
are not ubiquitous with one another. Participants can be symptomatic in the absence of DF;
and similarly, participants can be asymptomatic in the presence of DF. A prevalence of
67.99% DF was found in the current study. Of those with DF, 70.77% (75/106) had
symptoms (refer Figure 15). It is possible that chronic inflammation of the anterior ocular
surface caused changes in corneal morphology,220 leading to corneal hypoesthesia; thus
resulting

in

reduced

symptoms

in

the

presence

of

severe

infestation

and

inflammation.175,221,222 Therefore, subjectively reported symptoms are not always in line
with clinical signs of ocular surface disease; as was demonstrated in the present study. For
example, of the 106 individuals with DF, the quantity of DF discovered on microscopic
examination was similar between asymptomatic and symptomatic participants (3.00 IQR
1.00 – 7.00 versus 4.00 IQR 1.00 – 9.00 mites, respectively; MWU; p = 0.19). It is possible,
that chronic infestation and inflammation caused hypoesthesia at the ocular surface,
120

resulting in asymptomatic participants with increased quantities of DF. Although, as DF
inhabit in the eyelash follicle, the scuttling, scratching movement of DF would be expected
to cause an itching sensation: which would not likely be affected by corneal hypoesthesia.
It is more likely that not all DF were removed during lash epilation. This limitation of
eyelash epilation has been alluded to in previous studies.25,29,50 Throughout the present
study, it became apparent, particularly in cases where lashes were loose in damaged
follicles due to the presence of increased densities of DF, that the lash would fall away
during eyelash rotation: leaving the DF behind inside the lash follicle. Subsequently, further
investigation was conducted into the relationship between eyelash manipulation and
eyelash epilation techniques used during Demodex investigation. This is discussed in detail
in Chapter 8.
Individual symptoms commonly associated with DF have been reported previously:
itch, burning sensation, foreign body sensation, redness and crusts along the lid margins,
blurred vision and misdirection of eyelashes.6,13,15,16,46,47,49 In a study conducted by Koo et
al13 investigating the relationship between ocular discomfort and Demodex infestation, the
authors found dryness (74.7%), itching (42.78%), and irritation (39.1%) were the most
commonly reported symptoms described by participants with Demodex infestation. Kabataş
et al46 reported redness (80%), itching (63.6%) and foreign body sensation (55.6%) as the
most commonly reported symptoms in participants with DF infestation. Likewise,
Sędzikowska et al47 reported similar symptoms, but at lower prevalence values: itching
(28%), redness (21%), watery eyes (15%), and dryness (6%). It is not clear which symptom
questionnaire was used by Kabataş et al46, and Sędzikowska et al47 did not use a
questionnaire. Thus, symptom reporting was not prompted by the use of a questionnaire,
but depended on each participant complaining of a symptom of their own accord: the likely
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cause of the lower prevalence values reported in their study.47 The most common symptoms
reported by participants with DF in the current study were gritty–irritated eyes (72%),
followed by; itch (69%), dryness (68 %), watery (57%), photophobia (45%), red eyes
(45%), burning sensation (28%), and lids stuck together (21%). Several of these symptoms
were also commonly reported by participants that did not have any DF, and were not found
to be significantly associated with DF (refer Table 24). However, in keeping with previous
studies,16,46,47 the current study found that the symptom ‘itchy eyes’ was associated with
an increased presence of DF. Furthermore, one of the main and novel findings of the current
study was that the severity of ‘itchy eyes’ increased as the number of DF increased. This
further strengthens the basis for ‘itchy eyes’ as a significant symptom of DF infestation.
Dry eye is multi-factorial by nature and there can be discrepancy between signs and
symptoms of dry eye.223 The current study did not investigate the influence of non-dry eye
related symptoms. For example, the symptom ‘itchy eyes’ was also reported by many of
the participants who did not have DF. Itch is one of the hallmark symptoms of allergy. As
data collection took place over two years, it is possible that a history of allergy influenced
the severity of the symptom ‘itchy eyes’. However, chi-square analysis did not find any
significant correlation between the presence of allergy and the presence of general
symptoms, or symptoms of ‘itchy eyes’ amongst participants that did not have DF (X2; p =
0.79 and p = 0.09 respectively). The findings of the current study do not suggest that ‘itchy
eyes’ should be considered a diagnostic symptom of DF infestation; simply that ‘itchy eyes’
seems to be a more common and repeatedly reported symptom amongst participants
suffering with DF infestation. Furthermore, it is possible that the presence of the ‘itchy
eyes’ is in fact an allergic reaction to the presence of DF within the eyelash follicles, which
has been postulated previously.49,69
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A low, but significant, correlation was detected between increasing quantity of DF and
increasing ‘discomfort when watching television’. However, the total prevalence of
‘discomfort when watching television’ was low (32%), even amongst participants with DF;
and those that reported this symptom were significantly older. Therefore, it is likely that
the confounding effect of age – related dry eye changes contributed to this finding.
Nevertheless, presence and quantity of DF should still be considered as it is an age-related
change, and very few control participants reported discomfort.
The original OSDI questionnaire is one of the most commonly utilised symptom
questionnaires in DF related clinical trials.13,28,114 Results from the current study, and
previous studies outlined above, have established that a symptom of ‘itchy eyes’ is amongst
the most frequent complaint in participants with DF. However, no question exists on the
original OSDI to inquire about ‘itchy eyes’. Lee et al28 modified the OSDI questionnaire to
include a question on ‘itchy eyes’, and demonstrated that the overall OSDI score was
significantly associated with higher quantities of DF. Nonetheless, it was not clear if the
questionnaire modified and used by Lee et al28 had been validated. Therefore, the current
questionnaire was developed to include a question about ‘itchy eyes’ and has been validated
as discussed above. As such, the modified OSDI questionnaire was used to assess
symptoms in all the studies discussed in this thesis.
4.6 Conclusion
The novel modified OSDI questionnaire demonstrated good internal consistency
(Cronbach’s α was > 0.7 for both the total questionnaire and each of the subscales) and
good to very good repeatability (> 0.75) for both the total questionnaire and each of the
subscales in the test-retest ICC. The strong repeatability aspect of the questionnaire
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demonstrated that it can be employed as a valid method of observing subjective symptoms,
following treatment, over time in a clinical setting. This is progressively becoming more
important as patient reported outcomes become an essential element of patient-centred
management in the health sector.208
The questionnaire exhibited a reasonable sensitivity value of 70.75%, for correctly
detecting participants with DF infestation. However, with regards to confirming the
presence of DF infestation and establishing who requires further intervention, this would
not be sufficient. A thorough clinical work-up, involving eyelash manipulation, will always
be required for diagnosis but an awareness of risk factors for the disease will help
practitioners to better diagnose, treat and advise their patients.
The validation and use of the modified OSDI questionnaire have been published in
International Ophthalmology (refer List of Publications). A significant link was established
between the presence and quantity of DF, and severity of symptoms, using the modified
OSDI questionnaire that was developed during this research project. ‘Itchy eyes’ was
significantly associated with the presence of DF. In clinical practice it is important to
consider the presence of DF in patients reporting ‘itchy eyes’. As such, it would be
advisable to incorporate the modified OSDI questionnaire, or a similar questionnaire that
contains questions on symptoms of itch, when managing and treating anterior ocular
disorders such as blepharitis. Nonetheless, as mentioned previously, a detailed clinical
work-up is still necessary for differential diagnosis between various anterior ocular
disorders.
As with many anterior ocular disorders, subjective symptoms are often similar and are
not always present. As demonstrated in the current study, not all participants with DF were

124

symptomatic, even when infestation was apparently severe. The relationship between DF
infestation and corneal hypoesthesia requires investigation, including research into the
triggers that cause a patient to become symptomatic.
Although not all DF infestation is symptomatic, and not all DF infestation requires
intervention, it is important to be able to intervene in an effective manner when necessary.
The following chapter, Chapter 5, will discuss the results of a two-week pilot treatment
study and an extended four-week treatment study. The pilot study compared the efficacy of
OCuSOFT with baby shampoo for treating DF blepharitis. The four-week study compared
OCuSOFT, TTFW, and the effect of in-house microblepharoexfoliation treatment. The
four-week treatment study has been published in Contact Lens Anterior Eye, and is adapted
accordingly for Chapter 5.
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CHAPTER 5: THE EFFICACY OF BABY SHAMPOO, OCUSOFT LID SCRUB
PLUS,

DR.

ORGANIC

TEA

TREE

FACE

WASH

AND

MICROBLEPHAROEXFOLIATION IN THE TREATMENT OF DEMODEX
FOLLICULORUM BLEPHARITIS
5.1 Abstract
Purpose: To investigate and compare the efficacy of baby shampoo, OCuSOFT,
TTFW and microblepharoexfoliation at treating DF blepharitis.
Methods: A randomised, controlled, examiner blind, two – week interventional, pilot
study was conducted. Eighty-two eyes of 41 participants (21 male/20 female: median age
45.00 years) were examined for signs and symptoms of DF. Participants completed the
GHL and modified OSDI symptom questionnaires and were examined for the presence of
DF. Eight eyelashes, two from each eyelid, were manipulated and epilated for microscopic
examination. Adult DF count was recorded using the modified Coston method. Each
participant was given the treatment (OCuSOFT) for one eye, and a control lid hygiene (10%
solution baby shampoo) for the contra-lateral eye. Participants were advised to clean each
eye, using the relevant treatment, nightly for a fortnight.
Subsequently, 86 participants (38 males/48 females: median age 43.50 years) were
enrolled in a randomised, controlled, examiner blind, four-week interventional treatment
study. Participants completed the modified OSDI symptom questionnaire and were
assessed for the presence of DF. One eyelash from each eyelid, right and left, were
manipulated and epilated for microscopic examination, using the modified Coston method.
Participants were divided into three groups according to treatment: TTFW (A) (n=28),
OCuSOFT (B) (n=30), and in-house microblepharoexfoliation before nightly lid scrubs
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with OCuSOFT (C) (n=28). Participants were advised to clean their eyelids nightly for four
weeks with the specified treatment. Each participant was re-assessed for symptoms and
presence of DF after two weeks and four weeks of treatment.
Results: Demodex folliculorum was found on 61.00% of the 41 participants tested in
the pilot study. The overall total median number of DF per participant found pre-treatment
2.00 mites (IQR 0.00 – 8.00) There was no significant difference in quantity of DF pretreatment between the treatment and control groups (1.00 IQR: 0.00 – 3.00 and 1.00 IQR
1.00 – 4.00 respectively, p = 0.77). The quantity of DF was significantly reduced posttreatment to median 0.00 mites (IQR 0 .00 – 0.00) in the treated eye versus median 1.00
mites (IQR 1.00 – 2.00) in the control eye (p = 0.01). The presence and quantity of DF was
higher amongst symptomatic participants pre-treatment, but not significantly (p = > 0.05).
Demodex folliculorum was detected on 80.23% of the 86 participants tested in the
extended treatment study. The overall median quantity of DF found per participant pretreatment was 2.00 mites (IQR 2.00 – 5.00). There was no significant difference in quantity
of DF between the three treatment groups pre-treatment (p = 0.22). The quantity of DF
significantly reduced after four weeks of treatment in all three groups (p < 0.05). There was
no difference in efficacy between the three treatments at reducing quantity of DF (p = 0.50).
Subjective symptoms reported were significantly improved after two and four weeks of
treatment in all three groups (p < 0.05). There was no difference in efficacy between the
three treatments to reduce symptoms after two or four weeks (p > 0.50).
Conclusion: There was a relatively high prevalence of DF discovered amongst both
study cohorts. OCuSOFT applied nightly for two weeks significantly reduced the quantity
of DF found post-treatment in the preliminary study, but it did not eradicate the presence
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completely. Similarly, when treatment was extended to four weeks, all three methods tested
demonstrated good ability to reduce DF quantity, improve subjective symptoms and help
treat DF blepharitis. However, complete eradication was still not achieved. Baby shampoo
demonstrated no therapeutic effect on DF infestation and alternative treatment options
should be considered for the treatment of DF blepharitis.
5.2 Introduction
The structure and classification of DF has been described previously in Section 1.4.
As mentioned, DF are ubiquitous to human skin, feed on sebum and epidermal skin cells
and are therefore commonly found in larger quantities on the face: cheeks, nose, chin and
eyelashes.42,43,55 Although often considered a normal saprophytic component of our
biological flora and fauna,66–68 DF have also been noted as opportunistic parasites:
proliferating and causing inflammatory reactions in susceptible individuals.69 As such, DF
have been associated with inflammatory skin conditions such as rosacea,69,70,81 and
inflammatory eyelid conditions such as anterior blepharitis.7,43,46,49
Indications of ocular DF infestation reported in the literature include; CD, eyelash
abnormalities, anterior and posterior blepharitis, MGD, conjunctival and eyelid
hyperaemia, corneal superficial vascularisation and opacities.6,25,28,49,54,143 Symptoms of
ocular DF infestation are similar to dry eye symptoms; itch, irritation, redness, burning
sensation, visual disturbance.6,13,15,16,46,47 However, as was demonstrated in Chapetr 4 and
previously in the literature,25,49 not all patients with DF will be symptomatic. This can lead
to difficulties in deciding who requires treatment and when to begin.
Several of the risk factors associated with DF infestation have been discussed
previously in Section 1.6 and in Chapter 3. Age has consistently been found to be one of
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the most significant risk factors for the presence of DF infestation.13,28,77 Due to increasing
longevity, Demodex blepharitis in the elderly causing anterior eyelid abnormalities and
subsequent dry eye, ocular discomfort and ocular morbidity will increase, resulting in an
increased burden on the health system when patients seek treatment.121
To date, the majority of interventional studies have researched treatment of
Demodex skin infestation, with varying results.94,158–160,224–227 As mentioned previously in
Section 1.8.1, in recent years, researchers have found TTO to be effective at killing DF,12,53
and its use in treating DF blepharitis is expanding.6,13,15,228 It’s effectivity as a treatment is
undeniable, but it is not without its disadvantages. Even at the diluted concentration of 50%,
TTO is still toxic to the ocular surface. The College of Optometrists in the UK released
guidelines for the use of TTO in practice stressing that “daily lid scrub with 50% tea tree
oil … should be undertaken only by experienced practitioners as such preparations are
toxic to the ocular surface”.3 Increased chair time with specialist practitioners can be costly
to patients and or the governing health board. Also, the treatment experience can be
uncomfortable for patients. Additional studies have examined the efficacy of other antiparasitic medications, such as ivermectin and metronidazole, with varying reports of
success.34,36,38 However, the use of ivermectin and other systemic anti-parasitic drugs are
not without their complications,152–157 and may not be suitable for all patients.151 Alternative
therapies need to be available for those not suitable, or in countries were the drug has not
yet been licensed for human use.
There are many products available over-the-counter to consumers, marketed for the
treatment of blepharitis. However, a systematic review recently carried out by Lindsley et
al2 highlights the lack of knowledge and evidence based research available to clinicians
regarding the commercial products available and marketed for the treatment of blepharitis.
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The aim of the current study was to investigate the efficacy of different treatment methods
at reducing the quantity of DF. This was a patient-outcome focused, clinically relevant
study, with the potential benefit of being a more practitioner and patient friendly treatment
alternative to TTO. This study will provide evidence-based results on the performance of
commercial products available to patients and practitioners for the treatment of DF
blepharitis in a clinical setting; demonstrating that optometrists and ophthalmologists are
ideally placed to detect and begin first line treatment in many cases of DF infestation.
5.3 Methods
All participants were recruited through the National Optometry Centre, TU Dublin.
Written informed consent was obtained from all participants prior to enrolment. Participants
were eligible to participate if they were ≥ 18 years of age. Participants were excluded if
they; presented with ocular disease (apart from MGD and blepharitis), were currently using
blepharitis treatment or had used such treatment within the last six months or had ocular
surgery in the last six months.
5.3.1 Pilot Study
Minimum sample size required for statistical significance was calculated using
G*Power analysis. A priori analysis for repeated measures ANOVA between factors, two
groups two measurements, was conducted; alpha = 0.05, Power = 0.8, arbitrary effect size
= 0.5; minimum sample size required n = 26.
Fifty participants enrolled between October 2014 and March 2015. Following attrition,
41 participants completed the two-week treatment study. Each participant completed the
GHL and modified OSDI symptom questionnaires. Severity of subjective symptoms was
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graded according to the total modified OSDI symptom score (refer Table 20). Calculation
of the total modified OSDI symptom score, using the formula, has been discussed in detail
in Section 4.3.1. Slit lamp examination was conducted by one optometrist (the author:
Murphy, O). Clinical findings recorded were: conjunctival hyperaemia, MGD grade, CD,
and fluorescein TBUT. Tear break-up time was measured in seconds, approximately one
minute after the instillation of fluorescein. An average of three measurements was recorded.
Demodex investigation involved examining eight eyelashes, two from each eyelid, on a slitlamp biomicroscope (Topcon SL-D701, Topcon Medical Systems Inc., Dublin, Ireland).
Each eyelash was first manipulated (as described in Section 1.7.4) using sterile forceps and
was subsequently epilated for microscopic examination. Adult DF count was recorded
using the modified Coston method (described in Section 1.8.2).25
Each participant received a treatment pack containing both the treatment (OCuSOFT)
and a control lid scrub (10% baby shampoo) to use nightly for two weeks. In order to ensure
10% was used, vials with the exact measurement of shampoo were made up by the author
(Murphy, O) and instructions were given to patients on how to fill with water at home and
scrub the eyes (refer Appendix 5 (a)). The treated eye was randomised and blind to the
examiner. Participants returned following two weeks treatment and the process was
repeated and findings were recorded.
Following peer-review feedback received on the results of the pilot study, suggested
changes were incorporated, and the extended treatment study was developed. Firstly, the
study was extended to four weeks, to ensure sufficient time was given to tackle DF
infestation, given their lifespan is 14 – 18 days.40,42,43,61 Secondly, both eyes were treated
with the same treatment, to prevent cross-contamination through migration of DF from
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control eye to the treated eye. Thirdly, reviewers suggested comparing OCuSOFT to a tea
tree-based product (TTFW) as opposed to baby shampoo.
5.3.2 Extended Study
Minimum sample size required for statistical significance was calculated using
G*Power analysis. Effect size was calculated from the mean difference in quantity of DF,
pre and post treatment, from the treatment group in the pilot study and the SD of the pretreatment group. The pre-treatment group was chosen as it is representative of the
population not affected by experimental intervention: (2.32 – 0.66)/ 3.30 = 0.50. A priori
analysis for repeated measures ANOVA between factors, three groups two measurements,
was conducted; alpha = 0.05, Power = 0.8, effect size = 0.5; minimum sample size required
n = 33.
One hundred and six participants enrolled between May 2015 and May 2017.
Following attrition, 86 participants completed the four-week extended treatment study. As
with the pilot study, each participant completed the modified OSDI symptom questionnaire.
Participants underwent the same slit-lamp examination described above, and likewise were
examined for the presence of DF as previously described.
Participants were randomly divided into three groups according to treatment: TTFW
(Group A, n = 28), OCuSOFT (Group B, n = 30) and BlephExTM microblepharoexfoliation
device (Group C, n = 28). Each treatment has been previously discussed in detail in Section
2.4. Randomisation was achieved using the random number generator function on Excel.
Each treatment was randomly assigned a number from 1 to 108. Each participant chose a
number and was subsequently given the treatment assigned to that number. The examiner
(author; Murphy, O) was blind to the treatment throughout all stages of the study for Groups
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A+B. The examiner performed the BlephExTM treatment on participants in Group C and
was therefore not blind to treatment in this group.
The lid scrub routine was previously outlined in Table 6. In house
microblepharoexfoliation was carried out on Group C at the initial visit only. The procedure
was conducted as per manufacturer’s guidelines (refer Table 7). All participants returned
for a check-up appointment at two weeks and again for a final check at four weeks.
5.3.3 Statistical Analysis
Statistical analysis was performed using the SPSS (version 25.0). Data was assessed
for normal distribution using Shapiro-Wilk. All outcome measures investigated were
determined to have a non-normal distribution (p < 0.001). All summarised continuous data
was expressed as median and IQR. Between group data was assessed using the MWU test
and KW test where appropriate. Wilcoxon-signed ranks test (WSR) was used to analyse
within group data. The data between categorical variables was assessed using X2 analysis.
Spearman’s correlation co-efficient was used to assess scaled and continuous variables; p
≤ 0.05 was considered statistically significant.
5.4 Results
5.4.1 Pilot Study
Forty-one participants (21 males: 20 females) with a median age of 45.00 years
enrolled in the two-week pilot treatment study. At baseline, an overall prevalence of 68.23%
DF was found, with a median quantity of 2.00 mites (IQR 0.00 – 8.00) per participant
detected. Demodex folliculorum was discovered on 14 males (66.67%) and 11 females
(55.00%) (X2; p = 0.28).
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Table 26. Comparison of age, gender and symptoms for subjects with and without
Demodex folliculorum: Pilot Study. Age (median and IQR); A = Mann Whitney-U: B =
Chi-square. *Significant results highlighted in bold.
Demodex
Present
(n)

Age (yrs.)

Modified OSDI score
(0-100)

Presence
Symptom

No (n = 13)

27.00 (22.00 – 55.00)

10.00 (6.67 – 13.89)

40.63%

Yes (n = 28) 50.50 (45.00 – 59.00)

15.83 (11.67 – 21.67)

58.00%

*p = 0.02 (A)

p = 0.13 (B)

*p = 0.02 (A)

As can be seen in Table 26 above, participants with DF were significantly older than
those without (MWU: p = 0.02). Increasing age was also significantly associated with
increasing quantity of DF (rs = 0.44, p = 0.004). Figure 19 illustrates the positive

Quantity Demodex folliculorum (n)

relationship between increasing quantity of DF and increasing age.

Correlation between age and quantity of Demodex
folliculorum
25
20
15
10

R² = 0.1876

5
0
0

10

20

30

40

50

60

70

80

90

Age (yrs)

Figure 19. Scatter plot illustrating the positive correlation between increasing age and
increasing quantity of Demodex folliculorum.
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At baseline, participants with DF had a significantly greater modified OSDI score than
those without (MWU: p = 0.02). (refer Table 26). However, no significant correlation was
detected between increasing quantity of DF and increasing modified OSDI score (rs = 0.21:
p = 0.19). Likewise, there was no association found between quantity of DF and severity of
symptoms (KW: p = 0.38).
Bulbar conjunctival hyperaemia was graded using the Efron grading scale. Presence
and quantity of DF were not significantly associated with conjunctival hyperaemia (X2 p =
0.312 and rs = 0.074 p = 0.508). Most subjects with DF did have trace or mild conjunctival
hyperaemia; however, overall most subjects had trace or mild conjunctival hyperaemia
(refer Figure 20). A low positive correlation was detected between quantity of DF and
severity of conjunctival hyperaemia, but it was not significant (rs = 0.074 p = 0.508).

Presence of Demodex folliculorum (n)

Presence of Demodex folliculorum and Severity of
Conjunctival Hyperaemia
25
20
15
DF Negative

10

DF Positive
5
0
G0: None

G1: Trace
G2: Mild G3: Moderate
Conjunctival Hyperaemia

Figure 20. Bar chart illustrating the relationship between presence of Demodex
folliculorum and severity of conjunctival hyperaemia (X2 p = 0.312).
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As mentioned previously, CD has been established as a pathognomonic sign for DF.25
As expected, both the presence and quantity of DF were significantly associated with
increased severity of CD (X2: p < 0.001 and rs = 0.68: p < 0.001 respectively). Figure 21
illustrates the significant relationship between presence of DF and grade of CD. As can be
seen from Figure 11, the majority of participants without CD also had no DF, and ≥ G2 CD
was considerably associated with the presence of DF. The definition of CD severity grades

Presence of Demodex folliculorum

applied in the study can be seen in Table 4

Presence of Demodex folliculorum and Severity
of Cylindrical Dandruff
25
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DF Negative
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DF Positive
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G0

G1

G2

G3

G4

Cylindrical Dandruff

Figure 21. Bar chart illustrating the relationship between presence of Demodex
folliculorum and severity of cylindrical dandruff (X2 p < 0.001).

Figure 22 demonstrates the correlation between quantity of DF and severity of CD. As
can be seen from Figure 22, the quantity of DF increases significantly with increasing
severity of CD (rs = 0.68, p < 0.001).
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Figure 22. Box plot illustrating the relationship between quantity of Demodex
folliculorum and severity of cylindrical dandruff (rs = 0.68, p < 0.001).

Similarly, there was a significant relationship detected between presence and quantity
of DF and MGD (X2 p = 0.01 and rs = 0.23, p = 0.04 respectively) (refer Figure 23). There
was no significant relationship demonstrated between DF presence or quantity and TBUT
(MWU: p = 0.38 and rs = 0.11: p = 0.50 respectively).
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Figure 23. Box plot illustrating the relationship between quantity of Demodex
folliculorum and meibomian gland dysfunction (rs = 0.23, p = 0.04).

Other significant findings from the pilot study included: a higher quantity of DF
detected amongst participants who cleaned their bed linen more frequently (KW: p =
0.002), and a lower presence and quantity of DF amongst participants who wore makeup
compared to those that didn’t (X2 p = 0.03 and MWU p = 0.01) (refer Figure 24). However,
further analysis showed increasing age was a significant factor amongst those that wore
makeup and cleaned their bed linen more frequently, which is likely to have skewed that
result (MWU: p = 0.002 and KW: p = 0.03). No significant relationship was found between
frequency of eyelid hygiene and presence or quantity of DF (KW p = 0.77).
Figure 24 shows a box plot illustrating the quantity of DF amongst female makeup
wearers and non-makeup wearers. Males were excluded from this analysis as no males in
the study reported wearing makeup. Females who wore makeup demonstrated a lower
prevalence of DF infestation (45.22% versus 80.00%; X2: p = 0.05) and quantity of DF
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(median 0.00 IQR 0.00 – 2.00 versus median 4.00 IQR 3.25 – 6.00; MWU p = 0.006).
Participants who wore makeup were younger, but not significantly (47.00 years IQR 33.00
– 56.00 versus 57.00 years IQR 51.00 – 69.00. MWU: p = 0.07).

Figure 24. Box plot illustrating quantity of Demodex folliculorum found amongst
female makeup wearers and non-makeup wearers.

Each participant was given two treatments, OCuSOFT and 10% baby shampoo, one to
use on each eye nightly for two weeks, to assess the efficacy of each treatment against DF
infestation. Pre and post treatment results for DF quantity can be seen in Table 27. There
was no significant difference in mean number of DF pre-treatment between the treatment
and control eye. OCuSOFT demonstrated better efficacy at treating DF infestation than
baby shampoo (refer Table 27). The presence of DF pre-treatment in the OCuSOFT eye
was 65.85%. This dropped slightly to 51.22% post-treatment, but complete eradication of
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DF was not achieved. Baby shampoo had no impact on DF infestation. Presence of DF in
the baby shampoo cohort was 56.10% pre-treatment and 58.54% post-treatment.
Table 27. Quantity of Demodex folliculorum detected pre-treatment and posttreatment for each treatment group.

Quantity
Demodex
folliculorum

OCuSOFT

Baby shampoo

p - value

Pre

1.00 (0.00 – 3.00)

1.00 (0.00 – 4.00)

MWU p = 0.77

Post

0.00 (0.00 – 0.00)

1.00 (1.00 – 2.00)

MWU p = 0.01*

p - value

WSR p = 0.001*

WSR p = 0.71

5.4.2 Extended Study
Eighty-six participants (median age 43.50 years (IQR 29.00 – 63.50), 38 male:48
female) completed the four-week extended treatment study. Each participant completed the
GHL and modified OSDI questionnaires at baseline and were examined for signs of dry
eye and DF. At baseline, an overall prevalence of 80.23% DF was found, with a median
quantity of 2.00 mites (IQR 2.00 – 5.00) per participant detected.
There was no significant difference detected between presence or quantity of DF and:
contact lens wear (X2: p = 0.28 and MWU: p = 0.96, respectively), use of makeup (X2: p =
0.19 and MWU: p = 0.36, respectively), frequency of lid hygiene (X2: p = 0.26 and KW: p
= 0.16, respectively), frequency of cleaning bed linen (X2: p = 0.45 and KW: p = 0.39,
respectively), medical conditions (X2: p = 0.26 and KW: p = 0.12, respectively), allergies
(X2: p = 0.52 and KW: p = 0.58, respectively) or skin conditions (X2: p = 0.76 and KW: p
= 0.51, respectively).
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The relationship between prevalence and quantity of DF and type of lid hygiene is
shown in Table 28. As can be seen from Table 28, there was a significant difference in
prevalence and quantity of DF depending on the type of lid hygiene used. Bonferroni corrected
post-hoc analysis (p ≤ 0.05/28 = 0.0018) showed that only difference between J+J lid scrubs
and ‘other method’ was found to be significant (p = 0.001). However, there was considerable
difference in sizes and age between those two sub-groups which is likely to have had an impact
on results.
Table 28. Type of lid hygiene descriptives: age, prevalence and quantity Demodex
folliculorum: Extended Study. Age (median, IQR), Demodex folliculorum quantity
(median, IQR); A = Kruskal-Wallis: B = Chi-square. *Significant results highlighted in
bold
N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

None

24

51.50 (46.00 – 61.00)

87.50

3.00 (2.00 – 9.00)

Cleanser/
Toner

14

31.00 (26.00 – 43.00)

35.71

0.00 (0.00 – 1.75)

Makeup
Remover

7

44.00 (28.00 – 82.00)

100.00

1.00 (0.00 – 5.00)

Face
Wipes

6

61.00 (26.00 – 72.00)

100.00

5.00 (1.00 – 7.00)

J+J Lid
Scrubs

3

69.00 (69.00 – 69.00)

100.00

15.00 (9.00 – 17.00)

Other Lid
Scrubs

3

49.00 (39.00 – 81.00)

66.67

1.00 (0.00 – 21.00)

Other
Method

19

36.00 (31.00 – 57.00)

89.47

2.00 (1.00 – 5.00)

Multiple

10

34.50 (29.00 – 47.00)

80.00

5.50 (0.00 – 8.00)

p = 0.17 (A)

*p = 0.001 (B)

*p = 0.01 (A)
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The relationship between prevalence and quantity of DF and temperature bed linen
was washed at was also found to be significant (refer Table 29). Five participants reported
not knowing what temperature the bed linen was washed at, and they were removed from
analysis. As can be seen from Table 29, as the temperature increased, the prevalence and
quantity of DF decreased. However, Bonferroni corrected post-hoc analysis (p ≤ 0.05/3 =
0.0167) showed that none of the differences between the sub-groups were found to be
significant (smallest p = 0.018 30°C versus 60°C).
Table 29. Temperature bed linen washed descriptives: age, prevalence and quantity
Demodex folliculorum: Extended Study. Age (median, IQR), Demodex folliculorum
quantity (median, IQR); A = Kruskal-Wallis: B = Chi-square. *Significant results
highlighted in bold.
Temp (°C)

N

Age (yrs.)

Prevalence (%)

Quantity Demodex (n)

30

19

40.00 (31.00 – 61.00)

100.00

5.00 (3.00 – 11.00)

40

43

43.00 (39.00 – 57.00)

79.07

2.00 (2.00 – 5.00)

60

19

49.00 (33.00 – 58.00)

57.89

1.00 (1.00 – 5.00)

p = 0.93 (A)

*p = 0.01 (B)

*p = 0.048 (A)

Presence of DF was not significantly associated with grade of conjunctival hyperaemia
(X2 p = 0.62). There was a significant correlation detected between quantity of DF and
grade of conjunctival hyperaemia (rs 0.24 p = 0.03). As can be seen in Figure 25, quantity
of DF appears to be associated with moderate hyperaemia (G2) but not severe (G3).
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Figure 25. Box plot illustrating the relationship between quantity of Demodex
folliculorum and conjunctival hyperaemia (rs = 0.24, p = 0.03).

There was a significant correlation between quantity DF and increasing severity of CD
(rs = 0.61: p < 0.001) (refer Figure 26). There was also a significant positive correlation
between age and CD (rs = 0.37: p < 0.001).
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Figure 26. Box plot illustrating the positive correlation between cylindrical dandruff
and quantity of Demodex folliculorum (rs = 0.61: p < 0.001).

A significant correlation was also detected between quantity of DF and MGD grade (rs
p = 0.25: p = 0.03). This is illustrated in Figure 27 below. Increasing age was also
significantly associated with increasing grade of MGD (rs = 0.56: p < 0.001).
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Figure 27. Box plot illustrating the positive correlation between meibomian gland
dysfunction and quantity of Demodex folliculorum (rs = 0.25: p = 0.03).

Participants were then divided into three groups according to treatment (refer Table
30). Participants who did not have any DF were used as controls, therefore statistical
analysis on quantity of DF was only applied to individuals found positive for DF (n = 69).
Table 30. Number of participants with Demodex folliculorum and number of control
participants in each group.
Participants with DF
(n)

Control (n)

Total (n)

Group A: TTFW

22

6

28

Group B: OCuSOFT

24

6

30

Group C: BlephExTM

23

5

28
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Overall, the mean habitual logMAR visual acuity improved post-treatment (logMAR;
1.08 ± 0.26 at baseline, 1.13 ± 0.27 at two weeks, and 1.16 ± 0.26 at four weeks, Friedman’s
p = 0.02). Post-hoc analysis using WSR test, after alpha adjusted for Bonferroni correction
(α = 0.016), showed that only the difference between baseline and four weeks was
statistically significant (WSR p = < 0.001).
There was no significant difference in age between the three treatment groups.
However, DF positive participants in group A and group B were significantly older than
their respective control participants (refer Table 31).
Table 31. Age of participants with Demodex folliculorum and control participants in
each group. *Significant results highlighted in bold.

Participants
with DF
Control
MWU

Group A
TTFW (yrs)

Group B
OCuSOFT (yrs)

Group C
BlephExTM (yrs)

44.00
(39.00 – 67.00)
27.00
(25.00 – 28.00)

47.00
(37.00 – 57.00)
26.00
(26.00 – 67.00)

49.00
(33.00 – 67.00)
33.00
(23.00 – 58.00)

p = 0.01*

p = 0.01*

p = 0.21

KW
p = 0.99
p = 0.62

Overall, participants with DF had a higher modified OSDI score compared to those
without DF (median OSDI 26.67 IQR 20.83 – 35.00 versus 11.67 IQR 8.33 – 33.33, MWU:
p = 0.03). However, no significant correlation was detected between increasing quantity of
DF and increasing modified OSDI score (rs = 0.10 p = 0.35). Table 32 shows the breakdown
of symptoms in all three treatment groups over the duration of the study. Total modified
OSDI score reduced in all three treatment groups, however only Group B and Group C were
found to be significant (Friedman’s; p = 0.003 and p < 0.001, respectively). Nonetheless,
there was no significant difference in symptoms or quantity of DF between each treatment
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group at any visit over the duration of the study (Table 32). Results are for participants with
DF only.
Table 32. Participants with Demodex folliculorum: Severity of symptoms and
quantity of Demodex folliculorum in each group at baseline, two weeks, and four weeks.
Severity of symptoms: Total modified OSDI number (median, IQR). Quantity of
Demodex folliculorum (median, IQR). *Significant results highlighted in bold
Group A
TTFW

Group B
OCuSOFT

Group C
BlephExTM

KW

Symptoms
25.00 (10.00 – 36.67) 20.83 (11.67 – 33.33) 25.83 (18.33 – 33.33)

p = 0.84

Two weeks

12.08 (5.00 – 18.33)

8.33 (5.00 – 18.33)

11.52 (8.33 – 11.67)

p = 0.63

Four
weeks

12.02 (8.33 – 15.00)

8.33 (3.33 – 10.71)

8.33 (6.67 – 16.67)

p = 0.42

Friedman’s

p = 0.16

p = 0.003*

p = 0.001*

Baseline

2.00 (1.00 – 5.00)

1.50 (1.00 – 4.00)

3.00 (2.00 – 6.00)

p = 0.22

Two weeks

0.00 (0.00 – 2.00)

0 00 (0.00 – 3.00)

1.50 (0.00 – 3.00)

p = 0.70

Four
weeks

0.00 (0.00 – 2.25)

0.00 (0.00 – 3.00)

0.50 (0.00 – 2.00)

p = 0.49

Friedman’s

p < 0001*

p < 0001*

p < 0001*

Baseline

Quantity
DF

Although, overall, the majority of participants with DF were severely symptomatic:
asymptomatic (n = 18), mild (n = 12), moderate (n = 11), and severe (n = 28): no statistically
significant correlation was found between DF quantity and severity of symptom grade or
modified OSDI score at baseline visit (KW: p = 0.47 and rs = -0.08: p = 0.54). As can be
seen in Table 16; symptoms reduced progressively throughout the four weeks of treatment
in each group. For groups B and C the reduction in symptoms over the four weeks was
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significant. For group B post hoc analysis with WSR pairwise comparisons, α adjusted for
Bonferroni correction (α = 0.016), indicated that the improvement in symptoms was
significant between baseline and week two (p = 0.001) and baseline and week four (p =
0.001) only. For group C post hoc analysis indicated that the improvement in symptoms
was significant between baseline and week two (p < 0.001) and baseline and week four (p
< 0.001).
Table 32 also demonstrates the reduction in numbers of DF over the course of the
four weeks for each treatment group. Post-hoc analysis WSR test pairwise comparison,
after Bonferroni correction applied, revealed: Group A significant reductions from baseline
to week two (p = 0.002) and baseline and week four (p < 0.001), Group B significant
reduction from baseline to week four (p = 0.005), and Group C significant reductions from
baseline to week two (p = 0.002) and baseline to week four (p = 0.001). Similar to
symptoms, the quantity of DF did continue to decrease from two weeks to four weeks,
although the reduction in quantity between week two and week four was not significant
(WSR; A: p = 0.87, B: p = 0.94, C: p = 0.43).
Participants with DF were more symptomatic than participants in the control group.
However, although a significant correlation was found (X2: p = 0.005), it was concluded
that it was not a valid comparison due to the difference in sample size between the two
groups. Furthermore, participants with DF were significantly older than control
participants, and the impact age has on dry eye symptoms has been well established.144 This
is a confounding factor; therefore it cannot be assumed that the increased symptoms
witnessed amongst participants with DF were as a result of DF alone.
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There was no significant difference in control participants’ symptoms at baseline
between the three groups. There was no significant change in control participants’
symptoms after treatment in group A and group C (Table 33). Group B did demonstrate a
significant reduction in symptoms post treatment over time (Friedman’s p = 0.02).
However, due to the small sample size, it is difficult to take any relevance from this finding
at present.
Table 33. Control participants: Severity of symptoms in each group at baseline,
two weeks, and four weeks. Severity of symptoms: Total modified OSDI number
(median, IQR). *Significant results highlighted in bold.
Group A
TTFW
(n = 6)

Group B
OCuSOFT
(n = 6)

Group C
BlephExTM
(n = 5)

7.50
(5.00 - 31.67)
7.50
(3.33 – 15.00)
7.50
(1.67 – 15.00)
p = 0.28

10.00
(5.00 – 33.33)
5.28
(1.67 – 13.33)
3.33
(0.00 – 26.67)
p = 0.02*

13.33
(11.67 – 33.33)
8.33
(3.33 – 21.67)
8.33
(0.00 – 35.00)
p = 0.17

KW

Symptoms
Baseline
Two weeks
Four weeks
Friedman’s

p = 0.89
p = 0.97
p = 0.86

5.5 Discussion
A reasonably high prevalence of DF was detected in both the pilot and extended study
groups (61.00% and 80.23%, respectively), which is in good agreement with previous
studies.28,46,77 The overall median number of DF detected, per participant pre-treatment,
was very similar between the two study groups (2.00 mites IQR 0.00 – 8.00 and 2.00 mites
IQR 2.00 – 5.00 for the pilot and extended study respectively). As has been mentioned
previously, the accepted consensus at present is that Demodex in low numbers are a normal
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part of our microbiological flora and fauna.66,229 However, when quantities of Demodex
begin to proliferate, and the density of the mites increases beyond a critical density,65,71
Demodex adopt a pathogenic role and can cause skin and ocular abnormalities. No
significant relationship was detected between DF and skin conditions or allergies in either
the pilot study or the extended treatment study: however, there were very few participants
with skin conditions that took part to get statistically relevant results.
Increased quantities of DF have been associated with blepharitis,7,43,46,49
chalazia,26,230,231 corneal disturbance6,143 and an increase in symptoms.13,28,46,47 Similarly,
both the pilot and extended studies, found significant associations between DF and
increasing severity of CD, MGD and symptoms: adding further evidence to the
pathogenicity of Demodex. Age was associated with increasing severity of CD and MGD.
Cylindrical dandruff has been shown to be a bi-product of increased quantities of DF, and
it is likely that age is not an influencing factor in this finding,25,189 Age-related changes to
the meibomian glands contribute to MGD,210 and increasing age has also been repeatedly
associated with increased quantities of DF.13,28,77,78 As such, it is not possible from the
results of the current studies to say whether the higher quantities of DF detected amongst
subjects with MGD were as a result of participants with MGD being older, or if MGD alone
is a risk factor for increased quantities of DF. Future studies should be age and sex-match
controlled to avoid this.
Although the presence of DF was found to be significantly associated with increasing
severity of symptoms, and the majority of participants with DF were found to be
symptomatic, no correlation was detected between increasing quantity of DF and increasing
symptoms in either the pilot or extended study. Again, age may be an influencer on this
result144: it may be age-related dry eye that is causing the symptoms and not just DF.
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However, treatment administered to reduce the quantity of DF significantly improved
symptoms to normal levels; even though complete eradication was not achieved. In the
extended study, the majority of control participants were asymptomatic, and treatment did
not significantly reduce modified OSDI score. This adds further support to the theory that
lower quantities of Demodex may be considered normal and of no immediate concern.
Furthermore, as symptoms improved to normal levels in the absence of complete Demodex
eradication; it could be argued that the aim of treatment does not need to be complete
eradication, and that treatment could be considered successful when Demodex density is
returned to normal levels.
As mentioned previously in Section 1.1, lid hygiene, using a ‘variety of measures’, is
the first line management recommended by both the AAO and College of Optometrists,
regardless of the type of blepharitis.1,3 The aim of lid hygiene is to reduce the bacterial load
at the eyelid margin, helping to improve signs and symptoms associated with blepharitis.3
Lid scrubs with diluted concentrations of baby shampoo have been the longstanding ‘goto’ treatment for practitioners to advise their patients to use for regular home management
of blepharitis. It is not entirely clear where baby shampoo as a treatment for blepharitis
originated. However, in 2018, Sung et al186 demonstrated that baby shampoo has a negative
effect on goblet cell density, and thus could be more damaging to the tear film and ocular
surface than therapeutic. Currently the AAO still recommend baby shampoo, or other
dedicated cleansing pads, as first line management for blepharitis,1 but the College of
Optometrists have removed it from their clinical management guidelines in their most
recent review.3 At the time this study was conducted, the effect of baby shampoo on goblet
cell density had not been established, and it remained on the recommended guidelines for
practitioners. Furthermore, investigation into the comparative efficacy of different lid
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hygiene measures had been recommended.2 Gao et al12 found that the survival time of DF
in 50% baby shampoo solution was > 150 min, and patients treated with baby shampoo lid
scrubs for up to 350 days showed no significant change in DF quantity. The results from
the pilot study demonstrated a similar inadequacy by baby shampoo to treat Demodex
blepharitis. There was no reduction in quantity of DF achieved on the eye treated with baby
shampoo, compared to a significant reduction in quantity of DF achieved on the eye treated
with OCuSOFT.
A ‘variety of measures’ now exist for the treatment of blepharitis.3 Over-the-counter
eyelid cleansers for blepharitis have become available in recent years, but little evidence as
to their ability to treat the condition currently exists.2,3 OCuSOFT is marketed as a product
for moderate to severe blepharitis sufferers, with bacterial/Demodex involvement. The
active ingredient for killing DF used in OCuSOFT is 1,2-Octanediol. As mentioned in
Section 2.3.2, 1,2-Octanediol is a surfactant with antimicrobial abilities. Burgess et al187
investigated the efficacy of 1,2-Octanediol at treating head lice infestation, and
demonstrated that a 5% solution of 1,2-Octanediol, left on for eight hours over night,
effectively eliminated an established head louse infestation, with an 80% cure rate after
only one use. Observations from the same study demonstrated that lower concentrations of
1,2-Octanediol solutions (1%) also killed head lice, but at a slower rate.187 It was proposed
that the chemical disrupted the cuticular lipid of the lice, causing them to become
dehydrated and die.187 It has been established previously that DF die when they become
dehydrated.40 Thus, it is possible that this proposed method works similarly on Demodex.
The effect of pediculicides is not always instantaneous and subsequently some microorganisms may survive long enough to lay eggs following treatment. Burgess et al187 also
found that 5% 1,2-Octanediol reduced head lice egg laying. However, previously laid eggs
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were unaffected, and could potentially survive to start a new infestation.187 OCuSOFT
formula contains a 0.5% concentration of 1,2-Octanediol to ensure the product is nonirritating, yet still effective when used repeatedly for a period of time. As the formula is
non-irritating, this promotes better participant compliance and willingness to use the
treatment over multiple uses. The pilot and extended study both found that OCuSOFT was
effective at reducing quantity of DF over both a two- and four-week period. Even after four
weeks, complete elimination was not achieved. As the treatment does not appear to effect
previously laid eggs, it is conceivable that these eggs hatched to give rise to the next
generation. Additionally, complete coverage is required to be effective. If coverage by an
applicant is incomplete, some DF mites may survive to lay and hatch more DF: although
with continuously reducing quantities. However, Burgess et al187 also specified that with
5% 1,2–Octanediol egg laying was completely inhibited and previously laid eggs did not
mature to hatch. It is possible that 0.5% 1,2-Octanediol does not have the same toxic effect
on eggs. Likewise, Burgess et al187 investigated efficacy on head louse and not Demodex.
Although both are ectoparasites, no study could be found that compared the similarities and
differences between the two. Furthermore, as mentioned earlier, complete eradication may
not be necessary for successful treatment.
In recent years, TTO and ivermectin have emerged as the go-to-treatment options for
Demodex blepharitis.6,12,13,15,34,36,38 As mentioned in Section 2.4.3, it has been established
that terpinen-4-ol is the active ingredient in TTO effective at killing DF in a dose dependent
manner.12,53 Several studies have found that 50% TTO applied weekly is effective at
reducing DF infestation,6,13,15 and even at as low a concentration as 5% TTO is effective at
killing Demodex when applied twice a day.35 Although application of 50% TTO is the
recommended treatment for Demodex blepharitis,1,3 the disadvantages of this (ocular
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irritation and toxicity) have been discussed in detail in Section 2.4.3. Following feedback
from the pilot study, the aim was to incorporate a tea tree-based treatment that could
potentially serve as a good alternative to baby shampoo. Hence, the extended study
investigated the efficacy of nightly lid scrubs with TTFW for the treatment of DF
blepharitis. The TTFW used in the current study had a 38% concentration of terpinen-4-ol
and has shown to effectively reduce DF count over a four-week period. The extended study
focussed on the use of TTFW as a treatment for blepharitis; as such, participants only
scrubbed their eyelids. However, the TTFW can be used on the entire face; theoretically
providing the ability to treat DF, if present, on the facial skin also. Furthermore, if Demodex
on the face are also being treated, this reduces the risk of migration of mites back to the
eyelashes again following topical treatment. The results of the extended study show that
TTFW was effective at reducing signs and symptoms of Demodex blepharitis. An
advantage of TTFW is that it can be applied at home as part of a routine facial cleaning
regime, and does not require experienced practitioner application, thus reducing chair time
and cost for the patient. However, irritation was still a factor with the TTFW, which could
impact patient compliance in the long run.
The extended study also included a third treatment group: BlephExTM was used as an
adjunct therapy with OCuSOFT for Group C. BlephExTM lid scrub was given to participants
in-office before they began nightly home lid scrubs with OCuSOFT, similar to the way 50%
TTO lid scrubs were performed in office for participants in previous studies.6,13,15 The aim
was to incorporate the BlephExTM in an effort to help reduce the bacterial load prior to
commencing home lid scrubs. The results of the extended treatment study found the greatest
reduction in DF quantity and greatest improvement in symptoms in the BlephExTM group.
Even among the control participants who had no DF, they reported a significant
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improvement in symptoms after two weeks. The authors’ postulate that this is as a result of
the scrubbing and exfoliation action of the BlephExTM; which leaves the eyelids feeling
completely cleaned and refreshed regardless of the presence or absence of ocular disease.
5.5.1 Limitations
A strength and limitation of the pilot study was that treatment was administered to only
one eye. This allowed age and sex-match control for treatments and kept compliance of
treatment and control the same. However, it did not prevent the possibility of crosscontamination of DF from the control eye to treated eye. Secondly, treatment was
administered for a two-week period initially, which is slightly less than the lifespan of DF
(14 – 18 days). This time frame was chosen as the first follow up for participants as the aim
of the study was to find an effective treatment for Demodex blepharitis that can be easily
administered and managed by optometrists in practice. Treatment non-compliance is an
issue affecting efficacy of treatments in all facets of the medical profession.232 As such, the
treatment protocol was chosen to be easy to follow, as non-time consuming as possible in
order to fit in with daily routines, and a short duration to help improve compliance. This is
a realistic working timeframe for practitioners to administer and patients to use in practice
with good compliance. A third comment made by peer-review was the lack of a tea treebased treatment for comparative purposes.
The extended study attempted to account for these limitations and improve on them.
Treatment was applied to both eyes, treatment duration was extended to four weeks, and
TTFW was incorporated as a comparative treatment. However, the extended study was not
without its own limitations. One such limitation of the extended study is that the group of
control participants was a much smaller and younger group than the participants with DF
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(Table 30). As a result, no comparisons have been made between the two groups with
regards to symptoms. Given the unequal sample sizes, and the association between dry eye
and increasing age, it was concluded that it would not be a valid comparison. To completely
understand the relationship between DF infestation and symptoms, and the effect of
treatment on those symptoms, future study cohorts should be age and sex – matched
controlled.
It should also be noted that in both studies, the quantity of DF among some participants
with DF pre-treatment was recorded as zero. As mentioned previously, a limitation of
eyelash epilation is that sometimes DF remain within the follicle and are not removed with
the eyelash, although the DF tails are clearly visible on slit lamp examination. This occurred
mainly in highly infested damaged follicles where the lashes were loose. As a result, an
accurate account of DF quantity that reflects severity of infestation is difficult to achieve
from eyelash epilation and microscopic counting alone. Mastrota50 describes eyelash
rotation as an alternative technique to eyelash epilation to confirm DF infestation. This
finding prompted investigation into incorporating eyelash manipulation to help accurately
diagnose the severity of infestation and thus provide better information clinically to
practitioners, in order to understand and know who and when to treat. This is discussed in
detail in Chapter 8.
None of the treatment methods tested in both the pilot and extended treatment study
fully eradicated DF in all participants. Potential reasons for this could be; the duration of
treatment, frequency of application, participant compliance, and migration of DF.
Participants scrubbed their eyelids nightly for two to four weeks. This may be too short a
time frame to treat generations of DF. Similarly, treatment was only applied once a day, at
night, and may be more successful if applied in the morning also. Furthermore, it is possible
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that participants did not follow lid scrub instructions carefully, which could impact efficacy
of treatment. Future studies could monitor compliance by requesting participants to return
empty and/or unused treatments at the end of the study. Finally, DF can reside in other hair
follicles on the face and body, not just the eyelashes. Therefore, it is possible that DF may
have migrated back to the eyelashes from other locations; hence, total eradication of DF
may not be possible using a local treatment.
5.6 Conclusion
These studies have demonstrated that nightly lid hygiene with both OCuSOFT and
TTFW

are

effective

at

reducing

DF

quantity

and

symptoms.

In-house

microblepharoexfoliation has a greater impact on symptoms. Baby shampoo has no
therapeutic effect on quantity of DF and can be considered ineffective for the treatment of
Demodex blepharitis. The current study provides evidence-based results for the use of
commercial products available for the treatment of DF blepharitis in a clinical setting.
The safety of using these products on the ocular surface has not been fully investigated.
The following chapter examines the effect of OCuSOFT, TTFW and baby shampoo on the
tear film and ocular surface.
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CHAPTER SIX: THE EFFECT OF LID HYGIENE ON THE TEAR FILM AND
OCULAR SURFACE
6.1 Abstract
Purpose: To evaluate the effect blepharitis lid cleansers have on the tear film and
ocular surface, and to examine the prevalence of DF in a young population.
Methods: Forty-eight university students completed a randomised, controlled,
investigator-masked, eight-week clinical trial. Three eyelid hygiene products were
investigated: blepharitis eyelid cleanser (OCuSOFT® Lid Scrub® PLUS foam), diluted
baby shampoo (10% Johnson’s® No More Tears®) and a TTFW (dr.organic®). Cooled
boiled water was used as a control. Participants attended for four visits: baseline, two
weeks, four weeks and eight weeks. At each visit, subjective symptoms, NITBUT, and
ocular surface staining were assessed to evaluate any positive or negative effect on the tear
film and ocular surface. DF investigation involving eyelash manipulation and epilation was
conducted to examine for the presence and quantity of DF. Osmolarity was measured at
baseline and week eight only.
Results: The overall prevalence of DF found at baseline was 14.60%. Subjective
symptoms improved in all groups, including control. There was no significant difference in
mean osmolarity between the groups or within each group after eight weeks. There was a
significant increase in osmolarity inter-eye variability in the baby shampoo group (p =
0.03). There was no significant change in NITBUT or ocular surface staining after eight
weeks of eyelid hygiene.
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Conclusion: A low prevalence of DF can be found in a young student population. All
blepharitis lid cleansers used in the current study demonstrated subjective improvement in
symptoms, with no negative effects on TBUT or ocular surface staining. OCuSOFT and
TTFW revealed no adverse effect on mean osmolarity or inter-eye variability. Baby
shampoo did not cause a significant increase in mean osmolarity, but demonstrated a
significant increase in inter-eye variability, signifying a possible increase in ocular surface
inflammation.
6.2 Introduction
Blepharitis has been previously defined and classified in Section 1.1 and Section 1.7.2.
This chronic inflammatory process at the eyelid margins has been shown to disrupt tear
film stability, causing ocular surface irritation and dry eye.233 Despite the relatively high
prevalence of blepharitis in ophthalmology and optometry clinics, the exact aetiology
remains unknown, and there is still no ‘cure’ for chronic blepharitis.2 As discussed above
in Chapter 5 (Section 5.5), lid hygiene remains the first line treatment for anterior
blepharitis,1,3 and manufacturers are increasingly developing lid scrubs and washes for
practitioners to recommend and distribute to their patients. At present there is no ‘one-forall’ treatment for blepharitis. Antibiotics have shown good efficacy against bacterial
blepharitis,1,2,234 antifungals against seborrheic blepharitis,235–239 and TTO and antiparasitic therapy have demonstrated notable ability to treat Demodex blepharitis.15,35,52
OCuSOFT and TTFW are two of the over-the-counter treatments that were used in the
pilot and extended treatment studies (refer Chapter 5) and have shown good efficacy at
treating Demodex blepharitis.52 The active ingredients and potential toxicity of each product
has been previously described in Section 2.4.2and Section 2.4.3 respectively. Although at
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higher concentrations, terpinen-4-ol and 1,2-octanediol are considered toxic to the ocular
surface,3,150 their therapeutic abilities has meant that these chemical compounds have been
incorporated into eyelid cleansers at lower concentrations reducing the risk of toxicity:
TheraTears® SteriLid® (terpinen-4-ol: 0.02 mg/ml = 0.002%), Cliradex® (terpinen-4-ol:
4.61 mg/ml = 0.461%), OustTM Demodex® SwabstixTM (terpinen-4-ol: 0.29 mg/ml =
0.029%) and OCuSOFT® Lid Scrub® PLUS (1,2-octanediol: 0.5%).52,240 Several recent
studies have investigated the safety and tolerability of these eyelid cleansers.186,241,242
However, TTFW contains 38% terpinen-4-ol, and the impact of using such a high
concentration of terpinen-4-ol close to the ocular surface has not been established.
As listed above, many blepharitis products are currently available for practitioners to
recommend to their patients. However, as previously mentioned in Section 2.4.1, although
baby shampoo has been shown to have a negative effect on goblet cell function,186
practitioners still routinely recommend patients to use the ‘traditional’ method of a mild
dilution of baby shampoo for eyelid hygiene in the treatment of blepharitis.
The ocular surface comprises of the combination of the cornea, conjunctiva, lacrimal
glands, meibomian glands, eyelashes, eyelids and nasolacrimal duct.243 The tear film
lubricates the ocular surface, protecting it from foreign pathogens, maintaining a
homeostatic environment, preventing infection and inflammation and providing a clear
smooth refractive surface for vision.244 The migratory effect of substances applied near the
eyelid margins, such as makeup, to the tear film has been well established.245–249 Topical
products used for eyelid hygiene to treat blepharitis, inevitably come in close contact with
the ocular surface. However, to the best of the authors knowledge, the effect the products
have on the tear film and ocular surface has not been clearly established.
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Therefore, it is important to investigate the effects products have on the ocular surface,
to help inform practitioners in clinical practice. The primary aim of the current study was
to examine and compare the effect of home use lid hygiene products on the ocular surface
and tear film parameters. A secondary aim of the study was to investigate the prevalence of
Demodex blepharitis in a young population.
6.3 Methods
This was a single-centre, interventional, randomised, controlled, examiner masked
clinical trial. All participants were students recruited from the Department of Optometry in
TU Dublin.

Written informed consent was obtained from all participants prior to

enrolment.
Power calculations were made with osmolarity as the designated outcome. Effect size
was calculated with G*Power analysis using mean + SD of baseline osmolarity values of
the three groups used in the MGD warm compress study (discussed in Chapter 8). Effect
size computed was 0.518. Minimum sample size required for statistical significance was
calculated using G*Power analysis. A priori analysis for repeated measures ANOVA
between factors was conducted; alpha = 0.05, Power = 0.8, effect size = 0.5; minimum
sample size required n = 32: 8 participants per group.
Fifty-six participants in total, 14 per group, were enrolled from February to October
2018. Following attrition, 48 participants, completed the two-month treatment study. In an
effort to avoid confounding effects of age on tear film and ocular surface parameters,250
participants aged between 18 – 24 years were included. Participants were excluded if they
were using any systemic/topical medications known to affect the eyes (including artificial
tears), had used any blepharitis treatment or had ocular surgery within the previous six
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months. Contact lens wearers could take part, however, participants were required to wear
their spectacles on examination days.
Participants attended the National Optometry Centre for four visits in total: baseline,
week two, week four, and week eight. Ocular surface parameters were investigated at each
visit to note any changes over time with treatment. The exception was osmolarity, which
due to the associated costs was only performed at baseline and week eight only.
All examinations were performed in the following order at each visit, from least
invasive to most invasive170,171: Modified OSDI questionnaire (validation discussed in
detail in Chapter 4), NITBUT (Section 2.3.3), osmolarity (Section 2.3.4), and ocular surface
staining (Section 2.3.5). Each of these examination techniques has been described in detail
previously.
Previous studies in the literature have used differing parameters and cut-offs to
distinguish between dry eye and non-dry eye.176,177,251 As mentioned previously, a cut-off
of 308 mOsm/L is accepted as most sensitive to distinguishing normal participants from
participants with mild DED.176,177 As such, participants within each group were also subdivided into low tear osmolarity (< 308 mOsm/L) and high tear osmolarity (≥ 308 mOsm/L)
in order to assess the correlation between common signs and symptoms of DED with
increased tear osmolarity, and the effect that lid hygiene products has on participants with
low and high tear osmolarity.
Each participant was finally examined for the presence of DF using the eyelash
manipulation and eyelash epilation techniques described earlier (Section 2.3.9). Similar to
the pilot study and extended study discussed in Chapter 5, the presence of DF was defined
as one or more DF visible on eyelash manipulation and/or microscopic examination.
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Participants were randomly divided into four groups according to treatment: Group 1:
Cooled boiled water (control) (n = 12), Group 2: OCuSOFT (n = 12), Group 3: 10% baby
shampoo (shampoo) (n = 11), and Group 4: TTFW (n = 13). A 2 ml syringe and 20 ml
plastic test tube were provided to participants in Group 3 to make up the 10% shampoo
solution nightly (Appendix 5b). Randomisation was achieved using the random number
generator function on Excel. Each treatment was randomly assigned a number from 1 to 56.
Each participant chose a number and was subsequently given the treatment assigned to that
number.
Step-by-step instructions, similar to those provided in the pilot and extended treatment
studies, were provided to each participant for nightly lid scrubs at home (refer Table 6).
The lid scrubbing routine remained consistent between treatments. The only difference was,
that as per manufacturer’s guidelines, OCuSOFT formula was left on overnight; whereas
the shampoo and face wash were rinsed off after scrubbing.
Participants were asked to clean their eyelids nightly with their respective treatments
following the step-by-step instructions given to them and to return for repeat examinations
after two, four and eight weeks. The examiner remained blind to all treatments throughout
all stages of the investigation.
In an effort to monitor compliance, participants were asked to self-report, during return
visits, their treatment compliance for the previous 14 or 28 nights (at week two/four, and
week eight respectively). Participants were also asked to give feedback: if they would
recommend the treatment for participants with dry eyes or blepharitis.
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6.3.1 Statistical Analysis
Statistical analysis was performed using SPSS (version 25.0). The study eye used for
data analysis was chosen based on the eye with the greater tear osmolarity value. This
randomised the process, and is in keeping with previous studies and manufacturer
guidelines.174,176,177 Data was assessed for normal distribution using Shapiro-Wilk. All
outcome measures investigated were found to have a non-normal distribution (p < 0.001).
Friedman’s test was used to analyse repeated measures, within each group, across
different visits for non-parametric data. Post-hoc analysis was conducted, where
appropriate, using WSR test for pairwise comparisons, adjusted using Bonferroni
correction to avoid Type I error (α = 0.05/number of comparisons: α = 0.05/6 = 0.008).252
Kruskal Wallis H test was used to analyse data between categorical variables at baseline
and at different visits. Post-hoc analysis was conducted, where appropriate, using MWU
test for pairwise comparison, adjusted using Bonferroni correction (α = 0.05/number of
comparisons: α = 0.05/4 = 0.013).252 Data was expressed as median and IQR. Alpha level
≤ 0.05 was considered statistically significant, with the exception of Bonferroni adjusted
post-hoc analysis as described above.
6.4 Results
Forty-eight participants, with a median age of 19.50 years (IQR 19.00 – 20.75 years),
enrolled and completed the eight-week treatment study. An overall prevalence of DF of
14.60% was detected within this young study cohort. The overall median quantity of DF
detected was 0.00 mites (IQR 0.00 – 0.00) and 0.00 mites (IQR 0.00 – 0.00) on eyelash
manipulation and microscopic examination, respectively. As the presence and quantities of
DF found were so low, no further statistical analysis was conducted in that regard.
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The effect of home lid scrubs on symptoms, osmolarity, NITBUT and ocular surface
staining was evaluated over eight weeks. Compliance and subjective feedback from
participants were also analysed.
Median total symptom score for each treatment group at each time point is shown in
Table 34. A box plot illustrating change in symptom score from baseline for each treatment
groups over the duration of the study is shown in Figure 28. There was no significant
difference in total symptom score between the treatment groups, at any stage, over the two
months (KW p > 0.05). At baseline, all four treatment groups had a total symptom score >
12 and < 22, signifying ‘mild symptoms’ according to the OSDI classification.214

Table 34. Modified OSDI symptom (median, IQR) for each treatment at each
time point. KW: Kruskal Wallis, F: Friedmans. *Significant results highlighted in
bold.
Treatment

Baseline

Control

12.92
(10.83 – 16.67)
10.00
(5.00 – 23.33)
15.00
(3.33 – 31.67)
10.71
(6.67 – 16.67)
p = 0.78

OCuSOFT
Baby
Shampoo
TTFW
KW

Week Four

Week Eight

F

9.17
8.33
(5.83 – 12.50) (4.17 – 16.67)
9.17
5.00
(3.33 – 23.33) (2.50 – 19.17)
10.00
6.67
(3.33 – 16.67) (0.00 – 8.33)
6.67
10.71
(5.00 – 10.00) (1.67 – 13.33)
p = 0.80
p = 0.61

9.17
(5.83 – 12.50)
9.17
(3.33 – 23.33)
10.00
(3.33 – 16.67)
6.67
(5.00 – 10.00)
p = 0.82

*p = 0.01

Week Two
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*p = 0.047
*p < 0.001
*p = 0.04

Figure 28. Box plot illustrating change in modified OSDI symptom score for each lid
hygiene product at each time point. X represents the mean change in modified OSDI
score, small circles represent outliers.
The three treatment groups and control group all demonstrated a reduction in total
symptom score over time (Figure 28; Friedman’s p < 0.05). Wilcoxon signed-ranks test
post-hoc analysis is shown in Table 19. As can be seen from Table 35, after Bonferroni
correction was applied, only the reduction in total symptom score with shampoo from
baseline to week eight (p = 0.001) and week two to week eight (p = 0.004) was found to be
significant.
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Table 35. Total modified OSDI symptom score post-hoc Wilcoxon Signed Ranks test pairwise comparisons. Bonferroni adjusted alpha level α =0.0083. Significant results highlighted
in bold. B = baseline, W2 = week two, W4 = week four, W8 = week eight.

Control
(Friedmans, p = 0.01)
OCuSOFT
(Friedmans, p = 0.05)
Shampoo
(Friedmans, p < 0.001)
Face Wash
(Friedmans, p = 0.04)

B – W2

B – W4

B –W8

W2 – W4

W2 – W8

W4 – W8

0.04

0.07

0.01

0.72

0.06

0.14

0.22

0.41

0.03

0.50

0.12

0.24

0.31

0.01

0.001*

0.004*

0.01

0.92

0.03

0.02

0.04

0.94

0.44

0.24

Table 36 illustrates the median and IQR of the maximum osmolarity values recorded
at baseline, and the subsequent change in osmolarity value found for the same eye after
eight weeks of treatment, in each group. There was no significant difference in maximum
osmolarity value found between the treatment groups at baseline and week eight (KW p >
0.05), or within each treatment group after eight weeks of treatment (WSR p > 0.05).
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Table 36. Osmolarity (median, IQR) and inter-eye variability (median, IQR) before and after treatment. KW: Kruskal Wallis, WSR:
Wilcoxon signed ranks test, p < 0.05 significant. *Significant results highlighted in bold.
Variable
Osmolarity
(mOsm/L)

Inter-eye
variability
(mOsm/L)

Time
Baseline
Week
Eight
WSR:
Baseline
Week
Eight
WSR:

Control (n=12)
304.50
(298.00 – 309.50)
299.50
(296.00 – 304.00)
p = 0.09
4.50
(1.00 – 10.00)
6.00
(3.00 – 15.00)
p = 0.15

OCuSOFT (n=12)
310.50
(300.50 – 333.00)
305.00
(301.50 – 310.50)
p = 0.37
6.00
(4.50 – 8.00)
4.50
(2.00 – 10.50)
p = 0.89
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Shampoo (n=11)
305.00
(300.00 – 313.00)
303.00
(299.00 – 308.00)
p = 0.22
3.00
(2.00 – 8.00)
15.00
(8.00 – 21.00)
p = 0.03*

Face wash (n=13)
308.00
(298.00 – 309.00)
301.00
(290.00 – 311.00)
p = 0.96
4.00
(3.00 – 11.00)
11.00
(4.00 -18.00)
p = 0.10

KW
p = 0.42
p = 0.50

p = 0.74
p = 0.13

Inter-eye variability is also shown in Table 36. There was no significant difference in
inter-eye variability found between the groups at baseline, or at week eight (KW p > 0.05).
Within group analysis revealed that there was no significant difference in inter-eye
variability found between baseline and week eight with the control, OCuSOFT and face
wash treatments (WSR p > 0.05). However, the inter-eye variability with shampoo was
significantly greater after eight weeks of lid scrubs than it was at baseline (15.00 mOsm/L
IQR 2.00 – 8.00 vs 3.00 mOsm/L IQR 8.00 – 21.00, respectively; WSR p = 0.03).
Furthermore, with shampoo, the overall presence of tear film instability increased from
27.27% at baseline to 81.81%, resulting in a 54.54% increase in the presence of instability
after eight weeks of treatment. None of the other treatments resulted in such an increase in
instability. Presence of tear film instability increased by 8.34%, 16.67% and 23.08% with
control, OCuSOFT and face wash, respectively.
Data was also analysed for any differences depending on low or high tear osmolarity
(refer Table 37). There was no significant difference in signs and symptoms associated with
DED between low and high tear osmolarity at baseline. Expectedly, there was significantly
greater inter-eye variability in the high tear osmolarity group (MWU p = 0.03). Statistical
analysis within each treatment group is not given as there was insufficient data for statistical
significance. Table 37 also shows eight week results for both osmolarity groups and
treatment sub groups. Inter-eye variability remained higher in the high tear osmolarity
group (MWU p = 0.004). Symptoms were found to be significantly lower post-treatment in
the high tear osmolarity groups (MWU p = 0.047). There was no significant difference in
NITBUT or ocular surface staining between low and high tear osmolarity after eight weeks
of treatment. The median and IQR for quantity of DF for all treatment groups in both low
and high tear osmolarity was 0.00 (0.00 – 0.00) and has not been included in Table 37.
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Table 37. Baseline and eight week descriptives for low and high tear osmolarity sub-groups. U: Mann-whitney U. *Significant results
highlighted in bold.
Baseline Descriptives

Osmolarity
(mOsm/L)

Variability
(mOsm/L)
Percentage
Variability
(n)
Modified
OSDI
(0 – 100)
NITBUT
(secs)

Control
(n = 8)
300.50 (295.50
– 304.50)
Control
1.50 (1.00 –
8.00)
Control
25.00% (2)
Control
13.33 (12.08 –
25.83)
Control
4.77 (3.04 –
14.85)

Ocular
Surface
Staining
(0-15)

Control
0.50 (0.00 –
1.00)

DF
Prevalence
(%)

Control
25.00% (2)

Low Tear Osmolarity (n = 25)

High Tear Osmolarity (n = 23)

P value

299.00 (297.00 – 302.50)
OCuSOFT
J&J (n = 6)
(n = 5)
299.00 (298.00 301.00 (300.00
– 302.00)
– 303.00)
3.00 (1.00 – 7.00)
OCuSOFT
J&J
5.00 (2.00 –
6.00 (3.00 –
6.00)
14.00)
24.00%
OCuSOFT
J&J
20.00% (1)
50.00% (3)
13.33 (6.67 – 31.67)
OCuSOFT
J&J
11.67 (8.33 –
23.33 (6.67 –
11.67)
45.00)
5.56 (3.29 – 11.82)
OCuSOFT
J&J
9.70 (5.85 –
5.94 (4.47 –
11.37)
11.73)
0.00 (0.00 – 1.50)
OCuSOFT
J&J
2.00 (1.00 –
00.50 (0.00 –
2.00)
2.00)
16.00% (4)
OCuSOFT
J&J
20.00% (1)
16.67% (1)

312 (309.00 – 318.00)
OCuSOFT
J&J (n = 5)
(n = 7)
331.00 (312.00 313.00 (312.00
– 335.00)
– 315.00)
7.00 (4.00 – 9.00)
OCuSOFT
J&J
7.00 (6.00 –
2.00 (1.00 –
9.00)
2.00)
39.13%
OCuSOFT
J&J
28.57% (2)
0.00% (0)
10.00 (3.33 – 16.67)
OCuSOFT
J&J
6.67 (3.33 –
3.33 (1.67 –
35.71)
20.00)
4.50 (3.20 – 6.47)
OCuSOFT
J&J
4.93 (3.00 –
4.13 (3.00 –
9.20)
4.23)
0.00 (0.00 – 1.00)
OCuSOFT
J&J
0.00 (0.00 –
1.00 (0.00 –
1.00)
1.00)
13.04% (3)
OCuSOFT
J&J
28.57% (2)
0%

<0.001U

TTFW
(n = 6)
297.50 (296.00
– 298.00)

Control (n = 4)
311.00 (309.50
– 312.50)

TTFW
2.00 (1.00 –
3.00)

Control
6.50 (5.00 –
10.00)

TTFW
0.00% (0)

Control
50.00% (2)

TTFW
18.33 (6.67 –
32.69)
TTFW
3.93 (2.77 –
4.03)

Control
10.83 (8.57 –
12.50)
Control
5.49 (3.90 –
9.89)

TTFW
0.00 (0.00 –
0.00)

Control
0.00 (0.00 –
1.00)

TTFW
0%

Control
0%

170

TTFW (n = 7)
309.00 (308.00
– 318.00)
0.03U
TTFW
11.00 (7.00 –
18.00)
TTFW
71.43% (5)
0.06U
TTFW
10.71 (6.67 13.33)
0.46U
TTFW
4.53 (3.77 –
12.93)
0.74U
TTFW
0.00 (0.00 –
1.00)
TTFW
14.29% (1)

Eight Week Descriptives
Low Tear Osmolarity (n = 25)
Osmolarity
(mOsm/L)

Variability
(mOsm/L)

Control
(n = 8)
297.50
(294.50 –
300.00)
Control
5.00 (1.50 –
12.00)

Percentage
Variability
(n)

Control
37.50% (3)

Modified
OSDI
(0 – 100)

Control
9.17 (6.67 –
17.86)

NITBUT
(secs)
Ocular
Surface
Staining
(0-15)
DF Prevalence
(%)

Control
3.77 (3.32 –
4.48)
Control
0.00 (0.00 –
0.00)
Control
37.50% (3)

299.00 (296.00 – 303.00)
OCuSOFT
J&J (n = 6)
(n = 5)
303.00
299.50
(303.00 –
(299.00 –
304.00)
303.00)
4.00 (3.00 – 9.50)
OCuSOFT
J&J
4.00 (3.00 –
8.50 (4.00 –
5.00)
10.00)
40.00%
OCuSOFT
J&J
20.00% (1)
66.67% (4)
6.67 (5.00 – 15.60)
OCuSOFT
J&J
5.00 (1.67 – 10.00 (5.00 –
10.00)
17.86)
4.77 (3.50 – 9.85)
OCuSOFT
J&J
7.10 (3.26 –
6.59 (3.47 –
7.73)
11.30)
0.00 (0.00 – 0.00)
OCuSOFT
J&J
0.00 (0.00 –
0.00 (0.00 –
0.00)
1.00)
20.00% (5)
OCuSOFT
J&J
20.00% (1)
16.67% (1)

High Tear Osmolarity (n = 23)
TTFW (n = 6)

299.00 (290.00
– 301.00)

Control (n =
4)
309.00
(303.50 –
312.00)

TTFW
3.50 (3.00 –
14.00)

Control
10.50 (5.50 –
16.50)

TTFW
33.33 (2)

Control
50.00% (2)

TTFW
5.18 (5.00 –
11.67)

Control
4.17 (0.83 –
9.17)

TTFW
7.27 (5.80 –
10.63)

Control
4.90 (3.38 –
8.34)

TTFW
0.00 (0.00 –
0.00)

Control
0.00 (0.00 –
0.00)

TTFW
0%

Control
0%
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309.00 (300.00 – 319.00)
OCuSOFT
J&J (n = 5)
(n = 7)
308.00
309.0 (300.00 –
(306.00 –
326.00)
311.00)
15.00 (6.00 – 24.00)
OCuSOFT
J&J
8.00 (1.00 –
21.00 (18.00
16.00)
– 27.00)
73.91%
OCuSOFT
J&J
57.14% (4)
100.00% (5)
3.33 (0.00 – 11.67)
OCuSOFT
J&J
3.33 (1.67 –
0.00 (0.00 –
28.33)
5.00)
4.67 (2.83 – 8.90)
OCuSOFT
J&J
6.67 (3.03 –
4.57 (2.83 –
10.93)
5.10)
0.00 (0.00 – 1.00)
OCuSOFT
J&J
0.00 (0.00 –
1.00 (0..00 –
0.00)
2.00)
4.35% (1)
OCuSOFT
J&J
0%
0%

P value
0.001U
TTFW
(n = 7)
310.00 (290.00
– 349.00)
0.004U
TTFW
13.00 (11.00 –
29.00)
TTFW
85.71% (6)
0.047U
TTFW
10.00 (0.00 –
15.00)
0.55U
TTFW
4.67 (2.60 –
5.70)
0.38U
TTFW
0.00 (0.00 –
1.00)
TTFW
14.29%

Mean NITBUT values, at baseline and subsequent visits, are shown in Table 38. There
was no significant difference within each treatment group (Friedmans p > 0.05) or between
the treatments (KW p > 0.05), at any time over the eight weeks. With the control treatment,
mean NITBUT reduced by approximately 3 seconds after eight weeks, although this drop
was not found to be significant (Friedmans: p = 0.25). For OCuSOFT, shampoo and face
wash treatments, NITBUT remained relatively stable over the eight weeks. Thus, none of
the over-the-counter lid scrub treatments used in the current study appeared to have an
adverse effect on NITBUT.
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Table 38. Non-Invasive tear break-up time (median, IQR) and ocular surface staining (median, IQR) before and after treatment. BL: Baseline,
W2: Week Two, W4: Weeks Four, W8: Week Eight, KW: Kruskal Wallis, F: Friedmans
Variable

Time

Control (n=12)

OCuSOFT (n=12)

Shampoo (n=11)

Face wash (n=13)

KW

Non-Invasive

BL

5.24 (3.34 – 13.89)

5.94 (3.12 – 10.54)

4.47 (3.27 – 6.40)

4.20 (3.37 – 8.85)

p = 0.92

Tear Break Up

W2

4.12 (3.05 – 8.04)

5.50 (3.03 – 10.73)

4.85 (3.30 – 7.33)

4.33 (2.90 – 5.63)

p = 0.81

Time (sec)

W4

5.30 (3.27 – 6.30)

6.10 (3.85 – 13.98)

6.27 (3.97 – 7.63)

4.13 (3.37 – 6.93)

p = 0.57

W8

4.04 (3.32 – 5.17)

6.94 (3.23 – 9.91)

4.57 (2.83 – 11.30)

5.70 (4.47 – 7.83)

p = 0.63

p = 0.25

p = 0.54

p = 0.81

p = 0.87

F
Ocular Surface

BL

0.00 (0.00 – 1.00)

1.00 (0.00 – 2.00)

1.00 (0.00 – 2.00)

0.00 (0.00 – 1.00)

p = 0.34

Staining

W2

0.00 (0.00 – 0.50)

0.00 (0.00 – 1.00)

0.00 (0.00 – 1.00)

0.00 (0.00 – 0.00)

p = 0.75

(0-15)

W4

0.00 (0.00 – 0.50)

0.50 (0.00 – 1.00)

0.00 (0.00 – 1.00)

0.00 (0.00 – 0.00)

p = 0.50

W8

0.00 (0.00 – 0.00)

0.00 (0.00 – 0.00)

0.00 (0.00 – 2.00)

0.00 (0.00 – 0.00)

p = 0.12

p = 0.20

p = 0.07

p = 0.71

p = 0.78

F
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Ocular surface staining median and IQR, at baseline and subsequent visits, are also
shown in Table 38. Due to the nature of the study cohort; young healthy individuals with
no ocular surface disease; there was very little ocular surface staining present at baseline in
all groups (KW p = 0.34). The aim was to see if any of the treatments caused an adverse
reaction, for e.g. increase in ocular surface staining with use. As can be seen from Table
38, there was no significant increase in ocular surface staining over the duration of the study
in any group.
Contact lens wearers accounted for 40% (n = 19/48) of the study cohort. The use of
contact lenses was not found to have any impact on baseline measurements (Table 39). Raw
data on the breakdown of baseline measurements between contact lens wearers and noncontact lens wearers within each treatment group is shown in Table 39. Statistical analysis
on contact lens wearers within each treatment group is not given, as there was insufficient
data for statistical significance. The median and IQR for quantity of DF for all treatment
groups in both contact lens wearers and non-contact lens weaers was 0.00 (0.00 – 0.00) and
has not been included in Table 39.
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Table 39. Baseline descriptives (median, IQR) for contact lens wearers and non-contact lens wearers. U: Mann-whitney U test
Baseline Descriptives

Osmolarity
(mOsm/L)

Variability
(mOsm/L)
Modified
OSDI
(0 – 100)
NIBUT
(secs)
Ocular
Surface
Staining
(0-15)

No Contact Lens Wear (n = 29)

Contact Lens Wear (n = 19)

307.00 (299.50 = 314.50)
OCuSOFT
J&J
(n = 9)
(n = 6)
315.00
303.50
(303.00 –
(300.00 –
335.00)
308.00)
6.00 (2.00 – 8.50)
OCuSOFT
J&J
7.00 (6.00 –
3.00 (2.00 –
9.00)
8.00)
11.67 (5.00 – 30.83)
OCuSOFT
J&J
11.67 (3.33 – 23.33 (3.33 –
15.00)
45.00)
4.93 (3.29 – 11.67)
OCuSOFT
J&J
4.93 (3.03 –
6.34 (4.13 –
9.70)
11.73)
0.00 (0.00 – 1.00)
OCuSOFT
J&J
1.00 (0.00 –
1.00 (0.00 –
2.00)
1.00)

305.00 (298.00 – 311.00)
OCuSOFT
J&J
(n = 3)
(n = 5)
302.00
312.00
(298.00 –
(303.00 –
309.00)
313.00)
4.00 (1.00 – 12.00)
OCuSOFT
J&J
4.00 (2.00 –
4.00 (1.00 –
5.00)
5.00)
11.67 (6.67 – 20.00)
OCuSOFT
J&J
8.33 (6.67 –
6.67 (5.00 –
31.67)
20.00)
4.35 (2.99 – 6.14)
OCuSOFT
J&J
6.03 (5.85 –
4.23 (3.00 –
11.85)
4.47)
0.00 (0.00 – 1.00)
OCuSOFT
J&J
1.00 (0.00 –
0.00 (0.00 –
2.00)
2.00)

Control
(n = 7)
307.00
(299.00 –
311.00)
Control
4.00 (1.00 –
8.00)
Control
13.33 (11.67
– 31.67)
Control
13.30 (4.50
– 15.23)
Control
0.00 (0.00 –
1.00)

TTFW
(n = 7)
301.00
(298.00 –
310.00)

Control (n =
4)
304.00
(297.00 –
305.00)

TTFW
3.00 (1.00 –
9.00)
TTFW
6.67 (3.33 –
11.67)
TTFW
4.03 (2.77 –
4.77)
TTFW
0.00 (0.00 –
1.00)
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Control
5.00 (1.00 –
12.00)
Control
11.67 (10.00
– 12.50)
Control
3.37 (2.70 –
3.57)
Control
1.00 (0.00 –
1.00)

P
value
0.56U

TTFW
(n = 6)
308.00
(297.00 –
309.00)
0.98U

TTFW
7.50 (3.00 –
18.00)
0.84U

TTFW
15.00 (10.71
– 32.69)
0.23U

TTFW
4.53 (3.9312.93)
0.89U

TTFW
0.00 (0.00 –
1.00)

Participants were asked to self-report on their compliance throughout the study.
Compliance results are shown in Figure 29. Only the control group demonstrated a
significant drop in compliance (Friedmans: p = 0.04). Post-hoc Bonferroni adjusted WSR
test pairwise comparison (adjusted α = 0.05/3 = 0.0167) found significant reduction in
compliance after two weeks: from week two to week four (p = 0.01) and from week two
to week eight (p = 0.007). The overall lowest compliance throughout the eight weeks was
seen with the shampoo group. After two weeks the compliance within this group was <
70%. The OCuSOFT group had the highest overall compliance throughout the study and
remained at > 70% over the eight weeks.

Compliance
Control
66.07%

72.32%
72.62%

OCuSOFT

Shampoo
64.77%

60%
Week Two

76.79%

67.53%
68.51%

68.68%
67.03%

Face Wash

55%

75.59%

69.35%

65%
Week Four

71.98%

70%

75%

80%

Week Eight

Figure 29. Self-reported percentage compliance over the duration of the study.
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Participants were also asked to give feedback regarding if they would recommend the
treatment for people with blepharitis or dry eyes. After eight weeks of treatment; 66.67%
of participants using control treatment, 83.33% using OCuSOFT, 72.73% using shampoo,
and 69.23% using face wash said they would recommend the treatment. The reasons given
for not recommending the treatments were as follows: The treatment made no difference
(Control n = 4, OCuSOFT n = 1, Shampoo n = 3, TTFW n = 1), the treatment was
uncomfortable and irritating during use (TTFW n = 3) and their eyes felt dryer after use
(OCuSOFT n = 1).
6.5 Discussion
As previously described in Chapter 3, Section 3.5, the overall prevalence of DF
reported in the literature varies greatly; likely due to the differences in participant ages and
techniques used for detecting presence of the mites. As mentioned in Chapter 1, DF has
consistently been associated with increasing age (Section 1.6.1),13,28,77,253 blepharitis
(Section 1.7.2),7,43,46,49,64,253 dermatological conditions (Section 1.6.2),69–71,81,82 and
systemic diseases (Section 1.6.3).20,24,92,93,107,108,113 Nonetheless, higher prevalence values
have also been established in normal, healthy individuals.23,46,254,255 Kemal et al23
discovered an overall prevalence of 26.67% on the eyelashes of normal individuals (mean
age 37.5 ± 16.5 years). In the same study, in control participants < 20 years of age, the
authors’ discovered a 16.67% prevalence of DF,23 which is in good agreement with the
results found in the current study (14.60%). Kaᶀatas et al46 discovered a higher prevalence
of 54.9% DF on the eyelashes of control participants, however they were considerably older
than participants in the current study: 54.6 ± 13.4 years. Zhao et al254 discovered an overall
prevalence of 67.6% DF in the skin of a young study cohort (aged 13 – 22 years). Karaman
et al255 discovered a 37% prevalence DF among college students living in shared
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accommodation. The higher prevalence values found by Zhao et al254 and Karaman et al255
in comparison to the current study are most likely due to the sampling methods used: skin
sampling versus eyelash epilation. The low prevalence of DF discovered in the current
study further re-enforces that DF can be found among young, normal, healthy individuals.
Evidence-based practice is steadily becoming a principal element of health care,
including optometry.256–259 Evidence-based health care is the clear and careful use of
current ‘best evidence’ in clinical decision making with respect to the treatment and
management of patients.260 In recent years, several studies have examined the clinical
efficacy of eyelid hygiene products with respect to Demodex blepharitis.13,15,35,52 However,
there is limited evidence available for practitioners on the safety of these products. The
results of the current study will help guide practitioners on the safety of such products that
are often used in close contact with the ocular surface.
Subjective symptoms improved in all treatment groups, including the control group
with water. In a meta-analysis of placebo controlled trials it was found that there was no
statistically significant difference in trials with continuous subjective outcome measures
between treatment and placebo.261 The placebo effect occurs when a participant experiences
a beneficial effect from the control treatment which cannot be attributed to the properties
of the treatment itself, and is therefore believed to be a psychological belief by the patient
in the treatment. However, in the current study, the control treatment used was water.
Participants were aware that it was water, and as predominantly students of optometry, were
also aware that the likelihood of water having a therapeutic effect was small. Yet, an
improvement in symptoms was demonstrated. It is possible that the control used did have
some therapeutic effect, as the physical nature of rubbing the eyelids nightly, even if just
using water, could help clean and remove some of the bacterial load at the eyelid margin.262
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This therapeutic rubbing of the eyelids could also account for the subjective improvement
detected across all four groups. Although subjective symptoms improved across all four
groups, the only significant reduction in symptoms was with the baby shampoo treatment.
The authors were surprised, as baby shampoo is a detergent and has previously been
reported to have a stinging and uncomfortable sensation when used.186,263 The authors
postulate that although no significant difference in symptoms was found at baseline
between the four groups, the baby shampoo group did have the highest symptoms of the
four groups (OSDI = 15.00 IQR: 3.33 – 31.67). High baseline scores have been associated
with high placebo responses,262 believed to be due to a ‘regression to the mean’.264
Tear osmolarity has been found to be one of the most effective methods for detecting
ocular surface inflammation and DED.176,206,251 The biological range of tear osmolarity
values in the lower tear meniscus varies from 275 mOsm/L to 400 mOsm/L; with higher
numbers indicating greater surface inflammation.206 Tear osmolarity values between 308
mOsm/L - 316 mOsm/L have been recommended in the literature as cut-off referent values
for dry eye diagnosis.176,177,251 A cut-off of 308 mOsm/L is considered most sensitive to
distinguishing normal participants from participants with mild DED.176,177 Whereas, a cutoff of 316mOsm/L is considered to better discriminate between mild and moderate – severe
dry eye, and has an overall predictive accuracy of 89%.251 In the current study, at baseline,
the mean osmolarity values for the control, shampoo and face wash treatment groups were
< 308 mOsm/L, and can therefore be considered within that normal range value. The
OCuSOFT treatment group had a slightly higher mean osmolarity value at baseline (315.8
mOsm/L), however it was still within the cut-off referent recommended by many previous
studies.177,251 Although the mean osmolarity in the OCuSOFT group was slightly higher at
baseline, KW comparison of means found no statistical significant difference between the
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four groups. Furthermore, the aim of the study was to assess if each of the treatments used
had a negative impact on tear film osmolarity. As can be seen from the current study, mean
tear osmolarity dropped in all four groups: although, not significantly. A study published
in 2014, comparing the efficacy of thermal massagers and artificial eye drops for the
treatment of DED, also found that osmolarity values improved post treatment in both
groups.265 The authors concluded that the improvement in lipids to the ocular surface helped
to improve tear film stability. The use of lid hygiene could be beneficial for reducing tear
osmolarity by reducing the overall bacterial load at the eyelid margin, and the pressure
applied to the eyelids during scrubbing effect may also provide an element of massage to
the eyelids.
A reduction in tear osmolarity suggests a reduction in ocular surface inflammation and
improvement in tear film stability. Inter-eye variability of > 8mOsm/L is considered an
indicator of tear film stability.176 Lemp et al176 found that the variability between two eyes
in normal, mild to moderate dry eye and severe dry eye patients was 6.9 ± 5.9 mOsm/L,
11.7 ±10.9 mOsm/L, and 26.5 ± 22.7 mOsm/L, respectively. In the current study, variability
values at baseline were in good agreement with those found by Lemp et al176: 4.50 (1.00 –
10.00) mOsm/L CoV 0.89% (control), 6.00 (4.50 – 8.00) mOsm/L CoV 0.45%
(OCuSOFT), 3.00 (2.00 – 8.00) mOsm/L CoV 0.99% (shampoo), and 4.00 (3.00 – 11.00)
mOsm/L CoV 1.36% (face wash). However, post treatment inter-eye variability was found
to increase slightly in all groups, and significantly with the shampoo group: 6.00 (3.00 –
15.00) mOsm/L CoV 1.30% (control), 4.50 (2.00 – 10.50) mOsm/L CoV 1.05%
(OCuSOFT), 15.00 (8.00 – 21.00) mOsm/L CoV 0.63% (shampoo), and 11.00 (4.00 –
18.00) mOsm/L CoV 1.02% (face wash). Variation in measurements detected in the current
study have been found to be less than that previously reported. TearLabTM has previously
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been shown to provide repeatable tear osmolarity measurements with CoV between 1.6% 1.9%.178 The increase in inter-eye variability detected in the shampoo group can be
considered clinically significant, as the increase in median is >8mOsm/L.
With the exception of OCuSOFT, post-treatment inter-eye variability values found in
the current study suggest mild-moderate dry eye according to Lemp et al176 standards.
Therefore, as symptoms and mean osmolarity reduced in the current study suggesting no
adverse effects of the treatments used, the inter-eye variability in osmolarity values suggests
the contrary. Although slight increases in inter-eye variability were detected in all groups,
only the increase with shampoo was found to be significant. This significant instability in
tear osmolarity with shampoo occurred even in the presence of relatively low participant
compliance within that group (< 70% over the eight weeks). A recent study by Sung et al186
discovered that the use of diluted baby shampoo appeared to negatively impact the tear film
by causing a reduction in levels of MUC5AC, a goblet cell-specific mucin; suggesting that
the use of baby shampoo caused a reduction in goblet cell density.266,267 Hyperosmolarity
acts as a stressor to the ocular surface, causing morphological and inflammatory changes
including a reduction in mucin producing goblet cells.268 In DED, the same is true in
reverse: a reduction in mucin producing goblet cells can cause tear film instability and
hyperosmolarity.269 Findings from the current study correlate well with Sung et al186: The
increase in tear film instability and inter-eye variability found post-treatment in the
shampoo group could be as a result of adverse changes to goblet cell density caused by the
baby shampoo.
Non-invasive tear break-up time and ocular surface staining can also be indicators of
tear film instability and ocular surface inflammation. However, in the current study none of
the eyelid hygiene products used caused negative effects on NITBUT or ocular surface
181

staining. This was in keeping with Sung et al186 who found no significant change in
NITBUT or ocular surface staining after four weeks of treatment with baby shampoo or
TheraTears® SteriLid® cleanser. Similarly, in a recent study by Ngo et al241 investigating
the short-term responses associated with eyelid hygiene products available for the treatment
of DF; the authors found a significant decrease in NITBUT using a 50% tea tree based
formula, but no significant change in NITBUT using any of the other eyelid cleansers,
including OCuSOFT and two other TTO based products (TheraLid® and Cliradex ®).
Although the timings of repeat measurements were different, and the eyelid hygiene
products investigated were different, the outcome is similar. It appears that regardless of
whether NITBUT was measured after 10 minutes,241 four weeks,186 or eight weeks of
treatment; common eyelid hygiene products do not appear to have a negative effect on
NITBUT.
The current study provides practitioners with a good insight into realistic compliance
from patients. It is possible that due to reduced compliance over the course of the study,
potential significant adverse events have not been elucidated in the current study. However,
as the current study may be more indicative of a ‘real-world’ blepharitis treatment scenario,
the authors believe that the study provides a good representation of the safety of the
blepharitis eyelid hygiene products used over the course of eight weeks. Longer studies
would be required to confirm absolute safety in the long-term. The lowest reported
compliance in the current study was within the shampoo group at 64.77%, and the control
group at 66.07%. However, these were still greater than that reported in a recent study
investigating patient compliance with eyelid hygiene over six weeks, in which self-reported
compliance was only 55%.270 In that compliance study, participants were also asked to
clean their eyelids using a diluted solution of baby shampoo or warm water. Reasons given
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for non-compliance included inconvenience, forgetfulness, and a belief that therapy was
not required.270 The authors believe that these underlying reasons are likely to also exist for
the control group in the current study. The OCuSOFT group had the highest overall
compliance throughout the study and remained at > 70% over the eight weeks. The authors
believe that this may be due to the convenient nature of using this type of treatment.
However, it is also possible that as the participants in this study were optometry students,
they may have had a better understanding of the potential benefits of eyelid hygiene and
subsequently overall compliance may have been greater as a result.
Participants were also asked if they would recommend the product to future blepharitis
patients. OCuSOFT received the highest recommendation (83.33%), followed by shampoo
(72.72%), face wash (69.23%) and control (66.67%). The control group received the lowest
recommendation due to its presumed lack of therapeutic ability. Although the face wash
was TTO based, and thus has anti-bacterial, anti-microbial and anti-inflammatory potential,
it received a lower recommendation due to the discomfort associated with the product. This
is in agreement with the study by Ngo et al241 that found that tea tree based eyelid cleansers
marketed to treat Demodex blepharitis caused varying degrees of ocular irritation. Ngo et
al241 also found that OCuSOFT caused minimal irritation which corresponded well with the
higher recommendation for its use from participants in the current study.
As participants were required to make their own 10% baby shampoo solution at home,
this could have caused differences in the % solution being used by the participants. It is
possible that this may have impacted the results, and future studies should have a more
standardised % solution to avoid this.
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6.6 Conclusion
A low prevalence of DF was found amongst young, healthy individuals. Overall, the
three eyelid hygiene products investigated were well tolerated. Symptoms improved for all
groups, and there were no negative effects on NITBUT or ocular surface staining. There
was a mild increase in tear film instability and inter-eye variability with both OCuSOFT
and TTFW. However, this also occurred with control lid hygiene scrubs with water, and
these changes were not found to be significant. In contrast, 10% baby shampoo caused a
significant increase in inter-eye osmolarity variability and tear film instability, suggesting
a possible increase in ocular surface inflammation. This study was conducted on healthy
participants with healthy tear films and ocular surface. Future studies should consider
inclusion of participants with compromised tear film and ocular surface to elicit a more
magnified response to treatment.
The results of the study indicate that Demodex blepharitis related eyelid hygiene
products OCuSOFT and TTFW, used in the pilot and extended treatment study,
demonstrated no significant adverse ocular reactions. A paper on the results of this study
has been recently accepted for publication in Contact Lens & Anterior Eye.
Thus far in this thesis, treatments for Demodex blepharitis have concentrated on the
traditional lid hygiene method, and the safety and efficacy of the different products tested.
As mentioned previously in Section 3.2, DF is susceptible to damage from heat. In the
treatment of MGD, heat is often applied to the eyelids, to help soften and improve the flow
of meibum to the tear film and ocular surface. Heat applied to the eyelids, must pass through
the eyelash follicles to reach the meibomian glands underneath. Therefore, in theory, heat
applied to the eyelids in the treatment of MGD, may have a dual therapeutic effect by also
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killing DF present within the eyelash follicles. The following chapter, Chapter 7, will
discuss the relationship between DF and MGD in more detail, and will examine the effect
that heat therapy can have on treating Demodex blepharitis. The results of this study have
been recently accepted for publication in Current Eye Research and has been adapted
accordingly for Chapter 7.
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CHAPTER SEVEN: THE EFFICACY OF WARM COMPRESSES IN THE
TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION AND DEMODEX
FOLLICULORUM BLEPHARITIS
7.1 Abstract
Purpose: To examine and evaluate the effect of warm compresses on MGD and DF
blepharitis.
Methods: Forty-two participants (13 males, 29 females; median age of 59.00 years)
enrolled and completed the two-month warm compress treatment study. Three warm
compress treatments were compared: Warm face cloth, MGDRx EyeBag® (Eyebag) and
OPTASETM Moist Heat Mask (Optase). Participants attended for four visits: baseline, two
weeks, four weeks, and eight weeks. Similar to previous studies, examinations at each visit
included: subjective symptoms, osmolarity, NITBUT, ocular surface staining, Schirmer I,
number of expressible glands and quality of expressed meibum. Eyelash manipulation and
epilation were conducted to assess for the presence of DF.
Results: Utilising a composite score of meibum quality and expressibility, MGD grade
reduced significantly with the Eyebag and the Optase (p < 0.05). No significant difference
in efficacy for treating MGD was observed between the two devices (p > 0.05). The Optase
was the only compress that significantly reduced the quantity of DF after eight weeks of
treatment. Symptoms and ocular surface staining also improved significantly with the
Eyebag and the Optase (p < 0.05), but not the warm face cloth (p > 0.05). There was no
significant change detected in osmolarity, NITBUT or Schirmer I with any treatment (p >
0.05).

186

Conclusion: Both the Eyebag and Optase exhibited superior efficacy in treating signs
and symptoms of MGD, compared to the use of a warm face cloth, over the eight-week
period. The Optase demonstrated dual therapeutic abilities, treating both MGD and DF
blepharitis. Repeated application of warm compresses remains an effective home-remedy
for the treatment of MGD.
7.2 Introduction
The meibomian glands are a group of holocrine glands found in the upper and lower
eyelids. Structurally, they consist of parallel rows of secretory acini organised around a
central duct, which opens onto the eyelid margin.271,272 As mentioned in Section 1.7.3, the
function of the meibomian glands is to supply meibum to the ocular surface: preventing
tear film evaporation, improving vision, and protecting against microbial agents and
organic matter such as dust.133–136 Disruption to this supply, often through terminal duct
obstruction or changes in glandular secretion, can interfere with the homeostasis of the tear
film and ocular surface: leading to inflammation and subsequent symptoms of
discomfort.135,273
The eyelash follicles are situated within the eyelids, anterior to the meibomian glands.
Due to their close proximity with one-another, anomalies of the eyelash follicles and the
meibomian glands are frequently seen in combination.4–7 For example, inhabitation of the
eyelash follicles and meibomian glands with Demodex.
The association between DB infestation and severe MGD and keratitis has been
described in the literature.6,274 Although DF are generally associated with anterior
blepharitis, the prevalence of DF in the eyelash follicles of MGD patients has been reported
to vary between 46.5% to 85%.7,30,48
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The mainstay treatment recommended for Demodex blepharitis is lid scrubs with
diluted quantities of TTO.15,35,52 Although lid scrubs have been indicated as an early
treatment option for patients with mild MGD, warm compress therapy remains the leading
treatment for MGD.138 For warm compresses to be effective, heat must pass through the
anterior eyelid structures, including the eyelashes, to warm and liquify thickened meibum
within the meibomian glands. The melting temperature of normal meibum is circa 32 °C,
and is higher at approximately 35 °C in obstructed glands with thickened secretions.138,275
Hence, it is suggested that warm compresses need to heat the inner eyelid to a temperature
of ≥ 40 °C, to be effective at treating MGD.192 However, both DB and DF prefer lower
temperatures, and Zhao et al197 have shown that temperatures above 37 °C are damaging to
DF. Higher temperatures cause death by protein coagulation and denaturation, and eventual
paralysis of the DF nervous system.197 Murakami et al276 have demonstrated that although
there are differences in the innermost eyelid temperatures achieved by various warm
compresses, most methods do manage to reach outer eyelid temperatures of ≥ 40 °C.
Therefore, as heat from the warm compress spreads through the eyelash follicles to heat the
inner eyelid, it could conceivably have a killing effect on DF within the eyelash follicle.
Traditionally, home based warm compresses were carried out using a warm face
cloth.138,277 However, this method has its limitations, including poor heat retention,278 and
inconvenience leading to reduced compliance.138 Over the years, more patient-friendly
warm compresses have become available, such as the Eyebag and the Optase. Although
both warm compresses are similar; they are heated in a microwave, and one heating is
required to provide 10 minutes of therapy; there are fundamental differences between them.
The Optase contains HydroBeadTM Technology, which absorbs moisture from the air, and
when heated, releases it to provide a moist heat. Optase manufacturers report temperatures
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from 50 °C to 41 °C over the 10-minute duration of therapy.279 The moist heat softens
eyelash debris in patients with anterior blepharitis, and restores moisture to the eye and
surrounding area, in conjunction with improving meibum flow, tear film quality and
reduced tear film evaporation.279 In contrast, the Eyebag contains flax seed and provides a
dry heat when applied to the eyelids. Manufacturers recommend it for relief of, including
but not limited to: MGD, blepharitis, dry eye syndrome, and rosacea. Previous research has
shown that the Eyebag achieves temperatures of 46 °C dropping to 39 °C after 5 minutes.280
However, their efficacy in the treatment of Demodex blepharitis had not previously been
investigated. As such, the aim of the current study was to assess the therapeutic effect of
these common home-based warm compresses on DF infestation in MGD patients.
7.3 Methods
This was a single-centre, interventional, randomised, controlled, examiner masked
clinical trial. All participants were recruited through the National Optometry Centre’s
private and student optometry clinics. Written informed consent was obtained from all
participants prior to enrolment.
Minimum sample size required for statistical significance was calculated using
G*Power analysis. Effect size was calculated from the mean and SD of the difference of
DF presentation on lash manipulation and microscopic examination from previous data
collected: 0.84/1.59 = 0.52. A priori analysis for repeated measures ANOVA between
factors was conducted (α = 0.05, 1-β = 0.80, effect size = 0.5: 3 groups, 2 measurements).
The minimum total sample size required was 33 participants; 11 participants per group.
Fifty participants in total enrolled between April 2017 and May 2018. Participants had to
be ≥ 18 years of age and have ≥ G1 MGD based on meibomian gland expression according
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to the diagnostic subcommittee of the International Workshop on Meibomian Gland
Dysfunction,185 to be eligible to participate. Participants were excluded if they: wore contact
lenses, were pregnant, had a systemic disease or were using topical/systemic medication
known to affect the eyes, presented with ocular disease (with the exception of MGD and
blepharitis), were currently using MGD/blepharitis treatment or had used such treatment
within the last six months, or had ocular surgery in the last six months.
Participants attended the National Optometry Centre for four visits in total: baseline,
week two, week four, and week eight. All examinations were conducted in the same room,
at the same time of day (+/- 30 minutes), by the same examiner (author OM). All
examinations were conducted in the same order at each visit, from least invasive to most
invasive170,171: modified OSDI questionnaire refer (Chapter 4), NITBUT (Section 2.3.3),
osmolarity (Section 2.3.4), ocular surface staining (Section 2.3.5), Schirmer I (Section
2.3.6), MGD evaluation (Section 2.3.8) and Demodex investigation (Section 2.3.9). Each
of these examination techniques has been described in detail previously. Participants were
considered to have ‘dry eye’ if found to have three or more of the following parameters;
modified OSDI ≥ 13, osmolarity ≥ 308 mOsm/L, inter-eye variability ≥ 8mOsm/L,
NITBUT < 10 secs, ocular surface staining ≥ 3 Oxford score or Schirmer I score ≤
5mm/5min. Cut-off values employed are in keeping with those recommended by DEWS
II.171 To grade MGD, composite scores were derived from the expressibility and quality of
meibum from both upper and lower eyelids and used for statistical analysis.185 Similarly, a
composite score was derived for quantities of DF found on upper and lower eyelids and
used for statistical analysis. The percentage of participants with DF in each group was also
determined. Positive DF infestation was defined as the presence of ≥ 1 DF detected on
either eyelash manipulation or microscopic examination. Based on work by Randon et al65
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the prevalence of DF was further classified into non-pathogenic (≤ 3 mites) and pathogenic
infestation (≥ 4 mites) per eye.
The ICC was determined to examine the agreement in pre-treatment results between
the right and left eyes for each participant. A two-way mixed analysis with absolute
agreement and 95% confidence intervals was conducted.281 Results are shown in Table 40.
As recommended, data analysis was conducted on one eye only for each participant.282 As
all correlations were between moderate to excellent, either eye was considered eligible for
selection. Therefore, in keeping with previous studies and osmolarity measurement
guidelines, the eye selected for data analysis was chosen based on the higher tear osmolarity
value at baseline.174,176,177
Table 40. Intraclass correlation co-efficient, two-way mixed effects, absolute
agreement, average of multiple measurements, 95% confidence interval. Values of less
than 0.5 indicate ‘poor’ agreement, between 0.5 and 0.75 ‘moderate’ agreement, between
0.75 and 0.9 ‘good’ agreement, and greater than 0.90 ‘excellent’ agreement.281
Outcome Measure

ICC

Reliability

Quantity Demodex
folliculorum

0.71

Moderate

MGD Grade

0.93

Excellent

Osmolarity

0.68

Moderate

Non-invasive Tear
Brake-Up Time

0.82

Good

Ocular Surface Staining

0.77

Good

Schirmer

0.91

Excellent

Dry Eye Prevalence

0.67

Moderate
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Participants were randomly assigned one of three treatments to use at home: Warm
face cloth (Group 1, conventional treatment: n = 12), Eyebag (Group 2, dry heat: n = 16),
Optase (Group 3, moist heat: n = 14). Randomisation was achieved using the random
number generator function on Excel. Each treatment was randomly assigned a number from
1 to 60. Each participant chose a number and was subsequently given the treatment assigned
to that number.
In accordance with manufacturers’ guidelines, each participant was provided with an
instruction leaflet (refer Appendix 6 (a – c)) and was directed to use the treatment for 10
minutes twice a day for the first two weeks. Frequency of treatment was reduced to 10
minutes once a day from weeks three to eight.
Participants in Group 1 were instructed to pour 200ml of boiled water into a bowl and
allow it to cool for 10 minutes before commencing treatment. This created a water
temperature ranging from 50 °C to 39 °C, over the 10-minute treatment time (tested using
an Easytemp thermometer (HYGIPLAS, Wellingborough, UK) and porcelain bowl).
Participants’ were advised to re-heat the face cloth every two minutes, by immersing it in
the same bowl of cooled, boiled water: to maintain temperature at therapeutic levels.191,192
Group 2 and Group 3 were instructed to heat their compress in the microwave for 15 – 30
seconds, depending on the power of their microwave, as per manufacturers’ guidelines.
7.3.1

Statistical Analysis

Statistical analysis was performed using SPSS (version 25.0). Normality was measured
using Shapiro-Wilk statistical test. Repeated measures ANOVA with Bonferroni post-hoc
analysis was used to analyse repeated measures within each group over time for parametric
data. Friedman’s test was used to analyse repeated measures, within each group, across
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different visits for non-parametric data. With Friedman’s test, post-hoc analysis was
conducted, where appropriate, using WSR test for pairwise comparisons, adjusted using
Bonferroni correction (α = 0.05/number of comparisons: α = 0.05/6 = 0.0083).252 One way
ANOVA with Bonferroni post-hoc analysis was used to analyse data between continuous
variables at baseline and at different visits for parametric data. Kruskal Wallis H was used
for non-parametric data. With KW, post-hoc analysis was conducted, where appropriate,
using MWU test for pairwise comparison, adjusted using Bonferroni correction (α =
0.05/number of comparisons: α = 0.05/3 = 0.0167).252 Parametric data was expressed as
mean ± SD, non-parametric data was expressed as median and IQR. A p-value ≤ 0.05 was
considered statistically significant, apart from Bonferroni adjusted post-hoc analysis as
described above.
7.4 Results
Fifty participants were enrolled between April 2017 and May 2018. The attrition rate
was 16%. Four participants withdrew from the study, without any known adverse reactions,
and were lost to follow-up. Two participants stopped as they felt their symptoms were
worsening. A further two were removed from data analysis as their records were
incomplete. Following attrition, 42 participants (13 males and 29 females) with a median
age of 59.00 (IQR: 50.00 – 69.00) years completed the two-month warm compress
treatment study. At baseline, the prevalence of DF detected within the entire study cohort
was 57.11%, with a median quantity of 0.5 (IQR 0.00 – 3.25) and 0.00 (IQR 0.00 – 2.00)
mites on lash rotation and microscopic examination respectively (WSR: p = 0.008). There
was no significant difference in age (Group 1: 60.00 (IQR 52.00 – 69.00), Group 2: 59.00
(IQR 52.00 – 72.50 , Group 3: 59.50 (IQR 32.00 – 68.00), KW: p = 0.75) or quantity of DF
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on either lash rotation or microscopic examination (KW: p = 0.78 and p = 0.85) between
the three groups before treatment.
Table 41 shows median and IQR for quantity of DF at each visit for each treatment
group. Figure 30 displays the change in quantity of DF detected on eyelash rotation within
each group over the eight weeks. Within treatment analysis showed that the quantity of DF
dropped significantly over the duration of the study in Group 3 (Optase) (Friedman’s p =
0.04). Post-hoc pairwise comparisons using WSR test (alpha adjusted for Bonferroni
correction) revealed only the change from baseline to week eight to be significant (mean:
2.64, Range: 0 – 11 versus mean: 1.42, Range: 0 – 8; WSR p = 0.008). There was no
significant change in DF quantity in Group 1 (Warm Face Cloth) or Group 2 (Eyebag) over
the eight weeks (Friedman’s p = 0.88 and p = 0.66, respectively). Between treatments
analysis did not show any significant difference between the treatments over the eight
weeks (KW p > 0.05, refer Table 39).
The mean and range for quantity of DF detected on microscopic examination at each
visit, for each group, are also shown in Table 41. In contrast to results detected on eyelash
rotation, there was no significant change in DF quantity detected on microscopic
examination over time in each group (Friedman’s p > 0.05) or between treatments (KW p
> 0.05).
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Table 41. Demodex folliculorum quantity (median, IQR), and MGD grade (median, IQR)
before and after treatment. B: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight.
Statistical Tests Applied: α ≤ 0.05 significant. *Significant results highlighted in bold.

Variable
Quantity
Demodex
folliculorum
(n)
Lash
Rotation

Time

Group 1
(Warm Face
Cloth)
N = 12

Group 2
(MGDRx Eye
Bag®)
N = 16

Group 3
(Optase Moist
Heat MaskTM)
N = 14

Kruskal
Wallis

BL

0.00 (0.00 – 5.25)

0.50 (0.00 – 2.00)

1.50 (0.00 – 4.25)

p = 0.78

W2

0.50 (0.00 – 1.75)

0.00 (0.00 – 2.00)

0.00 (0.00 – 1.00)

p = 0.69

W4

0.50 (0.00 – 3.50)

0.00 (0.00 – 3.00)

0.00 (0.00 – 4.00)

p = 0.91

W8

0.50 (0.00 – 8.50)

0.00 (0.00 – 0.00)

0.00 (0.00 – 1.50)

p = 0.28

p = 0.87

p = 0.64

p = 0.04*

Kruskal
Wallis

BL

0.00 (0.00 – 1.75)

0.00 (0.00 – 1.00)

0.00 (0.00 – 2.75)

p = 0.84

W2

1.00 (0.00 – 2.75)

0.00 (0.00 – 0.00)

0.00 (0.00 – 0.00)

p = 0.02

W4

0.50 (0.00 – 1.00)

0.00 (0.00 – 0.00)

0.50 (0.00 – 1.75)

p = 0.32

W8

0.00 (0.00 – 1.75)

0.00 (0.00 – 0.00)

0.00 (0.00 – 1.00)

p = 0.49

Friedman’s

Quantity
Demodex
folliculorum
(n)
Microscope
Friedman’s

MGD
Grade (0-3)

Friedman’s

F

p = 0.72

F

p = 0.67

F

p = 0.18

Chisquare

BL

2.00 (1.00 – 2.00)

2.00 (1.00 – 2.00)

1.00 (1.00 – 2.00)

p = 0.16

W2

2.00 (1.00 – 2.00)

2.00 (1.00 – 2.00)

1.00 (1.00 – 2.00)

p = 0.22

W4

1.00 (1.00 – 1.50)

1.00 (1.00 – 2.00)

1.00 (1.00 – 1.00)

p = 0.92

W8

1.00 (0.00 – 1.50)

1.00 (0.00 – 1.00)

1.00 (0.00 – 1.00)

p = 0.33

p = 0.008*

p = 0.002*

p = 0.002*

195

Post - hoc

Face Cloth

B – W2
B – W4
B – W8
W2 – W4
W2 – W8
W4 – W8

0.271
0.677
0.527
0.496
0.173
0.831

MGDRx
EyeBag®
0.730
0.523
0.344
0.713
0.713
1.000

OPTASETM Moist
Heat Mask
0.023
0.313
0.008*
0.500
1.000
0.125

Figure 30. Box plot illustrating the change in quantity of Demodex folliculorum at
two, four, and eight weeks, with each treatment. Post – hoc analysis: Wilcoxon signed
ranks test pairwise comparison with Bonferroni adjusted correction applied (α ≤ 0.0083
significant). X represents the mean change in quantity of Demodex folliculorum. B:
Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant results highlighted
in bold.
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Table 41 also displays MGD grade mean and SD at each visit, for each group. A
significant improvement in MGD grade with time for each treatment was detected
(Friedman’s p < 0.05, Table 39). The box plot in Figure 31 shows MGD grade at each visit,
for each group. However, post-hoc analysis using alpha adjusted WSR test pairwise
comparisons revealed; only improvements from baseline to week eight in Group 2 (Eyebag)
(WSR p = 0.008); and improvements from baseline to week eight (WSR p = 0.002) and
week two to week eight (WSR p = 0.003) in Group 3 (Optase); were found to be significant.
There was no significant difference found between the treatments at any time point over
the eight weeks (KW p > 0.05, Table 41).
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Median
(IQR)
p value

W2
W4
W8

Face Cloth

MGDRx EyeBag®

OPTASETM Moist
Heat Mask

0 (0 – 0.75)
-1 (-1 – 0)
-1 (-1.75 - 0)

0 (-1 – 0)
-0.5 (-1 – 0)
-1 (-1 – 0)

0 (0 – 0)
0 (-1 – 0)
-1 (-1 – 0)

F

p = 0.008*

Post - hoc

Face Cloth

BL – W2
BL – W4
BL – W8
W2 – W4
W2 – W8
W4 – W8

0.414
0.035
0.030
0.021
0.018
0.414

F

p = 0.002*

MGDRx
EyeBag®
0.527
0.035
0.008*
0.025
0.024
0.157

F

p = 0.002*

OPTASETM Moist
Heat Mask
1.000
0.180
0.002*
0.414
0.003*
0.058

X represents the mean change in MGD Grade. Post – hoc analysis: Wilcoxon signed
ranks test pairwise comparison with Bonferroni adjusted correction applied (α ≤ 0.008
significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant
results highlighted in bold.
Figure 31. Box plot illustrating MGD Grade, derived from composite quality and
expressibility scores of both upper and lower eyelids, at baseline, and two, four, and eight
weeks, with each treatment.

198

Table 42 demonstrates the prevalence of pathogenic and non-pathogenic infestation
for each treatment group, at each point in time. The overall prevalence of DF in each group
at baseline was: Group 1 (Warm Face Cloth) - 66.67%, Group 2 (Eyebag) – 50.00%, and
Group 3 (Optase) – 57.14%. No significant difference was detected between the groups
(KW p = 0.61). This reduced to an overall prevalence of: Group 1 – 58.33%, Group 2 –
25.00% and Group 3 – 50.00% after eight weeks. As can be seen from Table 42, Group 3
showed the greatest change in pathogenic infestation. This likely accounted for the reason
Group 3 appeared to have the greatest overall effect on DF quantity. Group 2 appeared to
have the greatest overall effect on DF prevalence. Nonetheless, no significant difference in
prevalence was established between the groups at week eight (KW p = 0.19). Furthermore,
no significant difference in prevalence of DF infestation was established within the groups
over the eight weeks: Group 1 (Friedman’s p = 0.99), Group 2 (Friedman’s p = 0.18) and
Group 3 (Friedman’s p = 0.49).
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Table 42. Prevalence of pathogenic and non-pathogenic Demodex folliculorum infestation in
each treatment group, at each time point. B: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight.
No Demodex %

Non-Pathogenic

Pathogenic

Overall

(n)

Infestation % (n)

Infestation % (n)

Prevalence

BL

33.33 (n = 4)

33.33 (n = 4)

33.33 (n = 4)

66.67% (n = 8)

W2

33.33 (n = 4)

41.67 (n = 5)

25.00 (n = 3)

66.67% (n = 8)

W4

33.33 (n = 4)

41.67 (n = 5)

25.00 (n = 3)

66.67% (n = 8)

W8

41.67 (n = 5)

25.00 (n = 3)

33.33 (n = 4)

58.33% (n = 7)

Difference

+8.34% (n = 1)

-8.34% (n = -1)

0.00% (n = 0)

-8.14% (n = -1)

Group 2:

BL

50.00 (n = 8)

31.25 (n = 5)

18.75 (n = 3)

50.00% (n = 8)

MGDRx

W2

62.50 (n = 10)

12.50 (n = 2)

25.00 (n = 4)

37.50% (n = 6)

EyeBag®

W4

62.50 (n = 10)

25.00 (n = 4)

12.50 (n = 2)

37.50% (n = 6)

(n = 16)

W8

75.00 (n = 12)

12.50 (n = 2)

12.50 (n = 2)

25.00% (n = 4)

Difference

+25.00% (n = 4)

-18.75% (n = -3)

-6.25% (n = -1)

-25.00% (n = -4)

BL

42.86 (n = 6)

28.57 (n = 4)

28.57 (n = 4)

57.14% (n = 8)

W2

50.00 (n = 7)

35.71 (n = 5)

14.29 (n = 2)

50.00% (n = 7)

Mask

W4

50.00 (n = 7)

28.57 (n = 4)

21.43 (n = 3)

50.00% (n = 7)

(n = 14)

W8

50.00 (n = 7)

35.71 (n = 5)

14.29 (n = 2)

50.00% (n = 1)

Difference

+7.14% (n = 1)

+7.14% (n = 1)

-14.29% (n = -2)

-7.14% (n = -1)

Time

Group 1:
Face Cloth
(n = 12)

Group 3:
OPTASETM
Moist Heat

Figure 32 illustrates a box plot of the modified OSDI score for each group at each
visit. Table 43 displays the mean and SD of the modified OSDI symptoms score for each
group, at each visit. There was a significant improvement in symptom score with time for
each treatment (repeated ANOVA p = 0.04, p = 0.02 and p = 0.02 for Groups 1 – 3,
respectively). As can be seen from Figure 36, the greatest reduction in symptoms appears
to be in Group 2 and Group 3. Post-hoc analysis with Bonferroni pair-wise comparison
revealed; only the reduction in symptoms from baseline to week two and baseline to week
eight (p = 0.03 and p = 0.008, respectively) in Group 2, and reduction in symptoms from
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baseline to week two and baseline to week eight (p =0.01 and p = 0.05, respectively) in
Group 3, were found to be significant. There was no significant difference in modified
OSDI symptom score between the treatments at any time point over the eight weeks
(ANOVA p > 0.05, Table 43).

Post - hoc

Face Cloth

MGDRx EyeBag®

BL – W2
BL – W4
BL – W8
W2 – W4
W2 – W8
W4 – W8

1.000
0.266
0.054
0.673
0.687
1.000

0.033*
0.078
0.008*
1.000
0.100
0.464

OPTASETM Moist
Heat Mask
0.013*
0.064
0.047*
1.000
1.000
1.000

X illustrates mean change in modified OSDI score. Post – hoc analysis: Bonferroni
(α ≤ 0.05 significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight.
*Significant results highlighted in bold.
Figure 32. Box plot illustrating modified OSDI symptom score for each treatment
groups, at each visit.
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Table 43. Dry eye parameters; Modified OSDI symptom score (mean ± SD), Osmolarity
(mean ± SD), tear film instability (%), NITBUT (median, IQR), ocular surface staining
(median, IQR), Schirmer I (median, IQR), before and after treatment. BL: Baseline, W2:
Week Two, W4: Week Four, W8: Week Eight. α ≤ 0.05 significant. *Significant results highlighted
in bold.
Variable
Modified
OSDI
Score
(0-100)

Time

Group 1

Group 2

Group 3

ANOVA

BL

24.21 ± 15.27

39.81 ± 23.21

39.01 ± 20.34

p = 0.12

W2

22.05 ± 15.29

27.40 ± 19.29

24.70 ± 18.87

p = 0.69

W4

15.71 ± 7.86

23.03 ± 19.55

23.65 ± 19.89

p = 0.41

W8

15.14 ± 12.75

16.67 ± 13.07

26.52 ± 17.15

p = 0.10

p = 0.04*

p = 0.02*

p = 0.02*

ANOVA

BL

304.17 ± 18.10

303.53 ± 9.55

318.86 ± 13.44

p = 0.008*

W2

301.27 ± 17.47

304.71 ± 12.98

310.27 ± 16.46

p = 0.41

W4

303.92 ± 18.88

299.93 ± 13.68

305.92 ± 14.69

p = 0.69

W8

305.50 ± 18.82

303.07 ± 11.91

312.86 ± 13.37

p = 0.19

p = 0.60

p = 0.86

p = 0.01*

Chi-square

BL

83.33%

40.00%

71.44%

p = 0.06

W2

54.55%

50.00%

63.67%

p = 0.91

W4

50.00%

53.33%

66.67%

p = 0.78

W8

41.67%

60.00%

64.22%

p = 0.53

p = 0.22

p = 0.87

p = 0.79

Kruskal
Wallis

BL

4.19 (2.81 – 13.46)

5.15 (2.98 – 11.44)

4.13 (2.60 – 5.60)

p = 0.16

W2

7.63 (2.60 – 13.64)

4.90 (2.83 – 11.32)

3.97 (2.60 – 8.20)

p = 0.69

W4

6.44 (2.83 – 11.10)

6.37 (2.64 – 8.21)

4.17 (.60 – 6.90)

p = 0.70

W8

4.14 (3.14 – 9.46)

6.78 (3.56 – 14.87)

5.13 (2.97 – 5.13)

p = 0.34

p = 0.95

p = 0.87

p = 0.60

Kruskal
Wallis

BL

1.00 (0.00 – 2.00)

1.00 (0.00 – 1.75)

0.00 (0.00 – 2.00)

p = 0.98

W2

0.00 (0.00 – 2.00)

1.00 (0.00 – 2.00)

1.00 (0.00 – 3.25)

p = 0.03*

W4

0.00 (0.00 – 0.75)

0.00 (0.00 – 1.00)

0.00 (0.00 – 1.00)

p = 0.72

W8

0.00 (0.00 – 0.75)

0.00 (0.00 – 0.75)

0.00 (0.00 – 0.75)

p = 0.95

p = 0.04*

p = 0.007*

p = 0.04*

Kruskal
Wallis

BL

10.50 (8.25 - 19.00)

32.00 (11.00 – 35.00)

21.50 (5.25 – 28.75)

p = 0.25

W2

8.00 (5.25 – 15.25)

18.00 (11.00 – 35.00)

13.50 (6.25 – 25.25)

p = 0.06

W4

13.50 (5.75 – 17.75)

28.00 (7.00 – 35.00)

13.00 (7.00 – 27.75)

p = 0.67

W8

8.00 (8 – 13.75)

20.00 (15 – 32.00)

17.00 (6.00 – 17.00)

p = 0.07

p = 0.21

p = 0.93

p = 0.57

Repeated
ANOVA

Osmolarity
(mOsm/L)
Repeated
ANOVA

Instability
(%)

Cochran’s Q

NITBUT
(secs)
Friedman’s

Staining
(0-15)
Friedman’s

Schirmer
(mm/5min)
Friedman’s
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Figure 33 displays a box plot of osmolarity values for each group at each visit. There
was a significant reduction in osmolarity for participants in Group 3 over the eight weeks
(repeated ANOVA p = 0.014, refer Table 43). Bonferroni post-hoc analysis showed that
this was significant from baseline to week four only (p = 0.017, Figure 33). There was no
significant change in osmolarity detected for participants in Groups 1 and 2 at any stage
over the eight weeks (repeated ANOVA p > 0.05, Table 43). Overall, repeated measures of
ANOVA taking treatment into consideration as a between participants’ factor, showed no
significant change in osmolarity overtime (p = 0.107).
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Post - hoc

Face Cloth

MGDRx EyeBag®

OPTASETM Moist
Heat Mask

BL – W2
BL – W4
BL – W8
W2 – W4
W2 – W8
W4 – W8

1.000
1.000
1.000
1.000
1.000
1.000

1.000
1.000
1.000
1.000
1.000
1.000

0.220
0.017*
0.980
1.000
1.000
0.699

X denotes mean change in osmolarity. Post – hoc analysis: Bonferroni (α ≤ 0.05
significant). BL: Baseline, W2: Week Two, W4: Week 4, W8: Week Eight. *Significant
results highlighted in bold.
Figure 33. Box plot illustrating osmolarity values for each treatment groups at each
visit.

Tear film instability, an inter-eye difference of ≥ 8mOsm/L, was also measured for
each participant. Table 43 displays the prevalence of tear film instability in each group, at
each visit. As shown in Table 43, after eight weeks tear film instability had reduced in
Group 1 (41.67%) and Group 3 (64.22%) but had increased slightly in Group 2 (60.00%).

204

However, none of these changes were found to be significant within each group over time
(Friedmans p > 0.05) or between each group at any point in time (KW p > 0.05).
Table 43 also demonstrates ocular surface staining mean and range for each group at
each visit. As can be seen from Table 43, there was a significant reduction in ocular surface
staining over time for each treatment (Friedman’s p = 0.04, p = 0.007 and p = 0.04 for
Groups 1 – 3, respectively). Post-hoc analysis, with Bonferroni corrected alpha, using WSR
test pairwise comparisons revealed; only a reduction in staining from week two to week
eight in Group 2 (1.71, range 0 – 8 versus 0.33, range 0 – 2; WSR p = 0.006), and week
two to week eight in Group 3 (mean: 1.77, range 0 – 9 versus mean: 0.50, range 0 – 4; WSR
p = 0.008), were found to be significant. There was no significant difference in ocular
surface staining detected between the treatments at any time over the eight weeks (KW p >
0.05).
Mean NITBUT and Schirmer I scores for each treatment group, at each time point, are
also shown in Table 43 above. No significant change in NITBUT, or Schirmer I score, was
detected over time in each group (Friedman’s p > 0.05), or between treatments (KW p >
0.05).
Employing the dry eye classification (if found to have three or more of the following
parameters; modified OSDI ≥ 13, osmolarity ≥ 308 mOsm/L, inter-eye variability ≥
8mOsm/L, NITBUT < 10 secs, ocular surface staining ≥ 3 Oxford score or Schirmer I score
≤ 5mm/5min), the prevalence of dry eye for each group, at each visit, is shown in Figure
34. No significant change in proportion of subjects with dry eye was detected in any of the
three treatment groups post-treatment (Group 1 – 3: Friedman’s p = 0.36, p = 0.77 and p =
0.28, respectively).
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PREVALENCE DRY EYE DISEASE

53.33

53.85

53.33

33.33

50.00

50.00

66.67

71.43
56.25

50.00

Percentage (%)

OPTASE

78.57

MGDRx EyeBag®

76.92

Face Cloth

Baseline

Week Two

W e e k Fo u r

Week Eight

Figure 34. Prevalence of dry eye disease in each warm compress treatment group at
each time point.
7.5 Discussion
As mentioned previously in Section 1.4.2, DB is most commonly associated with
MGD; however, an association between DF and MGD has also been established in the
literature.7,30,48 Currently, lid scrubs remain the principal treatment recommended for
Demodex blepharitis,3 and warm compress therapy for MGD.138 Intense pulsed light
therapy has been previously used, successfully, to treat DF infestation.283 However, to the
best of the authors’ knowledge, this is the first study to investigate the effect of heat therapy
using warm compresses on DF infestation. This study has shown that Optase may have a
double therapeutic effect, treating MGD and reducing DF in combination. Over the eight
weeks, moist heat therapy from Optase significantly reduced the quantity of DF detected
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using the eyelash rotation technique. No significant change was noted with the moist heat
from the warm face cloth, or the dry heat from the Eyebag. The reason for this is unknown
at present. It could be associated with the compresses ability to achieve a higher treatment
temperature. As mentioned previously, manufacturers of Optase report temperatures
ranging from 50 °C to 41 °C, over the 10-minute duration of therapy.279 However, the
Eyebag achieves temperatures from 46 °C dropping to 39 °C, which is less than the
recommended 40 °C,192 after 5 minutes.280 Similarly, the warm face cloth does not maintain
its heat for longer than two minutes, without needing to be re-heated.191,192 This could affect
the therapeutic temperature achieved by the face cloth with respect to treating DF
infestation. Furthermore, greater quantities of DF have been found in dryer skin.284,285 As
Optase is a moist heat device and Eyebag is a dry heat device, it is possible that moisture
may have played a role in the therapeutic efficacy demonstrated by Optase. However,
further investigation is warranted for verification.
There was a considerable improvement in prevalence of DF infestation in Group 2
(Eyebag) from 50.00% at baseline to 25.00% at week eight (Table 42); yet there was no
significant reduction in the quantity of DF detected on participants with DF in the same
group. Although there was no significant difference in mean quantity of DF between the
three treatment groups at baseline; Group 2 had the lowest quantity and lowest percentage
prevalence of participants with pathogenic infestation of the three groups at baseline.
Therefore, it is possible that these lower numbers of DF within Group 2 affected the
compresses ability to exhibit significant changes over time. As such, a post-hoc power
calculation was conducted on the data, and a low power (1 – β = 0.26) was detected; which
would have affected the power and significance of the results. Future research that focusses
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on pathogenic infestation (to ensure higher quantities of DF per participant), would help
reduce any limitations caused by lower numbers of DF.
Similarly, no significant change was detected in quantity of DF using the traditional
modified Coston method,25 for any of the warm compresses studied. Limitations of this
technique regarding under-counting of DF have been discussed previously in the
literature,25,29,50 and in Section 7.5. Similar to results from Chapter 7, the quantity of DF
detected whilst rotating the eyelash in-situ was significantly greater than that observed on
microscopic examination in the current study also (paired t-test p = 0.01, p = 0.01 and p =
0.007 for baseline, week four and week eight, respectively). No significant difference was
observed between both techniques in week two, where overall a low quantity of DF was
detected. The authors infer that the low quantity of DF detected in week two may be as a
result of participants using the warm compresses for 10 minutes twice a day; thus,
increasing the length of time DF were subjected to heat therapy. After week two,
participants reduced treatment time to 10 minutes once a day, and the quantities of DF
appeared to increase again slightly. The authors postulate that the reason for a lack of
significance found using the modified Coston method was due to the limitations of the
method, previously described (Section 7.5): resulting in under-counting and misrepresentation of the degree of DF infestation present.
As mentioned previously in Section 2.3.4, hyperosmolarity is accepted as one of the
characteristic signs of DED and ocular surface inflammation.117 In MGD, availability of
meibum to the ocular surface is decreased, either through reduced secretion (possibly due
to poor expressibility, or severe meibomian gland dropout), or a poor quality secretion; thus
causing quicker tear evaporation and, as one would expect, hyperosmolarity.286 Although,
reports in the literature differ with regards to this.286–289 In the current study, participants in
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Group 3 (Optase) demonstrated a significant improvement in osmolarity overtime.
However, participants in Group 3 had a greater osmolarity at baseline in comparison to
participants in the other two groups, which is likely to have influenced the overall reduction
in osmolarity values detected in Group 3. Comparable to the current study, Kim et al290
found a significant improvement in osmolarity post-treatment in participants with a baseline
osmolarity of > 307mOsm/L, but no significant improvement in osmolarity post-treatment
in participants with an osmolarity of < 307mOsm/L at baseline. The authors deduced that
heat treatment with a thermal pulsation device was effective at improving osmolarity in
participants with abnormal tear osmolarity, but did not have an effect on those with normal
osmolarity.290 In contrast, Godin et al287 discovered that treatment of MGD using thermal
pulsation on a cohort of participants with Sjogrens syndrome initially caused an increase in
osmolarity two months after treatment (305.2 vs. 315.6, p = 0.026), but no significant
increase one year after treatment (305.2 vs 311.0, p = 0.86). Baseline osmolarity values in
Group 1 (Warm Face Cloth) and Group 2 (Eyebag), in the current study, were similar to
those found by Godin et al.287 However, neither the heat therapy from the warm face cloth
or the Eyebag caused an increase in osmolarity values after two months of treatment.
Giannaccare et al288 investigated the performance of an ocular surface work-up, using
modern automated non-invasive techniques for diagnosing MGD: such as NITBUT,
osmolarity, lipid layer thickness and non-contact meibography. The authors discovered
significant differences between MGD participants and controls for NITBUT, OSDI
symptom score and meibomian gland loss. However, they found no significant difference
in osmolarity values between the two groups. Similar to the current study, and the study by
Godin et al287, Giannaccare et al288 found a low mean osmolarity value within their MGD
participants using the TearLabTM (303.5 ± 9.8 mOsm/L). The lack of significance
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discovered in the present study may be related to the low osmolarity found amongst MGD
patients.287,288 It has been proposed that MGD disease may not cause hyperosmolarity, as
the disease alone may not be enough to alter the homeostatic control in many
participants.288,289 In the present study, the authors have been unable to find an explanation
for the higher osmolarity values observed in Group 3 (Optase). TearLabTM has been shown
to provide repeatable and reproducible tear osmolarity measurements on a healthy ocular
surface,178 but becomes less repeatable and shows increased variability with increasing
disease severity.171,291 Participants in Group 3 were not significantly older, or more
symptomatic, and did not have a significantly greater quantity of DF, MGD, ocular surface
staining, reduced TBUT or tear secretion at baseline. Furthermore, repeated measures of
ANOVA, with treatment as a between participants’ factor, showed no significant change in
osmolarity overtime. Therefore, the authors infer that the hyperosmolarity observed at
baseline in Group 3 may be coincidence, or may be due to measurement errors that can
occur with TearLabTM.
Heat therapy increases the availability of meibum to the tear film and ocular surface,
helping to improve the stability of the tears, and thus, increase TBUT.191,280,292–294 In the
current study, the greatest improvement in NITBUT was with the Eyebag, a dry warming
device. These results are in keeping with Arita et al292 who found that only dry warming
devices were able to significantly improve the oily tear film layer, and reduce evaporation.
In the same study, no improvement was observed after the repeated use of a hot towel
compress, and the authors’ concluded that moisture on the surface of the eyelid skin could
give rise to evaporative cooling; thus limiting the beneficial effects of warming.292 There
was no significant increase in NITBUT demonstrated in the current study. This may be
accredited to the differences in measurement techniques and timings of measurements post210

treatment. In previous studies, TBUT has been evaluated invasively using fluorescein,294,295
or non-invasively using a TearScope Plus.280,293 Fluorescein dye is invasive and has been
shown to alter the tear film and affect the natural TBUT.296,297 TearScope Plus is a noninvasive method; however, it is a subjective measurement, and depends on the examiner
detecting the first perceptible break in the fine line pattern. In the current study, NITBUT
was measured using the automated Medmont E300 Corneal Topographer; which has
demonstrated good repeatability with a high sensitivity and specificity for diagnosing
moderate to severe DED.174 Therefore, all measurements were objectively taken by the
topographer, which is more sensitive to small tear film instabilities. Furthermore, in
previous studies, many TBUT measurements have been taken immediately after, 5-10
minutes after, or up to 1 hour after heat therapy has been applied.280,292,293 However, in the
current study, participants applied the warm compresses at home in the evenings. Therefore,
there was a longer time period between last warm compress and time of measurement.
While immediate effect of treatment has not been shown in the current study, the results do
demonstrate the ‘realistic effect’ of each treatment on participants’ tear film and ocular
surface.
Another shortcoming of the current study is that participants were applying the heat
therapy at home. As such, it was not possible to measure the temperature of the compress
each time it was used. Inadequate lid warming of warm compresses have been noted
previously.298,299 Although all participants were given written instructions, it is possible that
participants may not have heated the compress sufficiently, or did not complete the full 10minute therapy requested of them. To monitor compliance, at each aftercare, participants
were asked to report on how many evenings and for how long they used the warm compress
as instructed. At baseline overall reported compliance was 83.61%: 81.14% warm face
211

cloth, 84.02% Eyebag, and 85.16% Optase. This remained relatively stable over the
duration of the study. The overall reported compliance at the end of the study was 83.74%:
77.92% warm face cloth, 86.81% Eyebag, and 85.45% Optase. Poor compliance is a
problem with examining efficacy of treatments; thus, it would be preferable to have 100%
compliance and treatment delivered in-house by the examiner. However, the use of warm
compresses in the current study is likely a better indicator of warm compress use in ‘real
world’ environments. Nonetheless, the warm face cloth group had the lowest overall
compliance, and the potential impact that this may have had on the compresses ability to
demonstrate significant results for treating MGD of DF blepharitis cannot be excluded. It
is difficult to monitor compliance for use of warm compresses in the home. However,
following-up with participants at return visits, requesting they demonstrate how they use
the compresses, may be a good way to remind participants of the protocol, correct any
mistakes and overall help improve compliance.
The Eyebag and Optase significantly reduced the presence of MGD over the duration
of the study. Although some improvement in MGD was seen with the warm face cloth,
these changes were not found to be significant. Furthermore, the warm face cloth compress
had to be re-dipped every two minutes, as it lost its heat quickly. Therefore, compresses
that can be heated once and used for 10 minutes at a time are more efficient and convenient
for patients. A higher rate of attrition was also found in the warm face cloth group compared
to either of the other two groups, and overall compliance was lowest in this group. The
authors feel that this was due to the inconvenient nature of the treatment. As the study was
conducted on participants with a relatively low grade of MGD and DF infestation, this may
have impacted on the ability of the compresses to elicit change. Future studies should

212

examine participants with a greater severity of MGD and DF infestation to demonstrate a
more magnified response to treatment.
7.6 Conclusion
The microwaveable compresses, Eyebag and Optase, exhibited a greater ability to treat
MGD, reduce symptoms and reduce ocular surface staining, compared to the more
‘traditional’ warm face cloth compress. Optase demonstrated the ability to provide dual
treatment to patients with MGD and Demodex blepharitis. Further research is required to
investigate whether moisture, heat, or a combination of both are the underlying therapeutic
forces at play.
It has previously been reported that DF tails are visible within the eyelash follicle while
manipulating the eyelash in situ during a slit-lamp biomicroscope examination.50 In the
early stages of this research project it became evident that counting DF mites on
microscopic examination of the epilated eyelash alone was resulting in under counting and
mis-representing the degree of infestation present. In an effort to counter-act this, from
recruitment phase two onwards DF quantity on lash manipulation and lash epilation were
counted. Chapter 8 discusses the comparison of the two investigative methods used
throughout this research project. The results of this observational study have been accepted
for publication in Eye and Contact Lens and has been adapted accordingly for Chapter 8.
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CHAPTER EIGHT: THE CLINICAL USE OF EYELASH MANIPULATION IN
THE EXAMINATION OF DEMODEX FOLLICULORUM BLEPHARITIS
8.1 Abstract
Purpose: To compare the efficacy of using an eyelash manipulation technique to the
traditional eyelash epilation and subsequent microscopic examination technique, when
investigating for the presence of DF in a clinical setting.
Methods: Four hundred and twenty-eight eyelashes of 107 participants were selected
to evaluate the association between the quantity of DF visible on eyelash manipulation to
that counted on microscopic examination of the same epilated eyelash. Eyelash
manipulation was conducted as described in Section 2.2.9. As the eyelash was manipulated,
the number of DF seen emerging from the follicle was counted. The same eyelash was then
epilated and the number of DF on the epilated eyelash was counted using the modified
Coston method (Section 1.7.2). Data was analysed to check for agreement between the two
techniques.
Results: Intra-class correlation co-efficient showed moderately good agreement for
assessing the quantity of DF (0.78) between both techniques. However, the Bland-Altman
plot suggested consistently higher quantities were discovered on eyelash manipulation. The
overall median quantity of DF was also greater on eyelash manipulation than on
microscopic examination of the epilated eyelash (0.00 mites, IQR: 0.00 – 2.00 and 0.00
mites, IQR 0.00 – 1.00, respectively) (p = < 0.001). Weighted kappa (κw = 0.56) indicated
weak levels of agreement between the two methods for addressing severity of infestation.
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Conclusion: Eyelash manipulation exhibited larger quantities of DF than complete
epilation of the eyelash with microscopic examination. In a clinical setting, complete
eyelash epilation is not necessary to accurately detect Demodex blepharitis requiring
treatment.
8.2 Introduction
As mentioned in Section 1.4, DF typically reside in clusters within the eyelash
follicles41,43,62 (Figure 35 (a)) and DB typically reside in solitude, deeper in the sebaceous
and meibomian glands (Figure 35 (b)).41,61,62,65 The scraping movement of the mites within
the eyelash follicles damages the follicles,43,62 causing hyperplasia and hyperkeratinisation
of the epithelial cells, which becomes visible as CD at the base of the eyelashes (Figure
35(c)). Chronic Demodex infestation also causes the eyelash follicles to widen and the
eyelashes within to become looser, which can lead to trichiasis, madarosis, and eyelash
misdirection.49,62
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(a)

(b)

(c)
Figure 35. (a) Demodex folliculorum cluster on an epilated eyelash; (b) Single
Demodex brevis; (c) Cylindrical dandruff visible as a translucent cuff along the base of
the eyelash, black arrows.
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Confirming the presence of DF and thus diagnosis of Demodex blepharitis can be
achieved by eyelash epilation,25 and inspecting the eyelash under a light microscope, or
smartphone145; or

laser confocal microscopy, to view DF in-vivo.16,65,146 Previous

investigators have described the use of eyelash manipulation as an adjunct procedure prior
to eyelash epilation in an attempt to stimulate DF to move towards the opening of the
eyelash follicle.12,61 In 2013, Mastrota indicated that it was possible to view, on the slitlamp biomicroscope, DF tails emerging from the eyelash follicles as the eyelash was rotated
in-situ (as can be seen in Figure 36(a)).50
Eyelash epilation alone often results in miscounting, as many DF remain within the
follicle after the eyelash has been removed (Figure 36(b)).25,29,50 This became particularly
apparent during data collection for the pilot study. Clearly infested eyelash follicles were
being given a recorded count of zero DF on microscopic examination: as the eyelash would
fall out leaving all the DF behind within the eyelash follicle. This recurrent outcome
prompted this investigation into evaluating the benefit of incorporating eyelash
manipulation into the Demodex investigation routine. Furthermore, eyelash manipulation
removes the stress and discomfort for patients that can be associated with having the eyelash
epilated.
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(a)

(b)
Figure 36. Illustrates manipulation of the eyelash within the follicle to observe
Demodex folliculorum infestation in-situ (a) Demodex folliculorum visible emerging
from the follicle during eyelash manipulation, black arrow. (b) Demodex folliculorum
remaining within the follicle after the eyelash has been epilated, black arrow.
The current study aimed to show that complete epilation of the eyelash is not always
necessary in a clinical setting, and eyelash manipulation may be a better indicator for
severity of infestation than eyelash epilation.
8.3 Methods
Four hundred and twenty-eight eyelashes of 107 participants, one from each eyelid,
were chosen to compare the quantity of DF detected using the two techniques previously
described: eyelash manipulation (Section 1.8.4) and microscopic examination (Section
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1.8.2) of the same epilated eyelash. Participants were recruited through the National
Optometry Centre, TU Dublin.
Each participant was examined for the presence of DF on the slit-lamp biomicroscope
as previously described (Section 2.3.9). In keeping with the modified Coston method, lashes
with CD, if present, were selectively chosen to maximize the chance of finding DF.25 In the
absence of CD, eyelashes were chosen at random. As described previously, eyelash
manipulation stimulates DF within the follicle, to emerge from the follicle opening (arrow
Figure 36 (a)). However, often in severely infested follicles, after the eyelash was epilated,
all or most of the DF remained within the follicle (Figure 36 (b)). This resulted in an
inaccurately low count on microscopic examination of the eyelashes.
The quantity of DF visible on eyelash manipulation was compared to the quantity of
DF visible on the microscope. It was difficult to count precise numbers in highly infested
follicles, due to the greater quantities of DF present. Therefore, a ‘severity of infestation’
was categorised based on the quantity of DF counted on eyelash manipulation, as can be
seen in Table 44. This system was based on work by Randon et al65 using in-vivo confocal
microscopy, who distinguished ≤ 3 mites per follicle as a low rate of infestation, and
deemed non-pathogenic; and ≥ 4 mites per follicle as a high rate of infestation, and
considered pathogenic. In the current study, it was discovered that several follicles were
extremely infested (~ 10 mites visible in the follicle). As such, a second pathogenic group
was included for analysis: severely infested (≥ 7 mites).
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Table 44. Severity of Demodex folliculorum infestation of the eyelash follicle.
Grade

Description

0

No mites present

1

Mild: Non-Pathogenic
(1 – 3 mites present)

2

Moderate: Pathogenic
(4 – 6 mites present)

3

8.3.1

Severe: Pathogenic
(≥ 7 mites present)

Statistical Analysis

There are no previous studies that have directly compared the quantity of DF mites
visible on eyelash manipulation and microscopic examination. As a result, expected mean
and SD were not known. Data from the first 100 eyelashes were used to calculate the
minimum number of pairs required. This was calculated using MedCalc® (ver.18.9.1),
alpha 0.05, beta 0.8. From this, a minimum number of 255 pairs was required for a method
comparison study using the Bland-Altman plot.
Statistical analysis was performed using SPSS version 25.0. Wilcoxon signed-rank test
was used to compare the means of the two groups. Agreement between the two techniques
was measured using ICC and Bland Altman’s limits of agreement method300 for continuous
variables (quantity of DF) and κw for ordinal variables (severity of infestation).
8.4 Results
Four hundred and twenty-eight eyelashes of 107 participants (39 males: 68 females,
median age 54.00 years, IQR 33.00 – 65.00 years) were assessed for the presence of DF by
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means of eyelash manipulation in-situ and subsequent epilation of the same eyelash for
microscopic examination, by the modified Coston method.25 Demodex folliculorum was
detected on 44.16% of the eyelashes tested.
Quantity of Demodex folliculorum
Intra-class correlation co-efficient analysis was used to establish the level of agreement
between both investigation techniques. With regards to examining quantity of DF detected
using both techniques, the ICC was in moderately good agreement (ICC = 0.78: 95%
Confidence Intervals 0.69 – 0.84). A cross-tabulation of the quantities of DF found using
both techniques is shown in Table 45. Both techniques found no Demodex folliculorum on
239 eyelashes, non-pathogenic infestation (≤ 3 Demodex folliculorum) on 111 eyelashes
and pathogenic infestation on 29 eyelashes. However, pathogenic infestation was missed
on six eyelashes using eyelash manipulation in comparison to 43 eyelashes using
microscopic examination (WSR p < 0.001).
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Table 45. Cross tabulation of the quantity of Demodex folliculorum detected on
eyelash manipulation versus microscopic examination. Green numbers indicate the
quantity of eyelashes on manipulation that failed to detect pathogenic infestation (≥ 4
Demodex folliculorum). Purple numbers indicate the quantity of eyelashes on microscopic
examination that failed to detect pathogenic infestation.

Eyelash Manipulation Quantity

Microscope Quantity

Total

Total

0

1

2

3

4

5

6

7

9

16

0

239

10

3

0

1

0

0

0

0

0

253

1

21

22

3

1

0

0

0

0

0

0

47

2

13

10

8

2

0

1

0

0

0

0

34

3

8

4

3

3

3

0

1

0

0

0

22

4

3

3

5

5

5

1

0

0

0

0

22

5

1

0

2

3

1

2

1

0

0

0

10

6

4

4

3

2

4

0

2

1

0

0

20

7

2

1

0

0

0

1

0

0

0

0

4

8

0

2

0

0

3

2

1

0

0

0

8

9

0

0

0

1

0

0

0

0

0

0

1

10

0

0

0

0

1

0

1

0

0

0

2

11

0

0

0

1

0

0

0

0

1

0

2

12

1

0

0

0

0

0

1

0

0

0

2

13

0

0

0

0

0

0

0

0

0

1

1

292

56

27

18

18

7

7

1

1

1

428
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The level of agreement between both techniques was assessed using the Bland-Altman
method by examining the mean difference and constructing limits of agreement.300 As data
was not normally distributed (Shapiro-Wilk p < 0.001), a non-parametric form of limits of
agreement method was incorporated. This was achieved by ordering the data, and placing
the upper and lower limits of agreement at the top and bottom 5% of the ordered data
respectively.301 The difference between both techniques, eyelash manipulation (A) and
microscopic examination (B) (A - B), was plotted on the y-axis against the average of both
techniques (A + B)/2 on the x-axis (refer Figure 37). The mean difference value was 0.64
mites, with a 95% confidence interval of 0.45 and 0.83 mites. A clear positive trend can be
seen in Figure 37: as the average quantity of DF increases, the greater the difference
between the two methods. This implies that eyelash manipulation (method A) presents
higher quantities of DF than microscopic examination (method B), especially in severe
infestations. In agreement with this interpretation, the overall median quantity of DF
detected was significantly greater using eyelash manipulation (0.00 mites, IQR: 0.00 – 2.00)
compared to microscopic examination (0.00 mites, IQR: 0.00 – 1.00) (p = < 0.001).
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Quantity of Demodex folliculroum: Manipulation (A)
versus Microscopic Examination (B)
5

Difference (A - B)

4
3
2
1
0
-1
-2
0

2

4

6

8

10

12

Average (A + B)/2

Figure 37. Bland Altman plot illustrating the 95% limits of agreement between the
quantity of Demodex folliculorum on eyelash manipulation (A) and microscopic
examination (B). Purple lines show limits of agreement (Upper 4.0, Lower -1.00), and the
red line shows the mean value (0.64) of the differences.
To examine the repeatability of the eyelash manipulation versus microscopic
examination techniques, participants were asked to return for a subsequent check two weeks
later. Data from 280 eyelashes was analysed (70 participants, four eyelashes from each).
The results of the second analysis were in good agreement with the original examination.
A mean difference of 0.5 mites (95% confidence interval of 0.32 to 0.68 mites) with upper
and lower limits of agreement at 4.0 and -1.0 as previously were found. Figure 38 illustrates
the Bland-Altman plot constructed, which is very similar to that displayed above in Figure
37.
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Bland Altman Repeatability Plot.
Quantity of Demodex folliculorum: Manipulation (A) versus
Microscopic Examination (B)
10

Difference (A-B)

8
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4

6

8

10

Average (A+B)/2

Figure 38. Bland Altman repeatability plot illustrating the 95% limits of agreement
between the quantity of Demodex folliculorum on eyelash manipulation (A) and
microscopic examination (B). Purple lines show limits of agreement (Upper 4.0, Lower 1.0), and the red line shows the mean value (0.5) of the differences.

Severity of Infestation
In an attempt to counteract estimating DF quantity during eyelash manipulation, each
eyelash was graded from 0 – 3 according to severity of infestation. The frequency
distribution of severity of infestation detected using both techniques are presented in Table
46. For eyelash manipulation and microscopic examination respectively, the majority of
eyelashes were classified as Grade 0 (59.11% and 68.22%) or Grade 1 (24.06% and
23.69%). However, the percentage of eyelashes demonstrating pathogenic infestation,
either Grade 2 (12.15% and 7.47%) or Grade 3 (4.67% and 0.77%) was greater using
eyelash manipulation compared to microscopic examination.
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Additionally, eyelash

manipulation identified a greater severity of infestation on 95 eyelashes, in comparison to
only 20 eyelashes for microscopic examination (WSR p < 0.001).
Table 46. Severity of infestation frequency distribution.
Severity of Infestation
Eyelash Manipulation

Microscopic Examination

Grade

Description

Frequency
(n)

Percent
(%)

Frequency
(n)

Percent
(%)

0

No D. folliculorum

253

59.11

292

68.22

103

24.06

101

23.59

52

12.15

32

7.47

20

4.67

3

0.77

1
2
3

Mild, non-pathogenic
infestation
Moderate, pathogenic
Infestation
Severe, pathogenic
Infestation

Table 47 illustrates a cross-tabulation of the ‘severity of infestation’ groups. Using the
accepted technique of examining DF on microscopic examination, 292 eyelashes were
classified as having no DF on microscopic examination. However, of those 292 eyelashes;
42 (14.33%) were classified as mildly infested, eight (2.77%) moderately infested, and three
(1%) severely infested, when examined using eyelash manipulation. By comparison, 253
eyelashes were classified as having no DF on eyelash manipulation. Of those 253 eyelashes;
only 13 (5%) were classified as mildly infested, one (0.33%) moderately infested (grade 2),
and none were severely infested (grade 3) on microscopic examination.
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Table 47. Cross tabulation of the severity of infestation detected on eyelash
manipulation versus microscopic examination. Green numbers indicate the quantity of
eyelashes on manipulation that failed to detect pathogenic infestation (≥ 4 Demodex
folliculorum). Purple numbers indicate the quantity of eyelashes on microscopic
examination that failed to detect pathogenic infestation.

Eyelash
Manipulation

No Demodex
folliculorum
Mild, NonPathogenic

Moderate,
Pathogenic
Severe,
Pathogenic
Total

No D.
folliculorum

Microscope
Mild, NonPathogenic

Moderate,
Pathogenic

Severe,
Pathogenic

Total

239

13

1

0

253

42

56

5

0

103

8

27

16

1

52

3

5

10

2

20

292

101

32

3

428

To examine the level of agreement between both methods on an ordinal scale,302 κw
statistics were used. There were 313 (73.13%) observed agreements and 201 (46.96%)
agreements expected by chance. Weighted kappa (κw = 0.56) was slightly greater than
unweighted kappa (κ = 0.49). Nonetheless, the level of agreement between both techniques
for measuring severity of infestation appears to be relatively weak.200
8.5 Discussion
Infestation of the eyelash follicle with large quantities of Demodex has become a wellknown underlying cause of recalcitrant blepharitis.7,43,46,49,63,64 Clinically in practice, the
importance of ascertaining the quantity of DF is to establish if there is pathogenic
infestation (≥ 4 mites per follicle) or non-pathogenic infestation present. This will help a
practitioner in deciding whether to treat or monitor a patient. Currently, the most common
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method of investigation for infestation has required epilating the eyelash in order to count
any DF present. This technique, the Coston method,43 has been previously described in
detail in Section 1.8.1. However, there were several limitations to this method. The
modified Coston method (described in Section 1.8.2) was developed to account for these
limitations, which is the technique predominantly used by investigators today.25,30,32,45,52,303
However, even after modifications have been made to these epilation methods, as has been
noted previously25,29,50 and in the current study, often DF remain within the follicle after
the eyelash has been removed; resulting in under-counting on microscopic examination.
The present study has shown that eyelash manipulation without epilation is better at
detecting pathogenic levels of infestation than the modified Coston method.25 This
manipulation technique would work well in a clinical setting, and may help improve
practitioners’ confidence and ability to detect pathogenic DF infestation requiring
treatment. Although ICC revealed a moderately good level of agreement (0.78) between
both methods, the Bland-Altman method suggested consistently greater quantities of DF
visible on eyelash manipulation than on microscopic examination. This analysis was further
strengthened, as the overall median quantity of DF detected was greater on eyelash
manipulation and repeated examination on a second visit showed similar results. The
authors believe that the strong agreement between both methods with respect to no DF
present and low non-pathogenic levels of infestation was responsible for the higher level of
agreement detected with ICC. However, the eyelash manipulation method appeared to be
more effective with greater severity of infestation.
An overall greater range of DF was detected on microscopic examination (range 0 –
16) compared to eyelash manipulation (range 0 – 13). This was on account of the subjective
nature of observing the number of DF tails discernable on eyelash manipulation. By
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comparison, it is possible to precisely count the number of DF visible on a microscope slide.
However, as mentioned above, the recognised method of eyelash epilation and counting of
DF on the microscope can be imprecise and often leads to miscounting.25,50 Moreover, using
the eyelash manipulation technique, the differentiation between detecting the presence of
no DF or one to three tails compared with four to six tails, or greater than seven tails, is
quite unmistakeable; as can be seen from the strong agreement between both techniques in
non-pathogenic infestation (refer Table 40). Therefore, in a clinical setting where
pathogenic infestation can be considered ≥ 4 mites per follicle, exact numbers for large
quantities are not necessary: as it is evident that the follicle is severely infested.65
Furthermore, as can be seen from Table 39and Table 41, only six eyelashes (1.44% of
the eyelashes included in the study) detected pathogenic DF on the microscope and not on
eyelash manipulation. By comparison, 43 eyelashes (10.01%) detected pathogenic DF
infestation on eyelash manipulation but not on the microscope. Hence, there appears to be
almost a 10-fold greater likelihood of identifying pathogenic DF infestation on eyelash
manipulation than on microscopic examination of the epilated eyelash. This clearly
illustrates the limitation of using eyelash epilation and microscopic examination in isolation
when examining for DF infestation. These damaged eyelash follicles were visibly infested.
However, as the eyelashes were removed without removing all the DF within the damaged
follicle, the severity of infestation present was erroneous. There was an increased
discrepancy between both methods for detecting severity of infestation as the severity of
infestation increased, confirmed by the weak level of agreement detected with weighted
kappa (κw = 0.56). In clinical studies, agreement analysis between two methods is
conducted to assess if a new method is good enough to replace an old one; with a
recommendation of 80% as the minimum acceptable agreement value.200 This high level of
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agreement was not achieved in the current study. However, it is believed that the eyelash
manipulation technique outperformed the accepted eyelash epilation technique: thus,
causing the observed disagreement between the two techniques. As eyelash manipulation
appears a better indicator of pathogenic infestation, it should be considered more often in
clinical and research settings.
Apart from under-counting, a second disadvantage of eyelash epilation is the
discomfort and anxiety associated with epilating several eyelashes at each examination.
Manipulating the eyelash without epilation is less stressful and more comfortable for the
patient. Furthermore, in the current study, this technique was found to be more accurate for
determining quantity and assessing severity of infestation. Additionally, madarosis as a
result of chronic blepharitis has been previously reported in the literature.25,304 It was noted
that several patients declined to part-take in the study; they were apprehensive about having
their eyelashes removed when they felt they had so few eyelashes remaining. As such, from
a cosmetic viewpoint, eyelash manipulation is a preferred technique.
As mentioned in Section 1.8.3, confocal laser scanning microscopy is a relatively new,
non-invasive technique that has been used to detect DF in-vivo.16,65,146 Studies have
compared laser confocal microscopy to the modified Coston method, but found no
significant difference in prevalence or quantity of DF detected between either method.16,65
However, these studies had much smaller patient cohorts than the current study (n = 2565
and n = 1516), which may account for the lack of significance found. Additionally, confocal
laser scanning microscopes are expensive, specialised pieces of equipment, mainly utilised
in specialised clinics and research laboratories. General optical practices are not likely to
invest in such technology. On the other hand, all optical practices have access to a slit-lamp
biomicroscope, and the likelihood is that all optometrists will encounter patients attending
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with blepharitis and CD. As such, eyelash manipulation as part of a slit-lamp biomicroscope
routine to examine for presence of DF and assess severity of infestation may be more clinic
and practitioner friendly than a confocal laser microscope.
8.6 Conclusion
The results of this study confirm the early observations in the pilot and extended
studies (Chapter 5), that counting DF visible on microscopic examination alone was often
mis-representing the degree of infestation present. Eyelash manipulation demonstrated
greater quantities of DF than complete epilation of the eyelash and was superior for
identifying moderate to severe pathogenic levels of infestation. However, eyelash epilation
and microscopic examination will still be required in certain investigative settings.
Epilation is still required to distinguish between DF and DB, or in certain specialised
clinics/laboratories where isolation of bacteria from Demodex may be required. However,
in clinical practice, eyelash epilation is not essential to accurately identify pathogenic DF
infestation and Demodex blepharitis necessitating treatment. Hence, going forward,
practitioners should feel confident in being able to detect Demodex blepharitis in practice
without the need to epilate patients eyelashes.
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CHAPTER NINE: SUMMARY, CONCLUSIONS AND FUTURE RESEARCH
9.1 Summary and Conclusions
The research presented in this thesis provides optometrists and ophthalmologists with
evidence-based results into the safety and efficacy of over-the-counter products available
for the treatment of Demodex blepharitis. This provides practitioners effective alternatives
to TTO and ivermectin, which can be managed in-house without the need for further
referral. Furthermore, the current study highlights the ability to detect pathogenic
infestation requiring treatment without the need for eyelash epilation and microscopic
counting of Demodex mites on slides. In clinic, eyelash manipulation at the slit-lamp is a
more patient- and practitioner- friendly technique that is more effective at demonstrating
pathogenic DF infestation requiring treatment.
9.1.1

Development and validation of a General Health and Lifestyle questionnaire

Chapter 3 discussed the development and validation of the GHL questionnaire. Results
found that age remains the most significant risk factor for Demodex blepharitis, which was
in good agreement with previous research.13,28,77 An interesting potential association
between DF and makeup was detected. It appears that makeup may have a protective
mechanism against DF infestation. The questionnaire demonstrated moderate to good
repeatability. However, there were several limitations, especially with the variety in number
of response items to each question. As such, the questionnaire was not utilised after the
second recruitment phase. Instead, the research concentrated on the efficacy of treatment
products going forward.
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9.1.2

Development and validation of a modified Ocular Surface Disease Index

questionnaire
Chapter 4 discussed the development and validation of the modified OSDI symptom
questionnaire. The questionnaire was modified to include questions such as itch and debris
at the base of the eyelashes, which are commonly associated with blepharitis.16,28,46,47 The
modified OSDI questionnaire demonstrated good internal consistency and repeatability.
Good repeatability validated the use of the questionnaire to observe subjective symptoms
over time in a clinical setting. The questionnaire exhibited a sensitivity value of 70.75%.
This means that there is a 70.75% chance that a positive result using the questionnaire alone
would correctly identify the presence of DF. However, with regards to confirming the
presence of DF infestation and establishing which participants require further intervention,
this would not be sufficient. To the best of the author’s knowledge, this was the first study
to examine the prevalence of ocular DF infestation and its associated symptoms in an Irish
population. Furthermore, it was the first study to show an association between increasing
quantity of DF and increasing severity of the symptom ‘itchy eyes’. Results of the study
discussed in Chapter 4 have been published in International Ophthalmology.45
9.1.3

The

efficacy

of

baby

shampoo,

OCuSOFT,

TTFW

and

microblepharoexfoliation in the treatment of Demodex folliculorum blepharitis
Chapter 5 discussed the results of the pilot study and the extended treatment study. The
pilot study compared the efficacy of OCuSOFT to 10% baby shampoo in a two-week
treatment study. Results showed that OCuSOFT significantly reduced the quantity of DF,
but not presence; and baby shampoo had no effect on DF quantity or presence. The extended
treatment study was conducted to improve on limitations of the pilot study following peer-
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review. Firstly, the study was extended to four weeks, to ensure sufficient time was given
to treat DF infestation, given their lifespan is 14–18 days.40,42,43,61 Secondly, both eyes were
treated with the same treatment, to prevent cross-contamination through migration of DF
from the control eye to the treated eye. Thirdly, reviewers suggested comparing OCuSOFT
to a tea tree-based product (TTFW) as opposed to baby shampoo. The BlephExTM device
was also used on one group of participants to evaluate if any additional benefit was attained
from microblepharoexfoliation of the eyelids prior to home lid scrubs. Results of the
extended study demonstrated that both OCuSOFT and TTFW were effective at reducing
the quantity of DF. Tea tree-based face wash also has the added benefit of being used as a
face wash and treating DF in hair follicles all over the face and not just the eyelashes. The
use of BlephExTM demonstrated a greater reduction in symptoms although it was not
significantly better. Results of the extended study discussed in Chapter 5 have been
published in Contact Lens Anterior Eye.52
9.1.4

Effect of lid hygiene on the tear film and ocular surface

Chapter 6 evaluated the effect blepharitis lid cleansers have on the tear film and ocular
surface and examined the prevalence of DF in a young population. No adverse ocular events
were detected following the use of OCuSOFT or TTFW for up to eight weeks. However, a
significant increase in tear film instability was detected after eight weeks of lid scrubs with
10% baby shampoo. The findings from this study are in keeping with recent studies that
have found that baby shampoo could have a damaging effect on goblet cell density,186 and
provides further evidence to practitioners to move away from recommending lid scrubs
with baby shampoo when treating blepharitis. In agreement with previous research,23 a low
prevalence of DF was observed amongst the young study population. A paper on the results
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of the study discussed in Chapter 6 has been accepted for publication in Contact Lens &
Anterior Eye.
9.1.5

Effect of warm compress therapy on Demodex folliculorum infestation

Finally, Chapter 7 examined the efficacy of using heat from warm compresses to treat
DF blepharitis. Three warm compress treatments were compared: Warm face cloth,
MGDRx EyeBag® and OPTASETM Moist Heat Mask. Warm compress therapy was
conducted for eight weeks. Both the MGDRx EyeBag® and OPTASETM Moist Heat Mask
exhibited superior efficacy in treating signs and symptoms of MGD, compared to the use
of a warm face cloth, over the eight-week period. The OPTASETM Moist Heat Mask
demonstrated dual therapeutic abilities, treating both MGD and DF blepharitis. A paper on
the results of the study discussed in Chapter 7 has been recently accepted for publication in
Current Eye Research.
9.1.6

Clinical use of eyelash manipulation versus microscopic examination

Chapter 8 compared the efficacy of using an eyelash manipulation technique to the
traditional eyelash epilation and subsequent microscopic examination technique, when
investigating for the presence of DF in a clinical setting. A moderately good agreement for
assessing quantity of DF was detected between both techniques. However, the BlandAltman plot suggested consistently higher quantities were discovered on eyelash
manipulation. The overall mean quantity of DF was also greater on eyelash manipulation
than on microscopic examination of the epilated eyelash. A weak level of agreement was
detected between the two methods for addressing severity of infestation. This was caused
by the superior ability of eyelash manipulation to detect pathogenic infestation in
comparison to microscopic examination of the epilated eyelash. As such, complete eyelash
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epilation is not necessary to accurately detect Demodex blepharitis requiring treatment, in
a clinical setting. Results of the extended study discussed in Chapter 8 have been accepted
for publication in Eye & Contact Lens.305
9.1.7

Conclusions

Based on the results of the research conducted throughout this research project, DF
blepharitis can be effectively diagnosed and treated by practitioners in-house, without the
need for further referral in many cases. Investigation to assess presence and severity of
infestation should be performed using eyelash manipulation. The results from Chapter 7
have proven that there is no clinical requirement to epilate an eyelash when examining for
the severity of DF infestation. Practitioners can feel confident that recommending nightly
lid scrubs with OCuSOFT® Lid Scrub® Plus or a tea tree-based product will reduce
quantities of DF and improve patients’ symptoms. The use of BlephExTM is advised to help
start the lid scrubbing regime by reducing the extent of CD and bacterial load at the eyelid
margin. The benefit of using a tea tree-based face wash, is that it can be used to clean the
entire face, not just the eyelids and eyelashes. Hence, treating DF infestation in other
locations on the face. Practitioners should refrain from recommending baby shampoo for
lid scrubs going forward, as it has no impact on Demodex blepharitis, but also may be
harmful to the ocular surface in the long run.
9.2

Future research

Demodex remains a relatively novel research area within ophthalmology. Future
research regarding treatment such as: effect of BlephExTM on lid hygiene; effect of
OCuSOFT applied overnight versus washed off; effect of face cleansers compared to
TTFW; comparison between in-house lid scrubs scrubs with TTO versus TTFW at home;
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and the effect of lid scrubs used twice a day versus once a day; are all areas that require
further investigation. However, any future treatment-based investigation should make a
considerable effort to quantify participant compliance. Methods to improve participant
compliance in all treatment-based studies is a field that also requires further research and
investigation.
Over the course of this research project, it has become clear that there are several topics
that require further clarification with regards to Demodex, helping to improve practitioner’s
knowledge of underlying risk factors and associations.
There has been limited research conducted on the relationship between Demodex and
contact lenses. The majority of references to contact lens wear and Demodex is anecdotal,
and based around the work of Jalbert and Rejab114 and Tarkowski et al115. Both hard and
soft contact lens wearers were included in the study conducted by Jalbert and Rejab114, and
although this included a mix of daily, fortnightly and monthly soft contact lenses, and rigid
gas permeable lenses; no inter-lens modality analysis was conducted: just contact lens wear
and non-contact lens wear groups. Similarly, Tarkowski et al115 focussed on DF as a cause
of drop-out in previously successful contact lens wearers, but did not discriminate between
contact lens modality. Jalbert and Rejab114 found a 90% prevalence of DF within contact
lens wearers in their study. The authors’ suggested the higher prevalence may be due to
increased handling of and presence of bacteria, such as Staphylococcus epidermis and
Corynebacteria, on the eyelids of contact lens wearers,306 concluding that contact lenses
may provide a route for micro-organisms to grow and create an environment that favours
Demodex proliferation. However, it would be interesting to examine the relationship
between DF and contact lens modality, as re-usable contact lenses, such as fortnightly or
monthly lenses, are cleaned and stored in solutions that contain anti-microbial agents to
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help prevent infection. Hence, in theory, the use of re-usable contact lenses may reduce the
risk of DF infestation. Furthermore, if the quantity of DF is increased, handling of the
eyelids may make contact lens wearers more susceptible to DF infestation. A comparison
of participants who wear their contact lenses on a full-time basis compared to participants
who wear contact lenses occasionally could be carried out to investigate which cohort has
a higher risk of DF infestation. Contact lens modality was evaluated during the pilot study.
In contrast to Jalbert and Rejab114, non-contact lens wearers, and daily disposable soft lens
wearers, had higher quantities of DF than re-usable contact lens wearers. However, the
results were significantly impacted by age. As such, no reliable results could be ascertained
from the data. Future studies should have equal groups of contact lens wearers in the
different modalities, with age matched control non-contact lens wearers.
The use of makeup appeared to have a protective effect against DF infestation in the
pilot study. Similar to contact lenses, there has been very little research conducted on the
relationship between DF and makeup. Although several hypotheses exist, nothing
confirmatory has been established. As mentioned in Section 1.6.5, Horváth et al116 and
Elston and Elston79 suggested that makeup may reduce colonisation of DF in the hair
follicles of the skin and eyelashes. Elston and Elston79 suggested that it may be the presence
of exogenous lipids in cosmetics that could impact the proliferation of Demodex. Horváth
et al116 found a lower prevalence of DF among makeup wearers compared to non-makeup
wearers and provided three theories for their results. Firstly, the authors suggested that
makeup may obstruct follicles, inhibiting migration and proliferation of Demodex.116
Secondly, the authors suggested that makeup may contain chemicals that are toxic to
Demodex, thus preventing them from inhabiting skin covered with makeup.116 Thirdly, the
authors suggested that patients who wear makeup regularly are more inclined to remove
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makeup and clean their faces. Thus, the increased hygiene could help prevent Demodex
proliferation, or chemicals in the products used to clean the face may be toxic to Demodex:
preventing proliferation.116 Providing some consensus with regards to improved hygiene,
Koo et al13 did find that older participants with good eyelid hygiene had lower prevalence
of DF compared to younger participants with poor eyelid hygiene. However, further studies
are required to confirm any relationship between makeup and Demodex infestation and
establish the underlying mechanisms if such a relationship exists.
In Chapter 8, a low overall quantity of DF detected over the duration of the study
affected the power of some of the study results, namely the quantity of DF on microscopic
examination and MGDRx EyeBag®. Further investigation that concentrates on pathogenic
infestation, to ensure larger quantities of DF when testing, is required. Similarly, with
regards to the MGDRx EyeBag® and OPTASETM Moist Heat Mask, further research is
required to examine the therapeutic temperature achieved, and duration of such, at the inner
eyelid by each compress. Further investigation is required to evaluate any potential role that
moisture may have played in the therapeutic abilities demonstrated by the OPTASETM
Moist Heat Mask.
9.3 Dissemination to date
Dissemination of research findings is recognised as an integral aspect of the research
process. Within public health, dissemination of research findings provides evidence-based
results to practitioners, which can improve and develop their clinical management skills:
thus, providing best-practice care to their patients.307,308 Research results can be
disseminated in several different ways: peer-reviewed publications, research reports,
professional magazine articles, workshops, conference proceedings and social media
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platforms, to name a few.309 The research findings outlined in the above thesis have been
disseminated in peer-reviewed journals, optometry magazine articles, conference posters,
conference workshops at home and abroad, and in online lecture material.
9.3.1

Peer-reviewed publications

Results of the development and validation of the modified OSDI questionnaire
discussed in Chapter 4 have been published in International Ophthalmology (refer List of
Publications 1).
Results of the efficacy of OCuSOFT® Lid Scrub® Plus and dr.organic® tea tree face
wash for treating DF infestation discussed in Chapter 5 have been published in Contact
Lens Anterior Eye (refer List of Publications 2).
Results of the effect of OCuSOFT® Lid Scrub® Plus, dr.organic tea tree face wash
and Johnson’s® No More Tears® baby shampoo on the tear film and ocular surface,
discussed in Chapter 6, have been recently accepted for publication in Contact Lens &
Anterior Eye (refer List of Publications 3).
Results of the study examining the efficacy of warm compresses for treating DF
infestation, discussed in Chapter 7, have been recently accepted for publication in Current
Eye Research (refer List of Publications 4).
Finally, results of the observational finding that eyelash manipulation is better than
microscopic examination for detecting severity of DF infestation and is suffice in a clinical
setting, discussed in Chapter 8, have been published in Eye and Contact Lens (refer List of
Publications 5).
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9.3.2

Conferences and workshops

Murphy O. Demodex Blepharitis, Workshop, DIT, Dec 2014.
Murphy O, et al., Prevalence of Demodex folliculorum in symptomatic and
asymptomatic individuals and the efficacy of 1,2-Octanediol at treating Demodex
infestation, Poster Presentation, British Contact Lens Association, May 2015.
Murphy O, et al. The effectiveness of topical treatment with OCuSOFT Plus on ocular
Demodex folliculorum, Poster Presentation, European Academy of Optometry and Optics,
May 2015.
Murphy O. Dry Eye: Blepharitis – Meibomian gland dysfunction – Demodex, Lecture
Presentation, Association of Optometrists Ireland AGM, November 2015.
Murphy O. Dry Eye: Blepharitis – Meibomian gland dysfunction – Demodex, Lecture
Presentation, Irish Association of Dispensing Optometrists AGM, April 2016.
Murphy O. Demodex blepharitis: Diagnosis and Treatment, Workshop, Optometry and
Eye Health Conference, Sofia, Bulgaria, Oct 2018.
9.3.3

Other publications

Murphy O. Demodex blepharitis. Online Lecture. Wales Optometry Postgraduate
Education Centre. April 2018
Murphy O. Demodex blepharitis in practice. Optometry Today. May 2018, p.77-80.
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APPENDICES
Appendix 1: Informed Consent Letter
Patient Information Sheet
Project title: Comparison of traditional treatment methods and new techniques
including OCuSOFT® Lid Scrub® PLUS, BlephExTM and warm compress treatment
on Demodex folliculorum blepharitis and meibomian gland dysfunction.
You are being asked to consent to taking part in a post-graduate student clinical trial,
comparing traditional treatment methods for blepharitis with newer techniques.
Each participant will be asked complete a dry eye symptom questionnaire and will
undergo a series of dry eye tests and thorough examination of the front surface of the eye.
Each visit should take approximately 30 minutes.
One eyelash from each eyelid will be epilated using sterile forceps to confirm presence
or absence of Demodex. This procedure will be done using sterile forceps and is generally
painless. It is common for eye lashes to fall out and re-grow.
You may be allocated any treatment. Treatment will be administered for home use for
up to 8 weeks. You will be asked to return to the clinic for mid-treatment and post-treatment
check-ups.
1. Dry Eye: Blepharitis and Demodex
Blepharitis is a common condition of the eyelids where debris (crusts/scales similar to
dandruff) can build up around the base of the eyelash. It may be present with a common
mite which is found in skin and hair follicles called Demodex. This may result in symptoms
of itching and irritation around the eyelid margins.
Traditional treatment includes cleaning the eyelids with a diluted shampoo. New
treatment includes OCuSOFT® Lid Scrub® PLUS and tea tree face wash, both of which
containing antibacterial ingredients that has been shown to be effective against bacteria
commonly found on the eyelid.
BlephExTM is a handheld device with a spinning micro-sponge that is used to remove
scruff and debris by exfoliating along the base of the lashes. (BlephExTM will only be
administered in the clinic).
2. Dry Eye: Meibomian Gland Dysfunction (MGD)
MGD is a common condition which affects the glands around the eyelid margins.
These glands become blocked and cannot release oily secretions into the tears sufficiently.
This results in a reduced quality tear film which can result in gritty/dry eyes and blurred
vision. Traditional treatment includes applying heat compresses with a warm face cloth and
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massage to try to unblock the glands. Newer treatment includes wearing microwaveable
heat masks, MGDRx EyeBag® and OPTASETM Moist Heat Mask, which apply dry and
moist heat respectively to the glands over a longer time period.
A patch test will be carried out before proceeding with lid scrubs to ensure you have
no adverse reactions to the treatment. This will involve applying treatment to a small area
near the eyebrow with samples of each treatment. After 24hours if you have had no reaction
you may proceed with the treatment as instructed. In the rare event that you may experience
an adverse reaction; e.g. redness, itching, irritation, rash etc… - use cool compresses to
help soothe and do not proceed with treatment. We ask that you contact us to inform us if
this occurs.
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CONSENT FORM

Researcher’s Name: ORLA MURPHY

Title: MS

Faculty/School/Department:

SCIENCE/PHYSICS/OPTOMETRY
Title of Study: COMPARISON OF TRADITIONAL TREATMENT METHODS AND NEW
TECHNIQUES OCuSOFT® PLUS, BlephExTM AND WARM COMPRESS THERAPY ON DEMODEX
FOLLICULORUM BLEPHARITS AND MEIBOMIAN GLAND DYSFUNCTION.

To be completed by the: PATIENT

3.1 Have you been fully informed/read the information sheet about this study?

YES/NO

3.2 Have you had an opportunity to ask questions and discuss this study?

YES/NO

3.3. Have you received satisfactory answers to all your questions?

YES/NO

3.4 Have you received enough information about this study and any associated health and
safety implications if applicable?
YES/NO
3.5 Do you understand that you are free to withdraw from this study?
•
•
•

at any time
without giving a reason for withdrawing
without affecting your future relationship with the Institute

YES/NO

3.6 Do you agree to take part in this study the results of which are likely to be published?
YES/NO
3.7 Have you been informed that this consent form shall be kept in the confidence
of the researcher?

Signed_____________________________________

YES/NO

Date __________________

Name in Block Letters __________________________________________________________

Signature of Researcher ________________________________
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Date __________________

Appendix 2: Ethics Approval Letter
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Appendix 3: General Health and Lifestyle Questionnaire
Name: ____________________________ Reference: _______________
DOB: ____________ Age: ________________ Sex:________________
The following questions relate to your general health and lifestyle. Please tick the
appropriate box:
1. Do you wear contact lenses?
Dailies []

Two weekly []

Monthly []

Extended wear []

I don’t wear contact lenses []
2. Do you wear make – up?

Yes []

No []

a. What type of mascara do you use?

Regular []

Waterproof [] None []

b. What type of eyeliner do you use?

Liquid []

Pencil []

None []

3. How often do you clean your eyelids/lashes?
Every night []

3-4 times/week []

1-2times/week []

<once a week []

Never []
4. What type of lid hygiene regime do you mainly use?
Cleanser/Toner []

Eye makeup remover []

J+J Lid scrubs []

Other lid scrubs []

Face wipes []

Other []

None []

If other, please specify: __________________
5. How often do you currently wash your pillowcase/bed linen?
> Once a week []

Once a week []

Once a fortnight []

Once a month []

< Once a month []
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6. At what temperature do you currently wash your pillowcase/bed linen?
≤30°C []

40oC []

≥55 oC []

7. How do you currently dry your bed linen?
Air dry []

Tumble dry []

Launderette []

Dry Cleaner []

8. Do you suffer with any underlying medical conditions?
Diabetes []

High Blood Pressure []

Thyroid []

Arthritis []

Other []

None []
If other, please specify: ______________________________
9. Are you taking any systemic medications?

Yes []

No []

If Yes, please specify: ____________________________________________
10. Do you suffer with any allergies?
Seasonal (e.g. hay fever) []

Asthma []

Dust []

Skin sensitivities []

None []

11. Do you currently suffer with any of the following skin conditions?
Rosacea []

Dermatitis [] Eczema []

Psoriasis []

None []

Acne []

Sensitivity skin []

If you do not understand any of the above questions, please ask the Optometrist to help
clarify.
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Appendix 4: Modified OSDI symptom questionnaire
Answer the questions below in relation to dry eye symptoms. Please circle/tick
appropriately.
Please use this frequency list as a reference guide.
4: All of the time: All day, every day.
3: Most of the time: At least once a day, every day.
2: Half the time: e.g. At least once every second day
1: Some of the time: e.g. at least once every 2-3days
0: Rare/Not at all: Very rarely affected, practically not at all, never.

1. In the past fortnight have you experienced any of the following? Please circle the
most appropriate:
All of the

Most of the

Half of the

Some of

Rare/Not at

time

time

time

the time

all

Dry eyes?

4

3

2

1

0

Gritty/Irritated eyes?

4

3

2

1

0

Itchy eyes?

4

3

2

1

0

Red eyes?

4

3

2

1

0

Burning sensation?

4

3

2

1

0

Sensitivity to light?

4

3

2

1

0

Watery eyes?

4

3

2

1

0

Eyelids stuck together

4

3

2

1

0

in the mornings?
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2. With regards to the symptoms above, what time of the day are your symptoms worst?
Tick all that apply.
I don’t have any symptoms []
At night []

In morning on waking []

In the afternoon []

All day long []

3. In the past fortnight, have problems with your eyes limited your ability in
performing any of the following? Please circle the most appropriate:
All of the

Most of

Half of

Some of

None of

time

the time

the time

the time

the time

Reading?

4

3

2

1

0

Driving at night?

4

3

2

1

0

Using a computer?

4

3

2

1

0

Watching television?

4

3

2

1

0

4. In the past fortnight, have your eyes felt uncomfortable in any of the following
situations? Please circle the most appropriate:
All of the

Most of the

Half of

Some of

None of

time

time

the time

the time

the time

Windy Conditions

4

3

2

1

0

Cold Conditions

4

3

2

1

0

Air-conditioned environments

4

3

2

1

0
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Appendix 5: Instruction Leaflet for 10% solution of baby shampoo
(a) Pilot Study
Blepharitis is a common condition of the eyelids which can result in symptoms of eye
irritation (itchy, gritty, stinging eyes), intermittent blurred vision or you may have no
symptoms in the early stages. Demodex is a mite which commonly lives in the base of the
eyelashes and skin follicles, it becomes increasingly prevalent as we get older and can
sometimes cause irritation around the eyes.
You have been recommended the following treatment by your optometrist in order to
alleviate any symptoms or signs of this condition. Your progress will be monitored at a
check-up in two weeks’ time.
Ensure you wash and dry your hands thoroughly before beginning.
Right / Left Eye:
A. Traditional method: Diluted solution of Johnson’s and Johnson’s Baby Shampoo
1. Fill the vial to the point shown (see arrow)
with boiled water that has cooled.
2. Shake well to thoroughly mix the solution.
3. Pour the solution onto one of the cotton
pads provided.
4. Squeeze out excess liquid from the cotton
bud to prevent drips getting into your eyes,
which may irritate.
5. Gently clean down across the eye in
circular movements. Try to ensure you rub
along the base of the lashes.
6. With eyes still closed use side – to – side strokes to gently scrub the eyelid.
Again, paying particular attention, try to clean off any crusts at the base of the
eyelids.
7. Open the eyes, wrap the cotton pad around your index finger, as instructed,
look up and still using side to side strokes at the base of the bottom eyelashes
make sure all crusts have been removed and the lid is fully clean.
8. For the top lashes use side to side strokes in an upward movement as
instructed to ensure lashes are completely clean. Be careful not to scratch the
ocular surface.
9. After cleaning the eyelids, rinse off the shampoo from the eyelids, using a new
clean cotton wool pad.
10. Please do not dispose of vials. Keep and return them to the National
Optometry Centre on your aftercare visit.
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(b) Phase Four
Blepharitis is a common condition of the eyelids which can result in symptoms of eye
irritation (itchy, gritty, stinging eyes), intermittent blurred vision or you may have no
symptoms in the early stages. Demodex is a mite which commonly lives in the base of the
eyelashes and skin follicles, it becomes increasingly prevalent as we get older and can
sometimes cause irritation around the eyes.
Ensure you wash and dry your hands thoroughly before beginning.
Johnson’s and Johnson’s Baby Shampoo:
1. Using the syringe provided, insert 2ml of baby shampoo into the test vial
provided.
2. Fill the vial with boiled water that has cooled.
3. Shake well to thoroughly mix the solution.
4. Pour half the solution onto one of the cotton pads provided.
5. Squeeze out excess liquid from the cotton bud to prevent drips getting into
your eyes, which may irritate.
6. Gently clean down across the eye in circular movements. Try to ensure you
rub along the base of the lashes.
7. With eyes still closed use side – to – side strokes to gently scrub the eyelid.
Again, paying particular attention, try to clean off any crusts at the base of the
eyelids.
8. Open the eyes, wrap the cotton pad around your index finger, as instructed,
look up and still using side to side strokes at the base of the bottom eyelashes
make sure all crusts have been removed and the lid is fully clean.
9. For the top lashes, look down, and gently pull up on the upper lid. Using side
to side strokes in an upward movement as instructed to ensure lashes are
completely clean. Be careful not to scratch the ocular surface.
10. For the lower lid, look up, and still using side to side strokes at the base of the
bottom eyelashes make sure all crusts have been removed and the lid is fully
clean.
11. After cleaning the eyelids, rinse off the shampoo from the eyelids, using a new
clean cotton wool pad.
12. Repeat from 4-11 for the other eye.
Repeat this routine at night for two weeks and then return to the National Optometry Centre
for a follow-up appointment.
If you have any questions or need to re-arrange please contact:
Orla Murphy
E-mail: orla.murphy@dit.ie
Please note: Should you notice any discomfort or irritation of the eyes or skin around the
eyes please cease treatment and contact your Orla in the National Optometry Centre.
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Appendix 6: Warm Compress Instructions
(a) Warm Face Cloth

Warm Face Cloth Compress
Read the instructions carefully before using the Warm Face Cloth Compress and keep
them for reference. Always follow these instructions

1. Bring the kettle to the boil.
2. Pour boiling water into a bowl. Allow to cool for approximately 10 mins.
3. Place flannel in the water.
4. Remove flannel and squeeze excess water out. Ensure it is not too hot.
5. Laying in a comfortable position place the warm flannel over the eyes.
6. Keep in place for 10 minutes. Re-dip every two mins to keep flannel as hot as
possible (re-dip at 2 min, 4 min, 6 min, and 8 min).
7. Immediately after warming, massage the closed eyelids – upper and lower, to express
oil from the Meibomian glands. Gently but firmly sweep your clean finger, in circular
movements, over the skin at the edge of the closed eyelid from the nose outwards.
Repeat this several times for about 30 seconds.
8. Clean eyes of any loose debris from the eyelids.
Weeks 1+2: Twice a day
Weeks 3-8: Once a day
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(c) MGDRx EyeBag®
Read instructions carefully before use and keep them for reference
1. Remove the EyeBag® from packaging and place on a clean, microwaveable
plate. Do not use the metal griddle supplied with some microwaves as this may burn
your EyeBag®
2. Place in microwave and heat on full power according to the table below
Caution: If your microwave is greater than 1000w, you may need to reduce the time.
Power

Heating Duration

Above 750W

30 seconds

750W and below

40 seconds

3. Check the EyeBag® is comfortably warm but not too hot before placing it over the
closed eyelids and relaxing with the EyeBag® in place for 10 minutes.
4. Use the silk side as this is warmer and will stay warmer for the duration of the
therapy.
5. Immediately after warming, massage the closed eyelids – upper and lower, to express
oil from the Meibomian glands. Gently but firmly sweep your clean finger over the
skin at the edge of the closed eyelid from the nose outwards. Repeat this several times
for about 30 seconds.
6. Clean the eyelids of any loose debris.
Weeks 1+2: Twice a day
Weeks 3-8: Once a day
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(c) OPTASETM Moist Heat Mask
Read the instructions carefully before using the OPTASETM Moist Heat Mask
and keep them for reference. Always follow these instructions
1. Remove OPTASETM Moist Heat Mask from all packaging and place on a clean,
microwaveable plate. Do not use the metal griddle supplied with some microwaves as
this may burn and damage the heat mask.
2. Place in microwave and heat on full power according the table below.
Power

Heating Duration

900W and above

15 seconds

800W

25 seconds

Do not exceed a maximum of 30 seconds of heating
3. Check the heat mask is comfortably warm but not too hot before placing it over
closed eyelids.
4. Relax and keep the heat mask in place for 10 minutes.
5. Immediately after warming, massage the closed eyelids – upper and lower, to express
oil from the Meibomian glands. Gently but firmly sweep your clean finger in circular
movements, over the skin at the edge of the closed eyelid from the nose outwards.
Repeat this several times for about 30 seconds.
6. Clean the eyelids of any loose debris.
Weeks 1+2: Twice a day
Weeks 3-8: Once a day
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